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ABSTRACT 
 
Background 
The mechanism of CD4+ T-cell decline in Human Immunodeficiency Virus-1 (HIV-1) infection 
is unclear, but the association with plasma HIV-1 RNA-load suggests viral replication is 
involved.  Viraemic controller patients with low HIV-1 RNA-loads (<2000 copies/ml) typically 
maintain good CD4+ T-cell counts (>450 CD4+ T-cells/mm3).  However, within a cohort of 86 
viraemic controllers, a subgroup (18 ‘discord controllers’) was identified with low CD4+ T-cell 
counts (<450 CD4+ T-cells/mm3) which present clinical uncertainty.  The underlying 
mechanism accounting for CD4+ T-cell decline in the face of low or undetectable HIV-1 RNA-
loads is unknown.  The objective of the work described in this thesis was to investigate the 
virological and host immune system dynamics in discord controllers compared with typical 
controllers.   
 
Method 
Epidemiological features, HIV-1 subtype, cellular HIV-1 DNA-load, T-cell populations 
(CD4+/CD8+ naïve/ central-memory/ effector-memory subsets; CD45RA/RO ± CD62L) and T-
cell activation markers (CD38, HLA-DR) were examined for discord controllers and typical 
controllers as well as progressors with HIV-1 RNA-load >10000 copies/ml, <450 CD4+ T-
cells/mm3. 
 
Results 
Discord controllers and typical controllers were similar, based on epidemiological features and 
viral subtype distribution.  They resembled progressors, showing high HIV-1 DNA-load, 
depletion of naïve CD4+ T-cells and higher activation in all CD4+ T-cell subsets.  However, the 
CD8+ T-cell compartment in discord controllers was similar to typical controllers with 
preserved naïve CD8+ T-cells and low level CD8+ T-cells activation.   
 
Conclusion 
The data presented in this thesis is consistent with a relationship between CD4+ T-cell 
activation, HIV-1 DNA-load and disease progression but not HIV-1 RNA-load.  This suggests 
that in viraemic controllers, HIV-1 DNA-load may be a better marker of viral replication and 
disease progression than HIV-1 RNA-load. Furthermore, low level CD8+ T-cell activation 
correlate with low plasma HIV-1 RNA-load but not with HIV-1 DNA-load.   
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General Introduction 
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Human Immunodeficiency Virus (HIV) infection, the cause of AIDS (Acquired Immune 
Deficiency Syndrome), continues to be one of the most significant infectious diseases globally.  
An estimated 34 million people worldwide were thought to have been living with HIV infection 
at the end of 2010 [1].  The advent of antiretroviral treatment (ART) has reduced the rate of 
AIDS related deaths [2, 3].  However, access to therapy is not universal and despite huge strides 
having been made in understanding the basic biology of the virus, progress is slow in terms of 
finding curative treatments or an effective vaccine [4].  Therefore, it is clear that HIV infection 
will continue to be a significant public health problem for many years to come.    
 
Ever since HIV-1 was first discovered, the reasons for its epidemic spread and severe 
pathogenicity have been studied intensively.  Here is a summary of what is currently known 
about the virus with a focus on pathogenesis, natural history and clinical monitoring of disease.  
In addition, a group of patients termed ‘viraemic controllers’ are described who are infected 
with the virus, but in whom only low levels of the virus are found in blood.   
 
1.1   Origin and Classification of HIV-1 
 
In 1983, when Montagnier and colleagues at the Pasteur Institute first isolated the virus 
responsible for the AIDS epidemic, one of the first features noted about the virus was its reverse 
transcriptase (RT) activity [5].  This property placed the new agent in the family Retroviridae.  
The subsequent cloning and sequencing, revealing the genetic organisation of the virus, further 
placed it in the lentivirus genus, with close homology to non-human primate lentiviruses [6].  
As the name suggests (lenti - Latin for slow), lentivirus infection gives rise to a chronic course 
of disease with a long asymptomatic period.   
 
Two types of HIV have since been described: type 1 (HIV-1) and type 2 (HIV-2).  HIV-2 is less 
virulent, has lower transmission rates and has remained geographically limited to West Africa, 
with the highest prevalence rates in Guinea-Bissau and Senegal [7].  HIV-1 is sub divided into 
three distinct lineages: groups M (major), O (outlier) and N (non-M, non-O) [8].  It has been 
observed that various species of wild primates in Africa frequently harbour distinct lentiviruses 
(Simian Immunodeficiency Viruses, SIV) including African green monkeys, sooty mangabeys, 
mandrills, sykes, chimpanzees and gorillas [9].  SIV infection of these African nonhuman 
primates is often referred to as ‘natural infection’ as it is thought to represent an ancient virus 
that has evolved with its primate host and does not typically give rise to disease [10].  Genetic 
analysis of HIV with SIV led to the current belief that HIV-1 and HIV-2 represent at least three 
separate transfers of SIV from nonhuman primates [11].  A phylogenetic tree of HIV and 
various SIV is shown in Figure 1.1, together with a description of these transfers.  More 
13 
 
recently a fourth subgroup of HIV-1, called group P, was detected in two patients originally 
from the Cameroon [12, 13].  Like HIV-1 group O, it is thought to originate from an 
independent transmission of SIV from gorillas [12].    
 
Group M HIV-1 is further subdivided into subtypes or clades lettered A-D, F-H, J and K on the 
basis of phylogenetic analysis of the gene encoding the envelope glycoproteins (env).  The gene 
and protein sequences within a subtype are more closely related to one another than to the genes 
and proteins from other subtypes.  Subtypes A and F are divided into sub-subtypes A1-A4, and 
F1 and F2, respectively, since each set of sub-subtypes is more closely related to each other 
than to other subtypes [14, 15].  Subtypes B and D are also more closely related to each other 
than to other subtypes, but continue to be named as such to retain consistency with earlier 
published work [14].  This categorisation of HIV-1 into genetic subtypes based on viral 
sequencing is a powerful epidemiological tool with which to evaluate the HIV-1 epidemic.   
 
This thesis, including the rest of Chapter 1, will focus on HIV-1 and will only refer to ‘HIV’ 
generally if the paper being cited has not specified which type.   
 
Infection with differing HIV-1 isolates in an individual has been documented in small 
populations of high-risk individuals [16, 17].  All such cases were once thought to be the result 
of exposure to different isolates more or less simultaneously, before the immune response had 
matured.  However, it is now thought that ‘superinfection’ also occurs as a result of infection 
with the second isolate some time after infection with the initial isolate.  This highlights the 
insufficiency of the immune response to the first isolate in protecting against superinfection [17, 
18].  
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Figure 1.1   Phylogenetic relationship of primate lentiviruses.  Figure taken from Kuiken et 
al. [19].  Alignment of pol gene sequences of HIV-1, HIV-2 and SIV isolates; pol sequences 
were used as they are relatively conserved amongst lentiviruses even when other regions of the 
genome differ widely.  Within HIV-1, the subtypes in group M are phylogenetically equidistant 
from one another.  HIV-1 group M and N are phylogenetically similar to SIV which infects 
central chimpanzees, Pan troglodytes troglodytes (SIV CPZ P.t.t.) [20].  HIV-1 group O, which 
is phylogenetically closely related but distinct from these groups, has been found to be related 
to Gorilla SIV [21].  Each of these appear distinct from SIV CPZ Pan troglodytes 
schweinfurthii (SIV CPZ P.t.s.).  HIV-2 is related to SIV which infects sooty mangabeys, 
Cercocebus atys atys (SIV MM) [22].  These isolates are phylogenetically distinct from other 
SIV isolates including those which infect the African green monkey (SIV AGM), sykes (SIV 
SKS) and  mandrills (SIV MND). 
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In addition to the HIV-1 subtypes described, there are many inter-subtype recombinant isolates, 
often restricted to the dually infected individual in which they arose.  These forms contain 
clearly delineated sections from different subtypes and are thought to result from genetic 
recombination of viruses of differing subtypes (see Section 1.4).  If the recombinant virus is 
fully sequenced and found in three or more epidemiologically unlinked individuals it can be 
classified as a circulating recombinant form (CRF); isolates are referred to as unique 
recombinant forms (URFs) if these criteria are not met.  The CRFs are labelled with numbers 
instead of letters, in the order in which they were first described, followed by letters indicating 
the subtypes involved.  They must share an identical mosaic structure, i.e. they descend from 
the same recombination events [8].  For example, CRF01_AE was the first fully described CRF 
and found to contain components of subtype A and E, although no 'pure' full-length genome has 
been found for subtype E [8]. There are now more than 50 CRFs worldwide [23].  If three or 
more subtypes are found to make up a recombinant form, the isolate is designated as ‘cpx’ 
rather than a list of subtypes involved.  
 
1.1.1   HIV-1 Genomic Diversity  
 
The HIV-1 genome is extraordinarily diverse.  Genetic variation within a subtype is around 8-
17%, whereas variation between subtypes is usually 17-35% depending on which region of the 
genome is examined [24]. The greatest variability occurs in the region of the genome which 
encodes the envelope glycoprotein 120 (gp120) (see Section 1.3) [25].  Even within a single 
infected individual huge heterogeneity is observed, with this range of isolates being referred to 
as the ‘quasispecies’.  Incredibly, the genetic diversity of the HIV-1 quasispecies in an infected 
individual at the late stages of disease is comparable to the global annual genetic variation of 
the influenza virus [25].  This is particularly surprising since most infections are thought to arise 
from a single ‘founder’ virus [26, 27].  This genetic heterogeneity results from the rapid 
replication kinetics of HIV-1, mutations during viral replication, viral genomic recombination 
(see Section 1.4) and immune selection pressures (see Section 1.7) [28, 29].  Such diversity 
allows for selection of variants which readily escape control by host immune responses and 
ART, and accounts for much of the difficulty in vaccine development and in developing 
therapies against HIV-1. 
 
There is some evidence that genetic variation between subtypes or CRFs may result in differing 
viral properties, such as cellular tropism, kinetics of viral replication or differences in viral 
pathogenesis.  For example, Kanki et al. found that female sex workers in Senegal infected with 
a non-A subtype were eight times more likely to develop AIDS than were those infected with 
subtype A over the study period, suggesting possible decreased pathogenicity of subtype A 
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[30].  An increased pathogenicity of subtype D isolates has been reported by several groups [31-
33].  Infection with subtype CRF01_AE virus, commonly seen in Thailand, has been reported to 
cause more rapid progression and shorter median survival than that which is described in ART-
naïve individuals in high income countries where other subtypes predominate [34, 35].  The 
differing immunological status of the population in Thailand may account for these differences 
rather than viral subtype [35].  It has also been observed that certain subtypes or CRFs are 
associated with specific modes of transmission [36]; these observations will be discussed in the 
next Section.   
 
1.2   HIV-1 Epidemiology 
 
1.2.1   HIV-1 Risk Factors and Transmission 
 
The AIDS epidemic was first identified in the United States within the men having sex with 
men (MSM) risk group, in men and boys with haemophilia exposed to contaminated clotting 
factors, in recipients of blood transfusions and in intravenous drug users (IVDU) [37].  
Transmission as a result of exposure to contaminated blood products has virtually disappeared 
with the introduction of screening assays.  For example, current blood transfusion screening 
assays mean the risk of transfusion-transmitted HIV is estimated to be 1 case per 1.5 million 
transfusions [38].  However, the epidemic has since grown at an alarming rate with the major 
risk factors being heterosexual and homosexual intercourse, vertical transmission and 
intravenous drug use.  Heterosexual intercourse is the primary mode of transmission in sub-
Saharan Africa, although infections in MSM and IVDU are starting to be seen [39].  In Asia, the 
epidemic had long been concentrated in high risk populations, including IVDU, sex workers 
and their clients and MSM.  However, transmission is now increasingly seen in lower risk 
populations, with heterosexual transmission now being the predominant mode of spread in Asia 
[40].   Mode of transmission varies across Europe with 40% of transmission occurring in MSM 
in Western Europe, 29% due to heterosexual sex and only 8% in IVDU. In Central Europe these 
figures are 30%, 40% and 13% respectively.  In Eastern Europe 42% of new infections result 
from transmission due to heterosexual sex, only 0.4% amongst MSM, and 57% in IVDU [41].  
In Europe overall, the number of HIV reports among MSM increased by 39% between 2003 
and 2007 [42].  A large proportion of new diagnoses in Europe which were due to heterosexual 
transmission acquired the infection in a country with a generalised epidemic (mostly sub-
Saharan Africa, the Caribbean, and Asia) [42].     
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All studies show that unprotected anal intercourse is more risky than vaginal sex and that 
receptive sex is riskier than active sex [43].  A study of African HIV-1 serodiscordant couples 
(infected partner not treated) showed the unadjusted per-act transmission rate to be 0.0019% for 
male-to-female transmission and 0.0010% for female-to-male transmission during heterosexual 
intercourse [44].  The risk of transmission in receptive anal intercourse appears to bear the 
highest risk with per-act transmission rates of 0.04 - 3.0% [43].  The fragility of rectal muscoa 
compared with the female genital tract may account for this.  It seems that the stage of the 
disease in the infected partner is important, in that HIV-1 transmission per heterosexual coital 
act follows a U-shaped curve, being highest during primary infection, lower during the 
asymptomatic phase, and increasing with advancing disease [45].  This may be due to differing 
amounts of the virus in the blood over the course of increase, which is usually measured as 
plasma viral ribonucleic acid (RNA)-load.  Indeed, each log10 increase in viral RNA-load has 
been shown to increase the per-act risk of transmission by 2.9-fold (95% confidence interval, 
2.2-3.8) [44].  Other factors influence transmission rates via the various modes; for example, 
heterosexual sexual transmission rates in low-income countries are thought to be four to ten 
times higher due to as yet undetermined reasons [46].  The presence of genital herpes simplex 
virus (HSV)-2 infection has been shown to be a risk factor for HIV acquisition [47], as has 
active syphilis [48] and gonorrhea [49] amongst other sexually transmitted infections (STI).  
Such STI have been shown to facilitate HIV transmission by increasing both infectivity [50] 
and susceptibility to infection [45].  STIs which cause genital ulceration are thought to increase 
transmission as a result of disturbing the integrity of the genital mucosa [51].  Pregnancy also 
appears to be associated with increased male to female transmission of HIV [52].    
 
Mother-to-child transmission of HIV, which can occur during pregnancy, delivery or 
breastfeeding, accounts for the vast majority of HIV infection in children worldwide [1].  
Current prevention strategies, widely employed in developed countries (see Section 1.8), reduce 
mother-to-child transmission from around 25% to as low as 1% [53].  However, huge numbers 
of children continue to be infected in sub-Saharan Africa; UNAIDS (the Joint United Nations 
Programme on HIV/AIDS) estimate 330000 (190000 – 460000) were infected in 2009 alone  
[54]. 
 
Subtype B isolates appear to be spread mostly by homosexual contact and in IVDU, while 
subtype C and CRF01_AE are more closely associated with heterosexual contact.  Some studies 
have found decreased perinatal transmission of subtype D compared with other subtypes [55, 
56], whereas yet other studies have found no difference [57, 58] or high rates of subtype C 
transmission compared with subtypes A or D [59].  It has been shown that subtype C gives rise 
to high viral RNA-load and higher levels of vaginal shedding than subtype A or D [57].  This 
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may be related to the fact subtype C viruses have three NFκB sites in comparison to one or two 
in other subtypes [60]; during immune activation, these sites make HIV-1 more responsive to 
cytokines such as tissue necrosis factor (TNF)-α that enhance virus production.  The high viral 
RNA-load and vaginal shedding has been proposed to be the reason for the particularly rapid 
epidemic spread of subtype C HIV-1, although other factors co-existing in populations affected 
by this subtype may alternatively account for its rapid spread.   
 
1.2.2   HIV-1 Prevalence and Incidence  
 
UNAIDS estimate that at the end of 2010 34 million people were living with HIV worldwide 
[1].  Sub-Saharan Africa is by far the region most affected by HIV with 68% of all people 
infected with HIV worldwide living here; prevalence is estimated to be approximately 5%.  
Prevalence is similar in East Africa, whilst in West and Central Africa prevalence is lower at 
around 2% or under.  The Caribbean bears the second highest prevalence of HIV at 0.9%.  Latin 
America is also seriously affected with a lower but still significant prevalence of 0.4%.  In 
South and South-East Asia prevalence is low, 0.3%, compared with Africa, but the region’s 
significant total population means that a huge number of people are living with HIV.  Generally, 
prevalence in the Middle East and North Africa is thought to be low; however, reliable data in 
some of these regions is not available.  In Eastern Europe and Central Asia prevalence is 0.9%, 
in Western and Central Europe it is 0.2% and in North America 0.6% [1].   
 
There were an estimated 2.7 million new HIV infections in 2010, with 1.9 million of these 
occurring in sub-Saharan Africa [1].  Fortunately, gains appear to be being made as new 
infections are thought to be down 21% overall from the peak of the global epidemic in 1997, 
with incidence falling in 33 countries including those in sub-Saharan Africa, the Caribbean and 
Asia.  Yet UNAIDS report that between 2001 and 2010, there has been a 250% increase in the 
total number of HIV infections reported in Eastern Europe and Central Asia, of which 90% are 
accounted for by the Russian Federation and the Ukraine.  This increase appears to be due to 
infections in IVDU and as a result of heterosexual transmission.  The incidence in North 
America, Western and Central Europe has overall stayed static since 2004 despite the high 
standards of health care in these regions and access to ART [1].  
 
In the United Kingdom, the Health Protection Agency reports a year on year decline in new 
HIV infections with an estimated 6150 new diagnoses in 2011 compared with the peak of 7824 
in 2005 [61]. This represents a decreasing incidence of infection in heterosexual individuals but 
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an increasing incidence amongst MSM.  About 44% of people newly infected with HIV in 2007 
in the U.K. had acquired it abroad, mainly in sub-Saharan Africa [62].   
 
1.2.3   Global distribution of HIV-1 Subtypes 
 
Whilst groups N and O have remained confined to part of West Central Africa (Gabon, 
Cameroon and Equatorial Guinea), group M is responsible for the worldwide pandemic, 
representing more than 95% of global virus isolates.  The global distribution of each group M 
subtype and CRF has its own distinct geographic pattern.  Worldwide 48% of infections are due 
to subtype C, 12% subtype A, 11% subtype B, 8% CRF02_AG, 5% CRF01_AE, 5% subtype G 
and 2% subtype D [24].  Here is a summary of the predominant subtypes / CRFs (see also 
Figure 1.2) [24] : 
 
• Subtype C is almost the exclusive subtype causing the epidemic in South Africa, 
Ethiopia and India, but is also circulating in East Africa, South and South-East Asia.   
• Subtype A is the dominant subtype in East Africa and is also widespread in Eastern 
Europe and Central Asia.  It is also found in West and Central Africa and South and 
South-East Asia.  
• Subtype B dominates in North America, the Caribbean, Latin America, Western and 
Central Europe and Australia.  It also circulates in North Africa, South and South-East 
Asia, Eastern Europe and Central Asia.   
• CRF02_AG is a complex mosaic of subtype A and G sequences and circulates widely 
in West Africa and to a lesser extent in Central Africa, the Middle East and North 
Africa. 
• CRF01_AE is found mostly in South and South-East Asia, East Asia and to a lesser 
extent in Central Africa. 
• Subtype G is seen mostly in West and Central Africa.  
• Subtype D causes a large number of infections in East and Central Africa, where it has 
been co-circulating with subtypes A and C[24].  
 
As mentioned, in Western and Central Europe subtype B is dominant; however, other subtypes 
are increasing in prevalence [63].  Indeed, all major subtypes and many CRFs and URFs are 
detected.  In the U.K. 74.9% of isolates which have undergone sequence analysis are subtype B, 
10.0% are subtype C, 6.4% are subtype A and 1.8% are subtype CRF02_AG together with 
many other less frequent subtypes [64].  This appears to reflect the high proportion of HIV-1 
infected individuals in the U.K. who are MSM since most men are infected with subtype B 
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virus, although the proportion infected with non-B subtypes is increasing [65].  In contrast, data 
from England and Wales show that subtype C was the most prevalent subtype amongst infected 
heterosexuals [66].  London is a particular melting pot with the above mentioned strains 
represented, together with subtypes F, G, H CRF06_cpx, CRF11_cpx, CRF12_BF, CRF14_BG 
and many other CRFs and URFs [67].   
 
 
 
 
 
 
 
Figure 1.2   Geographical distribution of HIV-1 subtypes.  Genetic forms predominant in an 
area are shown in letters of larger size. The greatest diversity is found in Central Africa where 
all subtypes and many CRFs and URFs are represented.  Data taken from Hemelaar et al.  [24].   
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1.3   HIV-1 Genomic Organisation and Structure  
 
 
The organisation of the HIV-1 genome together with encoded proteins are shown in Figure 1.3.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3   Genomic organisation and viral structure of HIV-1.  Adapted from [68].  This 
figure is schematic and simplified for clarity.   
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The HIV-1 virion has a diameter of 100-120nm with spherical morphology and is surrounded 
by a lipoprotein membrane.  The envelope glycoprotein (gp), Env, is integrated into this 
membrane and is composed of a trimer of the external (gp120) and transmembrane (gp41) 
subunits [69].  The matrix protein p17 is anchored to the internal face of the lipoprotein 
membrane.  Inside this is a conical shaped capsid (composed of protein p24) which contains 
two genomic single-stranded positive sense RNA strands (diploid genome), each around 9.7 
kilobases and tightly bound to the nucleocapsid proteins p6 and p7, and the viral enzymes [70, 
71].   
 
As with other retroviruses, the HIV-1 genome encodes three main genes: gag (group-specific 
antigen), pol (polymerase) and env (envelope) arranged as 5’ LTR-gag-pol-env-LTR 3’. The 
LTR (long terminal repeat) regions represent the two end parts of the viral genome that are 
connected to the deoxyribonucleic acid (DNA) of the host cell after integration (see the next 
Section) and do not encode for any viral proteins.  LTR has a transcription-promoter function 
and contains regions important in reverse transcription [72] and genomic RNA dimerisation 
(non-covalent joining of the two RNA strands) [73].  The genomic organisation of HIV-1 is 
extremely efficient, employing all three reading frames and multiple splicing to encode 15 
proteins from a single mRNA [74].   
 
The env gene codes for the polyprotein gp160 which subsequently undergoes proteolytic 
cleavage to form gp120 and gp41.  The gag gene codes for the gag polyprotein (p55) which is 
cleaved to form the structural proteins p17, p24, p6 and p7.  A gag-pol polyprotein (p160) is 
cleaved to form the enzymes reverse transcriptase (RT, composed of two subunits p66 and p51), 
integrase (p32) and protease (p11).  In addition, HIV-1 encodes regulatory proteins ‘trans-
activator of transcription’ (Tat) and ‘regulator of virion expression’ (Rev) and accessory 
proteins ‘negative regulatory factor’ (Nef), viral infectivity factor (Vif), ‘viral protein R’ (Vpr) 
and ‘viral protein U’ (Vpu) [74].   
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1.4   HIV-1 Life Cycle 
 
The HIV-1 life cycle is shown in Figure 1.4.   
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HIV-1 cell entry requires cognate recognition of gp120 with the cell surface CD4 molecule on 
the surface of T-cells, monocytes, macrophages and dendritic cells.  A co-receptor is also 
required for attachment to cells and most viruses use one of two co-receptors, C-C chemokine 
receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4) [75, 76].  CCR5 and 
CXCR4 are chemokine receptors involved in regulating the inflammatory response.  As such, 
the expression patterns of CD4 and the co-receptor are major determinants of HIV-1 tropism.  
Based on this tropism, HIV-1 strains can be broadly divided into two categories, those using the 
CCR5 co-receptor (R5 viruses) and those which use the CXCR4 co-receptor (X4 viruses); also 
some isolates may use either [77].  CXCR4 is preferentially expressed on naïve, unactivated T-
cells, whereas CCR5 is expressed on the activated effector memory T-cell subset, and also on 
cells of the dendritic cell and macrophage lineage.  A large number of other chemokine 
receptors such as CCR3 can also act as a primary or secondary attachment sites but are not 
commonly involved in infection [78].   
 
After binding CD4 there is a significant conformational change in gp120 which in turn leads to 
conformational changes in gp41, resulting in fusion between the viral and cellular membranes 
and release of the viral capsid into the cell cytoplasm [69].   
 
Subsequently, a preintegration complex (PIC) is formed, which is a nucleoprotein complex of 
viral proteins (including Vpr, p17 and integrase), host proteins and the two strands of viral 
RNA [79]. Within the HIV-1 PIC, viral RNA is reverse-transcribed into complementary double-
stranded DNA (dsDNA) by the viral RT (also referred to as the RNA-dependent DNA 
polymerase).  The viral RT is particularly error-prone leading to frequent mutations and thus 
contributing to the generation of the viral quasispecies [80]. 
 
A single susceptible cell may be infected with two different HIV-1 isolates (different subtypes 
in a dually infected individual, or differing quasispecies).  Some progeny virions released by the 
cell will contain two viral RNA strands which are not identical (from each isolate), referred to 
as a heterozygous virus.  When the heterozygous virus infects a new cell, retroviral 
recombination occurs when the RT enzyme switches between these co-packaged RNAs during 
reverse transcription (‘template switching’) [81].  Retroviral recombination thereby enables 
beneficial mutations from different viruses to be combined in a single virion and deleterious 
mutations may effectively be lost.   
 
The PIC carrying the newly synthesised HIV-1 dsDNA enters the nucleus.  The viral integrase 
catalyses the integration of the viral dsDNA into the host cell genome; the integrated viral DNA 
is referred to as the ‘provirus’.  The site was once thought to be entirely random [82], but 
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further studies suggest integration may be at a transcriptionally active area of the chromosome 
[83, 84].  Integration at such a site might be important for efficient transcription from the viral 
genome.  Other studies have been able to link the integration site with viral RNA-load; in 
patients with low viral RNA-load the provirus was found to be integrated predominantly in GC-
rich regions, while in patients with high viral RNA-load the integration of viral genomes was in 
GC-poor regions [85].  The provirus is replicated as part of mitotic cell division and may persist 
in this form for long periods and through many rounds of division. 
 
A number of unintegrated viral dsDNA species are also generated and are considered terminal 
products of the reverse transcription process which are unable to sustain replication themselves 
[86, 87].  These unintegrated forms are linear or circularised and arise when the viral dsDNA 
fails to integrate into the host genome:  a 2-LTR circle is formed when the ends of the linear 
dsDNA join; a 1-LTR circle may result from homologous recombination between the two LTRs 
in a 2-LTR circle; or dsDNA may remain unintegrated in the linear form [87].  After integration, 
cellular transcription factors activate viral gene transcription from the provirus, producing 
numerous species of mRNA by multiple splicing [88].  About half of these are estimated to be 
full-length RNA which function as mRNA and genomic RNA for secreted virions.  Other 
mRNA transcripts encode Tat, Rev, and Nef  (see the next Section).   
 
Virions emerge from the infected cell by budding as immature non-infectious particles 
containing uncleaved Gag polyproteins [87, 89].  Gag is eventually cleaved by the viral protease, 
leading to a further assembly stage forming the mature cone-shaped capsid with generation of 
mature infectious virus particles.   Release of new virions often occurs at the site of contact 
between an infected and uninfected cell with the formation of a ‘virological synapse’ [90].  In 
this way virus may spread directly to the uninfected cell, without exposure to the humoral 
immune system [91].   
 
1.4.1   HIV-1 Regulatory and Accessory Proteins 
 
Tat is a transcriptional transactivator for the LTR promoter which vastly increases the level of 
transcription from the provirus.  It does this by preventing premature termination of provirus 
transcription through binding to the 5' ends of nascent HIV-1 transcripts (the trans-activating 
response element, TAR) enabling the production of full-length HIV-1 transcripts [92].  Tat is 
also actively secreted by infected cells and is endocytosed by uninfected cells.  It strongly 
increases the expression of HIV-1 co-receptors, thus favouring HIV-1 infection of the 
uninfected cell, and also modulates the production of immunoregulatory cytokines, thereby 
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contributing to immunosuppression [93].  Extracellular Tat is also thought to induce T-cell 
apoptosis [94].   
 
Rev has been shown to mediate the nuclear export of incompletely spliced RNA transcripts so 
that the structural proteins and RNA genome can be produced [95].  In the absence of the rev 
gene, the host RNA splicing machinery in the nucleus quickly splices the RNA so that only Rev, 
Tat and Nef can be produced.   
 
Nef is a major virulence factor which contributes to maintaining high viral RNA-loads and 
CD4+ T-cell depletion by inducing Fas-mediated apoptosis of uninfected bystander CD4+ T-
cells [96].  It also leads to endocytosis and degradation of cell surface molecules such as CD4 
and class I human leukocyte antigen (HLA), with the result that infected cells might evade the 
host cell-mediated immune response [88, 97].  The pivotal role of Nef is highlighted by the fact 
that SIV with deletion in the nef gene is attenuated and can serve as a live attenuated virus 
vaccine [98].   
 
Replication in non-dividing cells such as macrophages is promoted by Vpr, whereas its role 
appears less essential in other target cells [99].  It also induces cell cycle arrest in G2 and 
apoptosis in proliferating cells and so may significantly contribute to CD4+ T-cell depletion 
[100].  The function of Vif and Vpu are covered in the next Section.     
 
1.4.2   Host Restriction Factors which Target HIV-1 Replication 
 
Specific host proteins have evolved to limit retroviral replication.  Apolipoprotein B mRNA-
editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) and related family members are 
potent retroviral restriction factors.  They function by deaminating cytidine to uridine resulting 
in hypermutated viral DNA with frequent stop codons [101].  Vif acts to inhibit APOBEC3G 
activity by connecting the enzyme to a polyubiquitous complex leading to its proteosomal 
degradation [102].  Another intracellular factor, tripartite motif protein 5 alpha (TRIM5α) in 
rhesus macaque monkeys has been shown to cause rapid disassembly of the viral capid with the 
result that reverse transcription is not completed; this effect is not seen with human TRIM5α 
[103].  Tetherin, also produced as part of the innate immune system, exerts antiviral activity by 
opposing the release of progeny virions at the surface of infected cells and is opposed by Vpu 
[104].   Further aspects of the innate immune system are discussed in Section 1.7.4.  
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1.5   Natural History of HIV-1 Infection  
 
Figure 1.5 summarises the typical natural history of untreated HIV-1 infection over time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5  The natural history of HIV-1 infection.  HIV-1 RNA-load, peripheral blood CD4+ 
T-cell count, HIV-1-specific cytotoxic T lymphocyte (CTL) and antibody response over time 
following primary infection. 
 
1.5.1   Acute HIV-1 Infection 
 
The most common mode of HIV-1 infection is sexual transmission through the genital mucosa.  
It is likely that the initial infection by HIV-1 occurs in most patients by a single virus and that 
these ‘founder’ viruses tend to use the CCR5 as a co-receptor [105].  This would explain why 
persons who are homozygous for a deletion in CCR5 (CCR5∆32) are relatively resistant to 
infection with the usual HIV-1 R5 strains [106].  
 
Much understanding of the early events during HIV-1 infection has been obtained by the study 
of SIV infection of rhesus macaque monkeys, since it recapitulates the pathogenic effects of 
HIV-1 infection of humans [107].  Some such studies suggest that immunophenotypically 
resting CD4+ T-cells in the genital mucosa are the predominant cell type infected during 
heterosexual transmission, rather than activated cells as had been believed [108].  Dendritic 
cells also appear to play a role whereby they capture HIV-1 at the mucosal surface via C-type 
lectins, and then traffic the virus to lymph nodes and present it there to activated T-cells [109].  
The virus is then thought to remain localised in genital/rectal mucosa and draining lymph nodes 
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for around 10 days [110].  Immune activation in response to the infection leads to more 
activated CD4+ T-cells, in which efficiency of virus production is greater, thus enhancing 
dissemination of infection [111, 112].  Virus then spreads via the blood to other lymphoid tissue 
[113].  At these sites it replicates profusely and the level of free virus in the blood rises 
exponentially to reach a peak, often exceeding 106 copies/ml 21–28 days after infection [114].   
A mononucleosis like syndrome may occur during this phase [115].  Routine laboratory assays 
may detect infection with assays which detection the virus in the blood becoming positive first, 
following by serological tests (se  Section 1.6.1).   
 
Studies in acute SIV [108, 116, 117] and HIV-1 infection [118], suggest that during peak viral 
RNA-load there is a profound depletion of CD4+ T-cells (particularly effector memory CD4+ T-
cells) in extra-lymphoid effector sites, particularly in the GI (gastrointestinal) tract lamina 
propria [108, 118-120].  The GI tract lamina propria is particularly rich in CD4+CCR5+ effector 
memory T-cell targets for infection [121, 122].  CD4+ T-cell populations in blood and 
secondary lymphoid tissues (including the gut-associated lymphoid tissue, GALT) are not as 
dramatically affected at this early stage because CD4+CCR5+ effector memory T-cells are only 
minor components of the overall CD4+ T-cell compartment in these sites [118].   
 
Virus levels then fall over several months, rapidly at first, until a stable level is reached during 
the asymptomatic phase preceding progression to AIDS, and can vary among individuals by as 
much as 4 to 5 logs [123].  The extremely fast decline in viral RNA-load upon initiation of ART 
[124] suggests that the vast majority of this free form of the virus in plasma is produced by 
recently infected cells.  The cellular HIV-1 DNA-load, although not routinely measured, is a 
marker of viral replication and has been shown to follow a similar downward trend following 
acute infection as the viral RNA-load [125].   
 
1.5.2   Chronic HIV-1 Infection 
 
After the acute phase of infection and viral RNA-load set point is achieved, an asymptomatic 
phase ensues.  During this phase, HIV-1 replication largely evades immune control due in part 
to the presence of latently infected cells [126].  HIV-1 latency is defined as either pre-
integration or post-integration latency.  Pre-integration latency occurs where unintegrated HIV-
1 DNA exists in the PIC in the cytoplasm and decays over time [127].     Post-integration 
latency refers to a state whereby the virus has integrated into the host genome but is 
transcriptionally silent; these cells are typically long-lived [128].  The majority of cells 
exhibiting post-integration latency are resting memory CD4+ T-cells [129].  It has been 
proposed that latently infected cells result from HIV-1 DNA integrating into an activated cell 
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which subsequently returns to a resting state [130].  However, numerous alternate mechanisms 
have also been proposed including mutations in Tat [131], absence of cellular transcription 
factors [132], gene regulation by microRNAs [133] and proviral integration into 
transcriptionally silent sites [134].   
 
Macrophages are thought to play an important role in HIV-1 latency.  They are long-lived, 
terminally-differentiated tissue-resident cells which act to assist in clearance of pathogens and 
apoptotic cells, and also have a role in antigen presentation to T-cells [135].  They express the 
required cell surface receptors for HIV-1 infection and are thought to be the primary non T-cell 
reservoir for HIV-1 [136], demonstrating long-lived productive HIV-1 infection, often without 
obvious cytopathic effects [137].  Mature virus particles have been shown to remain trapped 
within surface invaginations giving the appearance of an intracellular budding compartment 
[138, 139].  It is thought that virus at this site is protected from the immune clearance.  It has 
been proposed that virions could be released from these invaginations over extended periods of 
time [139].  Furthermore, infected macrophages are thought to provide an ongoing source of 
infectious virus which is transmitted to susceptible CD4+ T-cells via a virological synapse [140].  
Growing evidence indicates an important role of infected macrophages in a variety of HIV-1-
associated diseases, including neurocognitive disorders [141]. 
 
During the asymptomatic phase there is a gradual depletion of circulating CD4+ T-cells.  It has 
been documented that in the blood a fast initial decline (5.2 cells/mm3 per week) of CD4+ T-
cells is seen over the first 5-6 months, followed by a slower rate of decline (1.9 cells/mm3 per 
week) [142].  CD4+ T-cells play a central role in the adaptive immune response to viral 
infections most importantly as they are critical for the maintenance of effective CTL function 
[143], but also through their capacity to help B-cells make antibodies, enhance microbicidal 
activity of macrophages and recruit cells from the innate immune system through production of 
cytokines and chemokines.  Therefore the ongoing depletion of CD4+ T-cells over the 
asymptomatic phase eventually results in immune dysfunction and the development of AIDS.  
AIDS is defined as a CD4+ T-cell count of <200 cells/mm3 or an AIDS defining opportunistic 
infection or neoplasm [144].  The average time from infection to symptomatic AIDS is around 
10 years [145].   
 
As infection progresses, there is an increased prevalence of X4 viruses with decreasing CD4+ T-
cell count [146].  However, X4 viruses emerge in only about half of the patients who progress 
to AIDS [147].  Given the long interval between infection and emergence of X4 variants it is 
plausible that their emergence is a consequence and not cause of disease progression.  Indeed, 
as mentioned in Section 1.1 subtype D has been associated with increased pathogenicity, which 
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might result from the fact that phenotypic assays have shown X4 viruses to be particularly 
prevalent in subtype D infection [148, 149], thus suggesting this subtype may have a greater 
propensity to switch to CXCR4 usage.     
 
1.6   Clinical Management of HIV-1 Infection 
 
1.6.1   Laboratory Diagnosis and Monitoring of HIV-1 Infection 
 
The laboratory diagnosis of HIV-1 infection is usually made by detection of virus specific 
antibodies by enzyme-linked immunosorbent assay.  Patients may be tested based on clinical 
suspicion or as part of a screening programme, e.g. during pregnancy.  Antibodies to HIV-1 
typically become detectable around 4 weeks after infection [150].  In addition to antibody, the 
British HIV Association (BHIVA) recommends that this initial assay simultaneously detects 
p24 antigen (the capsid protein) as these fourth generation assays may be positive 1 - 2 weeks 
earlier than antibody only assays [144].   
 
If positive, there is a requirement for the test to be confirmed with two further assays, one of 
which should distinguish HIV-1 from HIV-2.  The diagnosis of primary HIV-1 infection before 
seroconversion depends on detection of either p24 or a detectable viral RNA-load in plasma 
(positive approximately seven days before p24 assays) [151].  Several commercial HIV-1 RNA-
load assays are available which are highly automated, typically using real-time polymerase 
chain reaction (PCR) methods [152].  They are able to detect all subtypes within group M  HIV-
1 (some also detect group O) [152].  However, the genetic diversity of HIV-1 means that viral 
RNA-load is occasionally underestimated using a single assay [153].  In particular the Cobas 
AmpliPrep/Cobas TaqMan HIV-1 assays were shown to underestimate viral RNA-load in 
CRF02_AG subtype infection [154].  HIV-1 subtypes are usually determined by sequence 
alignment and phylogenetic analysis with reference strains.  
 
In the U.K. and other Western countries HIV-1 infection is usually diagnosed whilst in the 
asymptomatic phase.  The duration of this phase is variable and therefore the patient requires 3-
6 monthly follow-up visits where blood is taken for viral RNA-load and CD4+ T-cell count 
monitoring.  There remains some debate regarding whether absolute CD4+ T-cell count or CD4+ 
T-cell percentage (percentage of lymphocytes that are CD4+) is a more reliable marker of 
immune status in HIV-1 infected individuals.  General consensus and most treatment guidelines 
tend to use absolute CD4+ T-cell count [144].   
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During the clinic visit evidence of opportunistic infections or neoplasm is determined by 
thorough history taking and physical examination.  Assessment is made of any non-AIDS-
defining morbidities including cardiovascular, metabolic, renal and bone diseases.  The 
presence of commonly co-infecting organisms is determined using further blood assays: 
toxoplasma, syphilis, hepatitis B and C [144].  Guidelines suggest that once CD4+ T-cell counts 
fall below 450 cells/mm3 the patient should be seen more frequently in order to monitor count 
drops to 350 cells/mm3 which would necessitate the initiation of treatment [155].   
 
1.6.2   Treatment of HIV-1 Infection 
 
Treatment of HIV-1 with ART has significantly prolonged the time to both AIDS development 
and death in those infected [156], although significant challenges exist regarding toxicity, drug-
drug interactions and patient compliance.  Generally there is agreement that there is benefit in 
beginning treatment in asymptomatic patients with CD4+ T-cell counts below 350 cells/mm3 
[144].  There is debate regarding whether treatment is beneficial where the count is 350-450 
cells/mm3 [157].  
 
Many of the newer potent, once-daily regimens are now well tolerated and make durable 
suppression of viral RNA-load achievable for most patients.  To be effective, treatment must 
suppress viral RNA-load to below the limits of detection of current standard assays (typically 
40 -50 copies/ml) [144].   
 
The targets of commonly used ART agents are reverse transcription (nucleotide/nucleoside RT 
inhibitors, NRTI, and non-nucleoside RT inhibitors, NNRTI), protein cleavage (protease 
inhibitors), entry (fusion inhibitors) and integration (integrase inhibitors).  Examples of these 
are shown in Table 1.1.  The most important factor responsible for failure of ART is drug 
resistance and it is this which continues to drive the generation of new drugs.  The development 
of the protease inhibitor, ritonavir, was a particularly significant advance.  It can be used in 
combination at low dose to significantly boost plasma levels of other protease inhibitors as it is 
a potent inhibitor of cytochrome P450 3A4 (CYP3A4), thus avoiding the toxicities of using it at 
therapeutic dose and yet providing a much higher barrier to failure due to resistance [158].  A 
new class of drugs is the CCR5 co-receptor antagonists, which bind to the CCR5 co-receptor of 
the susceptible CD4+ T-cell, preventing viral entry [159].  A further group, called maturation 
inhibitors, specifically inhibit the final stage in Gag processing which causes an infected cell to 
produce virions which are non-infectious [160].  Highly active ART (HAART) refers to the 
combination of drugs which are typically given (often three drugs) since combining in this way 
enhances efficacy; common combinations are also shown in Table 1.1 [144].   
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Table 1.1  Common anti-retrovirals and HAART combinations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
New approaches to drug treatment include the induction-maintenance approach whereby 
HAART (induction), may be followed by a maintenance phase using one or two drugs [161] 
and intermittent therapy [162] but have been shown to be inferior to continuous HAART.   
 
A sharp decrease in viral RNA-load is usually seen quickly after starting treatment, with most 
patients achieving undetectable viral RNA-load by week 12 to 24 [144].  If this does not happen 
concern is usually raised about treatment adherence or viral resistance to treatment [163].  
Despite this rapid decrease in viral RNA-load, which suggests suppressed viral replication, 
some studies have shown that env sequences continue to evolve suggesting that replication is in 
fact ongoing [164].  In keeping with this, some patients with sustained undetectable viral RNA-
load occasionally experience intermittent episodes of detectable viral RNA-load (blips) [165].  
Following the suppression of viral RNA-load HIV-1 DNA is also seen to decline [86].   
 
An increase in total peripheral CD4+ T-cell counts follows the decrease in viral RNA-load 
following ART initiation.  An initial increase of 50-100 cells/mm3 may be seen followed by a 
more gradual increase [166].  The initial increase is thought to be due to redistribution of CD4+ 
Drug Group Common drugs within group 
Nucleotide/nucleoside RT inhibitors Abacavir 
 Emtricitabine 
 Zidovudine 
 Lamivudine 
 Tenofovir 
Non-nucleoside RT inhibitors Efavirenz 
 Nevirapine 
Protease inhibitors Darunavir (boosted with ritonavir) 
 Atazanavir  (boosted with ritonavir) 
Fusion inhibitors Enfuvirtide 
Integrase inhibitors Raltegravir 
CCR5 antagonists Maraviroc 
BHIVA currently recommends HAART containing two nucleos(t)ide reverse 
transcriptase inhibitor plus one of the following: a ritonavir-boosted protease 
inhibitor, an NNRTI or an integrase inhibitor [144]; these combinations are shown 
with the coloured lines on the right. 
 
33 
 
T-cells from lymphoid tissues into the circulation [167].  The subsequent gradual increase is 
thought to be due to an increased production of new CD4+ T-cells [164].  Treatment is also seen 
to reduce levels of immune activation which is thought to be important in disease pathogenesis 
(see Section 1.9.1) [166].     
 
1.7   Immune Response to HIV-1 Infection 
 
As with other viral infections, infection with HIV-1 elicits both cellular and humoral adaptive 
immune responses together with the innate immune system.   
 
1.7.1   Cell-Mediated Immunity 
 
Focusing first on cell-mediated immunity, HIV-specific T-helper cells (CD4+ T-cells) assist 
cytotoxic T lymphocytes (CTLs, specialised CD8+ T-cells) to kill HIV-infected cells, which 
present viral peptides associated with class I HLA molecules [168].  CTLs are the effector arm 
of the cell-mediated immune system for which the main function is to detect and destroy cells 
infected by intracellular pathogens.  CTLs target these pathogens by two main effector 
mechanisms: lysis of the target cell via Fas–FasL interaction or lysis by the delivery of 
granzymes and perforin to the target cell. Of these, the latter mechanism is the most rapid and is 
usually the most important in anti-viral defence [168]. Most HIV-1 infected individuals have 
very high numbers of virus-specific CTLs compared with the number of antigen-specific CTL 
produced during other viral infections [169]; it is not completely understood why viral 
replication continues in spite of this strong CTL response.  Nevertheless, HIV-specific CTL 
appear to play a crucial part in control of HIV-1 based on several observations.  During primary 
infection, there is a temporal relationship between HIV-1 and the virus-specific CTL response 
since these CTL appear in the blood just before viral RNA-load peaks.  This population then 
expands and contracts as viral RNA-load falls [170, 171].  Work with SIV-infected rhesus 
macaques demonstrated that during primary infection, viral RNA-load was not controlled in 
monkeys depleted of CD8+ lymphocytes (including T-cells and natural killer (NK) cells but 
predominantly CTLs) using anti-CD8 monoclonal antibody [172].  Therefore, HIV-specific 
CTLs appear crucial in bringing the high level viraemia during primary infection under control.   
 
Whilst in an acute viral infection, the efficiency of the CTL response is in general correlated 
with the frequency of virus-specific CTL, this association is less clear for chronic viral 
infections [173].  CTL proliferate in response to antigen, so therefore the frequency of CTL 
may be both a cause and an effect of the viral RNA-load [173, 174].  Indeed, work with SIV-
34 
 
infected rhesus macaques shows that in chronic infection CTL frequency is the cause of low 
viral RNA-loads, since depleting these cells during chronic infection led to a significant rise in 
viral RNA-load that was again suppressed when SIV-specific CD8+ lymphocytes were 
reinstated [172].  However, interpretation of the fact that there is an inverse relationship 
between frequency of HIV-specific CTL activity and viral RNA-load [175, 176] is more 
difficult.  Two competing explanations are that higher CTL frequency leads to control of viral 
RNA-load or higher viral RNA-load leads to greater HIV-induced immunosuppression leading 
to CTL loss.  The former rather than the latter appears to be the case, since when HIV-infected 
patients with high viral RNA-load are treated with ART, thus decreasing viral RNA-load, HIV-
specific CTLs are also seen to decrease [177-179].  However, the situation is likely to be more 
complicated than this given positive and negative correlations may be found at the same time in 
the same individual between viral RNA-load and CTL specific to different HIV-1 epitopes 
[180].  A potential explanation might be that ‘driver’ CTL specific to certain epitopes control 
the viral replication and hence viral RNA-load, whereas ‘passenger’ CTL specific to other 
epitopes proliferate in response to viral antigen without themselves having an effect on viral 
RNA-load [181].   
 
Further to the size of the CTL pool is the efficiency or ‘quality’ of the CTL response.  It has 
been demonstrated that HIV-specific CD8+ T-cells from viraemic patients are often 
dysfunctional.  This is demonstrated by low levels of perforin expression [182, 183], limited ex 
vivo killing capacity [184] and restricted cytokine production [180].  Polyfunctionality of HIV-
specific CD8+ T-cells (perform multiple effector functions simultaneously, including the 
secretion of several cytokines and chemokines as well as degranulation) is associated with 
control of viral RNA-load [185].  Furthermore, patients without progressive infection exhibit 
increased frequencies of polyfunctional HIV-specific T-cells compared with those with disease 
progression [186].  A greater breadth of virus specific CTL by analysis of their T-cell receptor 
(TCR) repertoire has also been shown to be associated with better clinical status [187].  In 
addition, antigen sensitivity (functional avidity) of epitope-specific CD8+ T-cells is associated 
with an effective HIV-specific T-cell response [186].   
 
CTL determinant selection appears to be important in control of viral replication.  A number of 
studies have found a positive association between responses targeted to Gag and viral control 
[188, 189].  One explanation which has been proposed for this is that changes in the Gag 
protein which facilitate viral escape may only occur to a certain extent before the associated 
change in structural or functional aspects of the protein leads to a compromise in replicative 
fitness [190].   
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Further evidence that CTLs have a significant role in ongoing containment of the virus comes 
from studies demonstrating that they select virus escape mutations as early as 30–54 days after 
the peak viral RNA-load of acute infection [83, 191] and continue to select mutations 
throughout chronic infection [192-194].  Correlation has been demonstrated between certain 
escape mutants and the prevalence of particular restricting class I HLA alleles in different 
cohorts [195].   
 
Since viral escape from effective CTL is often associated with a cost in terms of replicative 
fitness [190], it could be predicted that specific class I HLA alleles would influence the rate of 
disease progression.  This has indeed been shown to be the case as class I HLA alleles B57, 
B5801 and B27 are associated with slower progression to AIDS than individuals without these 
alleles [196-198]. 
 
The CD4+ T-helper cell response is essential in maintaining effective CD8+ T-cell responses to 
HIV-1.  The ‘help’ provided by the CD4+ T-cells enables CD8 T-cells to undergo secondary 
expansion upon re-stimulation [199].  They are activated when they bind a viral epitope 
presented on class II HLA molecules.  Upon activation they secrete interleukin-2 (IL-2) and 
other cytokines that enhance the CTL and humoral responses [200].  Levels of these cells are 
likely to be affected since CD4+ T-cells are the main target population for HIV-1.  However, the 
fact that CD4+ T-cell proliferative responses to p24 antigen (but not to cytomegalovirus antigen) 
in HIV-infected individuals were increased by administration of CD40 ligand and IL-12 (both 
agents which enhance responsiveness to antigen) suggests that qualitative differences, rather 
than merely depletion, may contribute to unresponsiveness in this compartment [201].   
 
1.7.2   Host-derived Suppression of the CTL Response  
 
As chronic infection ensues, HIV-specific CTLs typically begin to lose function [182, 184, 202].  
This may be a result of persistent antigenic stimulation, leading to chronic immune activation 
which can lead to immune exhaustion [203].  Regulatory T-cells (Treg) and T helper (Th) 17 
cells are two recently described lymphocyte subsets with opposing actions which appear critical 
to regulation of the CTL response.  Treg regulate chronic inflammation by suppressing the 
activation and proliferation of effector lymphocytes and therefore maintain tolerance to self-
antigens, but may also limit the vigor of the antimicrobial immune response [204].  Treg are 
CD4+ T-cells which constitutively express CD25 and CTLA-4, in addition to the transcription 
factor Foxp3+ [205].  The effect of Treg in HIV-1 infection is unclear since they may act to 
reduce activation (immune activation may drive HIV-1 pathogenesis, see Section 1.9.1) but 
may also limit HIV-specific adaptive responses [206].  Many studies report an expansion of this 
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population in the peripheral blood in HIV-1 and SIV infection [207, 208] and yet others find a 
decrease [209].  The differing methods used to identify these cells may account for these 
conflicting reports.  Detection of Treg in lymphoid tissue has been reported to be associated with 
viral RNA-load [209] and disease progression [210].  Further evidence for a role in chronic 
HIV-1 infection comes from the fact that depletion of CD4+CD25+ T-cells from peripheral 
blood mononuclear cells (PBMCs) from HIV-1 infected donors results in increased virus 
specific T-cell responses [211, 212].  Th17 cells appear to enhance host defences against 
infection and consequently appear to drive inflammation [213].  Further to this, it appears that it 
is an imbalance of Treg cells and Th17 cells which drives the pathogenesis of chronic viral 
infections such as hepatitis B [214].  Progressive HIV-1 infection has been shown to be 
associated with a decreased proportion of memory Th17 cells and a reciprocal increase in Treg 
cells [215].   
 
Several studies have examined the role of programmed-death 1 (PD-1), an inhibitory molecule 
upregulated on T-cells during HIV-1 infection [216].  Studies have been conflicting in terms of 
whether PD-1 expression (and the associated decreased CD8+ proliferative capacity seen) is an 
effect of high viral RNA-load [217] or whether its expression and associated T-cell dysfunction 
causes higher viral RNA-load [218].  Recent work suggests PD-1 is not merely a marker of 
viral RNA-load and exhaustion, since PD-1 blockade in vitro restores HIV-specific T helper 
responses [219].   
 
1.7.3   Humoral Immunity 
 
Following primary infection with HIV-1 and the subsequent development of specific CD4+ T-
cells a HIV-1 specific antibody response is detectable, although most of these antibodies are 
directed against virion debris [220].  Subsequently antibodies which bind to epitopes critical to 
viral entry are formed; these antibodies are termed ‘neutralising antibodies’ (nAb) due to their 
ability to block infection of susceptible cells [221].  For many years, it was thought that nAbs 
played little or no role in control of viral RNA-load during acute infection as these antibodies 
were found to be largely absent during this period [222-224].  Studies are likely to have been 
hampered by the fact that nAb responses to autologous viruses are difficult to measure because 
of the technical challenges associated with the preparation of autologous virus stocks.  However, 
subsequent studies show that these antibodies can develop within weeks of infection and so may 
contribute to early control of viral RNA-load [225, 226]. 
 
Most often the nAb response is highly isolate-specific, i.e. efficient responses against 
heterologous isolates are rare.  However, in some individuals the response matures and becomes 
37 
 
cross-neutralising, with prevention of infection by divergent strains (broadly nAbs) [227, 228].  
nAbs are typically directed against functionally important receptor and co-receptor binding sites 
in the gp120 subunit, and antibodies against the ectodomain of gp41 subunit have been 
identified.  In general, it appears that nAbs directed against gp120 are more potent but not as 
broad as nAbs against gp41 [229, 230]. 
 
Longitudinal studies show that HIV-1 rapidly escapes the nAb [226, 231, 232], which drives a 
continual evolution of envelope proteins.  This escape is so rapid it is considered to be the 
reason many studies show weak or no neutralisation of autologous virus by contemporaneous 
Abs [225, 226].   
 
The binding of antibody to the virion or infected cells may trigger downstream effector 
functions through its Fc portion.  Effector functions include activating the complement cascade 
or opsonisation by binding Fc receptors and can both reduce and enhance virus replication 
through different mechanisms [233].   
 
The HIV-1 virus employs a wide range of mechanisms by which it evades immune antibody 
recognition.  The Env spikes on the virion surface are largely protected through occlusion of 
epitopes within the trimeric structure [234], steric and conformational blocking of the receptor 
binding sites [235] and extensive glycosylation [226, 236].   
 
1.7.4   Innate Immunity 
 
NK cells, a central component of the innate immune system, have been found to play a 
significant role in the control of HIV-1 replication [237-239].  This effect is found to occur as a 
result of cell-mediated cytotoxicity as well as noncytolytic suppression of viral replication 
through the production of chemokines [240].  In addition, HIV-binding antibodies allow NK 
cells to mediate antibody-dependent cellular cytotoxicity (ADCC), which probably also 
contributes to control of virus [241].  Given the central role of NK cells in HIV-1 control, it is 
not surprising the virus has developed mechanisms to avoid killing by these cells.  For example, 
there is evidence for HIV-1 Vpu-mediated down modulation of NTB-A [242], which is 
important since NTB-A is a co-activating receptor necessary for NK cytolysis.   
 
The result of the interplay between host immune response and viral replication during the acute 
phase is the establishment of a viral RNA-load set point a few months after infection.  This is an 
important value since the higher it is the faster the rate of disease progression [243, 244].  
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1.8   Prevention of HIV-1 Infection 
 
Education about routes of transmission remains central to the prevention of infection and 
curbing the epidemic.  Numerous other interventions to prevent HIV-1 infection have also been 
studied.  Mother-to-child transmission may be reduced from around 25% to as low as 1% by 
starting the mother on ART during pregnancy, Caesarian section, post-exposure prophylaxis 
with ART for the neonate when born and avoidance of breast-feeding [53].  A body of evidence 
has accumulated suggesting male circumcision may have a protective effect against HIV 
acquisition.  This observation may be explained by the large number of HIV-susceptible 
dendritic cells in the foreskin [245].  Whilst the mechanism is not completely understood, it 
may be that this becomes part of effective HIV-prevention programmes [246].   
 
Other prevention strategies which employ the use of ART include post-exposure prophylaxis 
following needle-stick accidents, where an 81% reduction in the risk of infection is seen [247].  
Topical antiretrovirals such as tenofovir gel applied to the vaginal vault have been used to 
prevent transmission, with one study finding an overall 39% reduction in HIV-1 acquisition 
[248].  Trials using polyanionic microbicides have failed and may even have led to increased 
transmission [249].  The use of CCR5 antagonists as topical agents has a particularly strong 
rationale, and has been shown in rhesus macaques to protect against infection with CCR5-using 
virus [250].  Pre-exposure prophylaxis with oral ART has been studied in a large randomised 
double blind placebo controlled trial using once daily tenofovir with emtricitabine; a 75% 
reduction in HIV-1 transmission in serodiscordant heterosexual couples was observed [251].   
 
It is widely believed the development of an effective vaccine is the most cost-effective and 
globally applicable public health approach to controlling the epidemic.  The major difficulty in 
development is the marked heterogeneity of the virus [25].  Work in nonhuman primate models 
have demonstrated the protective effect of nAbs [252].  Furthermore, in humans the lack of nAb 
response to HIV-1 predisposes to superinfection [253].   
 
Unfortunately, most vaccine trials have not demonstrated efficacy [254].  However, one trial 
using a prime/boost vaccine (RV144), which induces antibodies which bound but do not 
neutralise the virus, demonstrated a modest 31% reduction in the acquisition of infection [255].  
No effect on post-infection viral RNA-load or CD4+ T-cell count was seen in vaccinees who did 
acquire the virus.  In addition, numerous T-cell vaccines have been developed which were 
hoped to protect from disease progression rather than from infection itself.  As yet these have 
been unsuccessful, with one trial which used a recombinant adenoviral vector containing viral 
proteins reporting an increased likelihood of acquisition in those receiving the active vaccine 
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[256].  This finding highlights the extreme complexity of immune protection and response to 
infection, and the fact that understanding of these is not yet complete. 
 
1.9   Mechanism of CD4+ T-cell Depletion in HIV-1 Infection  
 
The mechanisms leading to progressive decline of CD4+ T-cells in HIV-1 infection are still not 
yet fully understood.  The fact that higher viral RNA-load appears to predict CD4+ T-cell 
decline and that HIV-1 is cytopathic for T-cells in vitro initially suggested that progressive 
decline of these cells in vivo may be due to the direct effects of ongoing infection of these cells 
(over and above supply of new cells from the thymus).  However, subsequent studies have 
shown that during chronic HIV-1 infection more CD4+ T-cells die than can be accounted for by 
direct infection [257] and an increased death rate is observed even in non-target cells, such as 
CD8+ T-cells [258], suggesting an alternate mechanism.  Furthermore, it appears that the extent 
of viral replication as measured by viral RNA-load may explain less than half of the variability 
in the rates of CD4+ T-cell decline [259, 260].  Consequently, death of uninfected bystander 
cells via apoptosis has been proposed to play a major role in CD4+ T-cell death [261].   
 
1.9.1   Generalised Immune Activation in HIV-1 Infection  
 
One process by which HIV-1 might lead to apoptosis of uninfected T-cells is as a result of 
immune activation [262].  Chronic HIV-1 infection is characterised by high levels of activation 
of both CD4+ and CD8+ T-cells [263].  Other studies which support this include that by Giorgi 
et al. which demonstrated that immune activation of CD4+ and CD8+ T-cells (upregulated CD38 
expression) was strongly associated with shorter subsequent survival [264].  Sousa et al. 
demonstrated that in HIV-1 infection CD4+ T-cell depletion was associated with higher levels 
of CD4+ (upregulated HLA-DR and CD69 expression) and CD8+ T-cell activation (upregulated 
HLA-DR and CD38 expression) [265].  This group also report similar immune activation levels 
in HIV-1 and HIV-2 for a given CD4+ T-cell count, despite the much lower viral RNA-load in 
HIV-2 infection [265].  Other investigators have similarly reported a correlation between 
immune activation and disease progression in HIV-1 infection [263], with a stronger correlation 
of CD4+ T-cell decline with immune activation than with viral RNA-load [266, 267].   
 
Compelling evidence for the importance of T-cell activation in the pathogenicity of HIV-1 
comes from the study of natural and non-natural SIV infection.  As discussed in Section 1.1, 
wild primates in Africa frequently harbour natural SIV infection.  SIV infection of Asian 
primates, such as rhesus macaques, is not seen in the wild [268].  Silvestri et al. showed that 
although SIV MM infected sooty mangabeys (i.e. the natural host of the virus) develop high 
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viral RNA-loads, they do not experience CD4+ T-cell depletion or simian AIDS and increased 
T-cell activation is not seen (CD4+ T-cell activation as demonstrated by HLA-DR expression, 
CD8+ T-cell activation as demonstrated by CD69 expression).  By contrast when rhesus 
macaques are infected with SIV MM (i.e. not the natural host of this virus) chronic activation is 
seen with progression to simian AIDS [269].  Other investigators have since published similar 
findings implicating immune activation in pathogenicity of non-natural SIV infection [270, 271].  
The exact mechanisms underlying this phenomenon are still not completely understood, but it 
has been proposed that hosts of natural SIV down-regulate the immune responses to SIV via 
immune regulatory pathways [272].   
 
The process leading to HIV-induced immune activation is not well understood.  A potential 
mechanism which has been proposed is that HIV-1 Nef lowers the threshold required for T-cell 
activation via TCR stimulation [273].  Defective virions [274] and altered cytokine spectra 
[275] during HIV-1 infection have also been suggested as potential mechanisms leading to 
immune activation.  It has also been suggested to result from breakdown of the mucosal barrier 
due to the massive depletion of CD4+ T-cells at this site.  This may lead to the translocation of 
microbial products, such as bacterial lipo-polysaccharide (LPS), from the intestinal lumen to the 
systemic circulation, causing generalised immune activation [276].  
 
It is clear that immune activation is likely to be beneficial for HIV/SIV since the virus replicates 
far more efficiently in activated CD4+ T-cells compared with resting CD4+ T-cells [111, 277].  
Furthermore, bystander activation of uninfected CD4+ T-cells increases susceptibility to 
infection and subsequent virus production in vivo [112].  In this way it is likely the virus 
maintains the supply of target activated CD4+ T-cells despite overall declining numbers of 
CD4+ T-cells [112].   
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1.9.2   Specific Targeting of CD4+ T-cells by HIV-1 
 
Although there is significant evidence implicating immune activation in the mechanisms 
leading to CD4+ T-cell destruction, it is not fully understood why there is selective depletion of 
CD4+ T-cells when HIV-1 activates both CD4+ and CD8+ T-cells [265].  One proposed 
mechanism which may account for the specific destruction of CD4+ T-cells involves interferon 
(IFN)-α, a cytokine commonly produced directly in response to viral infection.  HIV-1 gp120 
induces monocyte and dendritic cell IFN-α production in vitro [278].  These in vitro models 
demonstrate that IFN-α may drive CD4+ T-cell apoptosis and death by upregulating TNF-α 
related apoptosis inducing ligand (TRAIL) expression in CD4+ cells [278, 279].  However, this 
proposal is far from clear since IFN-α has been shown to inhibit HIV-1 replication in vitro [280, 
281] and in vivo, albeit to a modest extent [282, 283].  In addition, there is evidence suggesting 
IFN-α may protect T-cells from apoptosis [284], highlighting further the complexity of its 
action in this setting. 
 
Another mechanism which might account for apoptosis of uninfected CD4+ T-cells results from 
interaction with the HIV-1 surface Env.  Env has long been suspected to be a likely candidate 
for inducing bystander cell death, since it is expressed on the surface of infected cells and is 
therefore readily available for interaction with nearby uninfected cells.  As it binds CD4 and co-
receptors, this might account for specific depletion of CD4 expressing T-cells [285].  Env may 
lead to bystander death through gp41-mediated hemifusion.  Hemifusion is a process whereby 
the outer membrane of the Env-expressing infected cell and bystander cells interact transiently 
without fusion causing membrane destabilisation and apoptosis in the uninfected cell [286].  In 
keeping with this, an in vitro study showed that a mutation in the fusion domain of gp41 results 
in a fusion-defective Env unable to induce apoptosis [286].  Whatever the balance of these 
alternate mechanisms, it is likely that the accelerated apoptosis of CD4+ T-cells in HIV-1 
infection is multifactorial [287].   
 
A further process by which Env may result in specific depletion of uninfected CD4+ T-cells in 
HIV-1 infection is NK cell-mediated killing of these cells.  This is thought to be a result of 
recognition of cellular ligand of NKp44 on CD4+ T-cells [288].  NKp44L expression on CD4+ 
T-cells is thought to be induced by a portion of HIV-1 gp41 [288].   
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1.9.3   Sequestration or Impaired Production of CD4+ T-cells in HIV-1 Infection 
 
Sequestration of CD4+ T-cells to secondary lymphoid tissues or other sites is another possible 
mechanism leading to apparent depletion of circulating CD4+ T-cells.  Circulating CD4+ T-cells 
represent only 1–2% of the body's total reservoir, with large proportions in muscoal sites and 
secondary lymphoid tissue [289].  Enhanced sequestration to secondary lymphoid tissues during 
chronic HIV-1 infection is supported by the observation that ART leads to increased circulating 
CD4+ T-cells due to redistribution from these sites [290].  The ability of lymphocytes to migrate 
to specific areas of the body, such as the skin or the gut, is mediated in part by cell-surface 
molecules that tether cells to molecular partners expressed on the vascular endothelium at those 
sites [291].  For example, migration of lymphocytes to GI tract is mediated by integrin α4β7 
[292].    
 
The reduction in CD4+ T-cell count over time also appears to result, at least in part, from 
impaired production of T-cells.  Evidence of suppression of multi-lineage haematopoiesis has 
been demonstrated in HIV-1 infection [293, 294].  Furthermore, HIV-1 infection has been 
shown to lead to a decline of both CD4+ and CD8+ naive T-cells in the peripheral blood as 
disease progresses [265, 295, 296] which may reflect decreased thymic production.   
 
These mechanisms are not mutually exclusive.  For example, the thymus (which may be 
defective to some degree) may replenish the increased loss of T-cells resulting from chronic 
activation for some time until a threshold is reached and supply cannot meet demand.   
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1.10   HIV-1 Viraemic Controllers 
 
Patients who remain healthy or achieve viral control in the absence of ART are crucial to 
understanding of HIV-1 pathogenesis.  Initial work focused on so-called long-term 
nonprogressors (LTNPs) who are HIV-1 infected and remain asymptomatic with CD4+ T-cell 
count >500 cells/mm3 for more than 10 years without treatment.  Most but not all of these 
patients have low viral RNA-loads [297].  Attention shifted somewhat since then to those 
patients who maintain low viral RNA-load without treatment, termed viraemic controllers 
(typically defined as <2000 copies/ml but definitions vary between investigators).  A rare 
subgroup of these controllers are termed ‘elite-controllers’ since viral RNA-loads are 
consistently below the limit of detection of current standard assays (typically 40 - 50 copies/ml) 
[298].   
 
The mechanism by which this apparent control occurs is not fully characterised.  Studies on 
elite controllers using co-culture assays and full genome sequencing of virus have revealed 
replication–competent virus without any gross defects [299].  More recent studies in which 
chimeric viruses containing gene segments from virus from elite controllers have shown that 
changes in gag and pol genes from these patients contribute to a virus which has low replicative 
fitness [300].  Whether this reduced replicative fitness is due to escape from effective CTL 
response, or elite controllers are infected with a virus with impaired replicative capacity, or a 
combination of these factors, is the matter of ongoing debate [190, 301].   
 
The fact that it has been observed that an elite controller maintained control when superinfected 
with a second HIV-1 isolate would argue that the host immune response is most important 
[302].  Further support for this comes from the observation that virus has been transmitted from 
a patient who subsequently progressed to AIDS to an individual who became an elite controller 
demonstrating control of the fully pathogenic HIV-1 isolate [303].   
 
The critical importance of the cell-mediated immune response in contributing to control in 
viraemic controllers has been well documented.  For example, the protective class I HLA alleles 
B57 and B27 discussed in Section 1.7.1 are over-represented amongst viraemic controllers 
[304].  Further sites in the class I HLA-C allele have also been identified as being associated 
with viral control in this cohort using whole-genome association analysis [305].  CD8+ T-cell 
polyfunctionality, as measured by secretion of multiple cytokines, has been shown to be 
stronger in elite controllers than in those with ART-mediated viral suppression [185].  
Interestingly, nonhuman primates achieving elite control of SIV (SIVmac239 infected 
macaques), in which there is an over-representation of class I HLA alleles Mamu-B08 or B17, 
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bind similar peptides to HLA B57 and HLA B27 [306].  This suggests that determinant 
selection is important in control of virus [306].  In line with this, it has been demonstrated that 
viraemic controllers show preferential CD8+ T-cell targeting of the HIV-1 Gag protein [304].  A 
further study has also shown selection of rare Gag mutants in HLA B57/B5801 elite controllers 
(compared with viraemic individuals) which have decreased replicative capacity and are a result 
of strong CTL responses [307].  Given the key role CD8+ T-cells play in maintaining viral 
control, it is likely that CD4+ T-cell help is also important.  HIV-specific CD4+ T-cells have 
been shown to demonstrate higher functional avidity in elite controllers than in patients with 
high viral RNA-load [200].   
 
Since the GI tract has been shown to be a site of persistent HIV-1 replication and CD4+ T-cell 
depletion [308], CD4+ T-cells populations and mucosal CD8+ T-cell responses have been 
studied in elite controllers, viraemic controllers, patients with uncontrolled viraemia (‘non 
controllers’, here defined as viral RNA-load >10000 copies/ml) and individuals on ART [309].  
Mucosal CD4+ T-cells were found to be significantly higher in elite and viraemic controllers 
compared with those in non controllers suggesting preservation of this compartment.  Mucosal 
CD8+ T-cell responses in controllers (elite and viraemic together) were found to be significantly 
stronger and more complex than in those patients on ART.  In addition, there was an increased 
frequency of rectal polyfunctional CD8+ T-cell response in controllers compared with non 
controllers and individuals on ART [309].  This suggests that CD8+ T-cell responses in the gut 
mucosa play an important role in viral control in elite and viraemic controller cohorts.   
 
In keeping with observations described in progressive HIV-1 disease, elite controllers have 
been shown to have lower levels of Treg cells compared with non controllers (here defined as 
viral RNA-load > 4000 copies/ml) [310].   This group also demonstrated a Th17/ Treg ratio that 
was similar in elite controllers compared with uninfected individuals and that this was lower 
than in non controllers and patients on ART [310].  Thus it appears that control of viraemia may 
be dependent on maintaining a normal balance between Th17 and Treg. 
 
The fact that nAbs select for HIV-1 escape mutants would suggest that these antibodies provide 
a significant contribution to viral control during chronic infection [226, 231, 232].  However, 
studies suggest that elite controllers do not harbour broadly nAbs as frequently as non 
controllers [228, 311].   It was therefore investigated whether nAbs in elite controllers might be 
directed specifically to autologous virus rather than a broad range.  A study by Bailey et al. 
showed that this was not the case since elite controllers had similarly low levels of nAbs to 
autologous, contemporaneous plasma virus compared with progressors  [312].    Low levels of 
nAbs in elite controllers may result from lack of antigenic stimulation, as suggested by low 
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plasma viral RNA-load.  Based on these observations it is currently unclear what contribution 
nAbs make to the elite or viraemic controller phenotype.    
 
Since HIV-1 DNA-load is associated with disease progression [313], this would predict that 
elite and viraemic controllers would have lower levels since rates of progression are slower in 
these groups.  In keeping with this Lambotte et al. studied 15 viraemic controllers from a cohort 
in France and found very low and stable HIV-1 DNA-loads in PBMC in all patients [314].   
 
It is likely that control of viral RNA-load is multifactorial; the specific complexities of that 
control are the subject of much ongoing research.   
 
Whilst low HIV-1 RNA-loads tend to be associated with more stable CD4+ T-cell counts [243, 
315] this is not the case for all patients.  Madec et al. identified 145 viraemic controllers (viral 
RNA-load <500 copies/ml) and found five experienced CD4+ T-cell decline [316].  Pereyra et 
al. examined 90 elite controllers (<50 copies/ml) and found that six patients had a median CD4+ 
T-cell counts of <500 cells/mm3 and two patients had a median of <300 cells/mm3 [317].  
Okulicz et al. compared CD4+ T-cell counts in 25 elite controllers with those in 153 viraemic 
controllers (viral RNA-load <2000 copies/ml).  Elite controllers experienced prolonged stability 
of their CD4+ T-cell count, whereas viraemic controllers demonstrated gradual decrease in 
CD4+ T-cell over time [318].  Boufassa et al. studied a group of 106 viraemic controllers 
(unconventional definition of viral RNA-load <400 copies/ml) and found that CD4+ T-cell 
counts fell in subgroups which experienced transient increases in viral RNA-load [319].   
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1.11   The Aims of this Thesis  
 
Prior to starting the work described in this thesis, a notable number of patients were being 
identified in the HIV clinics in East London with control of viraemia (viraemic controllers) and 
yet low CD4+ T-cell counts.  At that time only one of the papers described in the last section on 
this patient group was published [316]. 
 
For this reason work described in this thesis was designed to define this population of viraemic 
controllers with low CD4+ T-cell counts, referred to here as ‘discord controllers’, and to 
determine what features might distinguish them from ‘typical controllers’, those viraemic 
controllers with normal CD4+ T-cell counts. 
 
The specific aims of the work submitted were to: 
 
• Determine whether there are epidemiological or virological factors that distinguish 
discord controllers from typical controllers (Chapter 2).   
• Establish whether ART in discord controllers results in recovery of CD4+ T-cell counts 
(Chapter 2). 
• Determine whether changes in the T-cell compartment typically associated with HIV-1 
disease progression (naïve T-cell depletion and T-cell activation) are more marked in 
discord controllers compared with typical controllers (Chapter 3). 
• Determine whether HIV-1 DNA-loads are higher in discord controllers compared with 
typical controllers (Chapter 4).    
• Determine whether HIV-1 DNA-load in viraemic controllers predicts subsequent HIV-1 
RNA-load peak values or change in CD4+ T-cell counts (Chapter 5).   
• Investigate whether there are higher levels of migration of CD4+ T-cells to the GI tract in 
discord controllers (Chapter 5). 
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CHAPTER 2 
 
 
Epidemiological and Virological Characteristics of Discord 
Controllers and Typical Controllers, and Response to 
Antiretroviral Treatment of Discord Controllers  
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2.1   Introduction 
 
Viraemic controllers are rare patients with the capacity to control viral RNA-load in the absence 
of ART [298].  The reasons why control of viral RNA-load is possible in these patients is 
incompletely understood.  This cohort is composed of both viraemic controllers defined as those 
patients whose viral RNA-loads are below 2000 copies/ml and elite controllers in whom viral 
RNA-load is consistently below the limit of detection of current standard assays (typically 40 - 
50 copies/ml) [298, 304].  Whilst these patients usually maintain normal CD4+ T-cell counts, a 
subset have low or declining CD4+ T-cells counts as described previously [320, 321]; these 
patients are referred to here as ‘discord controllers’.   
 
The first aim of work described in this Chapter was to determine whether there are 
epidemiological features or viral factors which distinguish discord controllers (low CD4+ T-cell 
count) from typical controllers (normal CD4+ T-cell count).  To do this a local cohort of 
viraemic controllers was identified, with identification of the subset within them with low CD4+ 
T-cell counts (<450 cells/mm3); this group was then compared with those patients with normal 
CD4+ T-cell counts (>450 cells/mm3).  Whilst other groups have recorded age, sex and ethnicity 
of viraemic and elite controllers [304, 318], these groups did not examine how epidemiological 
characteristics were represented in viraemic controllers with normal CD4+ T-cell counts 
compared with those with low CD4+ T-cell counts as is presented here.   
 
The second aim of work described in this Chapter was to determine CD4+ T-cell count change 
over time in discord controllers started on ART to further determine whether their low CD4+ T-
cell counts were normal for the particular patient or a result of HIV-1 driven depletion; this 
latter possibility would be supported by CD4+ T-cell gains whilst on ART.  It was also 
considered of clinical interest to record whether CD4+ T-cell counts recover in the same way 
that they do in non controllers started on ART.  This was reported on during the course of this 
work by another group [322].  Findings presented here are compared and contrasted with 
findings by that group.  
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2.2   Methods 
 
The research protocol for work described in this and subsequent Chapters was approved by East 
London and The City Local Research Ethics Committee (No. 06/Q0603/59). 
 
2.2.1   Study Groups 
 
Patients were recruited, after obtaining informed consent, from outpatient clinics at Barts and 
The London NHS Trust and Homerton University Hospital Trust.   All patients were shown to 
be HIV-1 seropositive and HIV-2 seronegative with the exception of one patient.  For this 
patient, on whom serology was not available, sequence analysis of virus from blood 
demonstrated HIV-1 infection.   Elite controllers were defined as those with undetectable viral 
RNA-load, although occasional non-consecutive blips of viral RNA-load up to 1000 copies/ml 
were permitted.  Viraemic controllers were defined as those viraemic controllers who did not fit 
within the elite controller definition but have viral RNA-load below 2000 copies/ml.  Both 
definitions are based on at least three viral RNA-load measurements over at least 12 months 
without ART.  Patients were permitted to have been treated with ART previously (e.g. during 
pregnancy), as long as control based on three viral RNA-load over at least 12 months could be 
demonstrated.  These definitions are in line with those used by the International HIV Controller 
Consortium [298].  The viraemic controller cohort as a whole was divided into two groups 
based on the geometric mean of the last three CD4+ T-cell counts: typical controllers with >450 
cells/mm3 and discord controllers with <450 cells cells/mm3.   
 
Epidemiological data was recorded including age, sex, ethnicity, country of birth, and blood 
borne virus risk behaviour.  Date of first positive HIV-1 test was also recorded.  Co-morbid and 
intercurrent illnesses during follow-up were recorded for each patient.   
 
Patients followed up in the clinic were seen at 4 to 12 monthly intervals and had blood taken for 
routine laboratory evaluation including CD4+ T-cell count and viral RNA-load.   
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2.2.2   Routine HIV-1 RNA-load and CD4+ T-cell Measurements 
 
For patients recruited from Barts and the London NHS Trust, routine laboratory CD4+ T-cell 
counts and percentages were analysed by Barts and the London NHS Trust Department of 
Immunology.  The blood samples were processed with the BD FACS Sample Prep Assistant 
with Trucount beads and were then acquired on a BD FACSCanto II flow-cytometer.  
FACSCanto clinical software was used for data analysis.  Samples from patients recruited from 
Homerton University NHS Trust were processed by ‘The Doctors Laboratory’ using the 
Beckman Coulter Navios Flow cytometer. 
 
HIV-1 RNA-load was measured using Roche Ampliprep/COBAS Taqman HIV-1 Test v1.0 
(Roche Molecular Systems, Inc., Blanchburg, New Jersey; detection limit of 40 copies/ml).  At 
least one sample from each patient was also tested using a different assay to confirm the low 
viral RNA-load and thus ensure that the initial result was not simply due to underquantification 
by a single platform.  These assays were carried out by Barts and the London NHS Trust 
Diagnostic Virology Laboratory.   
 
Individual patient viral RNA-load and CD4+ T-cell counts are reported as the geometric mean 
of the last three measurements.  In addition to determining mean absolute CD4+ T-cell counts in 
each controller cohort, mean CD4+ T-cell percentage was calculated.  This was done by 
calculating the mean of the last three CD4+ T-cell percentage values.  If a patient had achieved 
viraemic control (viral RNA-load <2000 copies/ml) but subsequently viral RNA-load rose 
above this, the last date of viraemic control was determined to be the last date a viral RNA-load 
measurement would still contribute to a geometric mean of <2000 copies/ml.  The three viral 
RNA-load and CD4+ T-cell values prior to this date were used to calculate the mean for that 
patient.  Similarly, for patients who started ART during follow-up the three viral RNA-load and 
CD4+ T-cell values prior to starting ART were used to calculate the mean.   
 
Those discord controllers who were started on ART were followed: viral RNA-load, absolute 
CD4+ T-cell count and CD4+ T-cell percentage were recorded.   
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2.2.3   HIV-1 Subtype Analysis 
 
Some HIV-1 subtype data was available as part of the anti-retroviral resistance testing 
(sequence obtained from pol: whole of protease and amino acid 1-335 of reverse transcriptase).  
This was carried out by Barts and the London NHS Trust Diagnostic Virology Laboratory.  The 
assay has demonstrated efficacy in identifying a wide variety of subtypes including recombinant 
subtypes [67].  Other papers have demonstrated subtype determination (including recombinant 
subtypes) using assays which amplify this region of pol [323, 324].  This laboratory provides 
HIV-1 anti-retroviral testing widely for North-East and East London; the population of patients 
for which the laboratory provides HIV-1 assays will be referred to from here as the East London 
HIV-1 population.   
 
For patients on whom anti-retroviral resistance testing was unavailable, previously described 
env [325] and gag [323] nested PCRs were used in parallel to accurately determine recombinant 
subtypes.  DNA for this was extracted from cryopreserved PBMCs, prepared by Ficoll-Hypaque 
separation of ethylenediaminetetraacetic acid (EDTA) anticoagulated blood (see Appendix I), 
using the Qiagen EZ1 biorobot and DNA Tissue programme according to the manufacturer’s 
instructions into a 200µl eluate. 
 
For the env PCR a final 25µl PCR mixture containing 5µl of the DNA extracted from PBMC, 
10× Hotstar PCR buffer (Qiagen, containing 15mM MgCl2), additional 0.5mM MgCl, 0.2mM 
dNTPs, 0.5µM of each primer (F1 5'-TCT TAG GAG CAG CAG GAA GCA CTA TGG G-3'; 
R1 5'-AAC GAC AAA GGT GAG TAT CCC TGC CTA A-3') and 1.25 units of Taq. 
Thermocycling conditions; 95°C for 15 minutes; 40 cycles of 95°C for 30 seconds, 50°C for 30 
seconds, 72°C for 1 minute; and 72°C for 5 minutes.    1 µl of the first-round PCR product 
taken for second-round PCR in which the final concentration of reagents were the same as for 
the first except the primers which were used at a final concentration of 0.25µM (F2 5'-ACA 
ATT ATT GTC TGG TAT AGT GCA ACA GCA-3'; 5'- TCC TAC TAT CAT TAT GAA TAT 
TTT TAT ATA-3').  PCR cycling conditions were as the first round and produced a 445 
kilobase fragment.  For the gag PCR a final 25µl PCR mixture containing 5µl of PBMC DNA, 
10× Hotstar PCR buffer, additional 1mM MgCl, 0.2mM dNTPs, 0.5µM of each primer (F1 5'– 
TCACCTAGAACTTTGAATGCATGGG-3'; R1 5'–CTAATACTGTATCATCTGCTCCTGT-
3') and 1.25 units of Taq.  Thermocycling conditions; 95°C for 15 minutes; 40 cycles of 95°C 
for 30 seconds, 48°C for 30 seconds, 68°C for 1.5 minutes; and 68°C for 5 minutes.  1 µl of the 
first-round PCR product was used in each second-round PCR in which final concentration of 
reagents was the same as for the first round (F2 5'-AAAGATGGATAATCCTGGG-3'; 5'-
TCCACATTTCCAACAGCCCTTTTT-3').  Cycling conditions were 95°C for 15 minutes; 40 
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cycles of 95°C for 30 seconds, 55°C for 30 seconds, 72°C for 1 minute; and 72°C for 5 minutes, 
producing a 470 kilobase fragment.  Amplified products were detected on a 2% agarose gel and 
visualised using ethidium bromide.  The PCR product was cleaned using Qiagen QIAquick 
PCR purification kit and sequenced using the ABI BigDye Terminator V1.1, Perkin Elmer, 
Foster City, CA and an automated sequencer (ABI 3100 Genetic Analyser, used according to 
the manufacturer’s instructions).  Both strands of the PCR products were sequenced directly 
using the second round forward and reverse primers and then cleaned for processing using the 
Sodium Acetate Ethanol protocol advised by ABI.  The sequences were analysed using 
SeqScape V2.11 software.  Manual corrections were made to ensure that gaps did not alter the 
reading frame. These were submitted to the REGA online typing tool (Stanford University, 
2006) for genotype allocation, thereby allowing subtype prediction.   All nested PCR work and 
sequencing reactions were carried out as part of the work presented in this thesis.  Sequences 
generated were analysed by Dr David Bibby, in the Barts and the London NHS Trust 
Diagnostic Virology Laboratory. 
 
2.2.4   Statistical Analysis 
 
Statistical analysis and graphical presentations were performed using Prism (version 4.0, 
Graphpad) and results were considered significant if p<0.05.  To determine significant 
differences in age, time since first positive test between each cohort, a Mann-Whitney U test (2-
tailed) was applied.  Fisher’s exact test (2-tailed) was used when comparing sex distribution, 
ethnicity, country of birth, risk behaviour and subtype.   
 
Due to the rarity of viraemic controllers even in a large total HIV-1 infected cohort, power 
calculations were not undertaken to determine sample sizes; instead, all patients fulfilling the 
controller inclusion criteria and available to consent to the study were included.  Because small 
sample sizes increase the likelihood of Type II error, a lack of statistical significance in 
comparison between groups should be interpreted with caution.     
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2.3   Results    
 
2.3.1   HIV-1 RNA-load and CD4+ T-cell Values for Discord Controllers and Typical 
Controllers 
 
A cohort of 82 viraemic controllers was established:  64 typical controllers and 18 discord 
controllers.  Approximately 3000 patients attend the clinics, thus controllers represent 2.7% 
(discord controllers 0.6%, typical controllers 2.1%) of all infected patients.  Figure 2.1 shows 
viraemic controllers with low viral RNA-load (<2000 copies/ml over at least 1 year), divided 
into typical controllers and discord controllers based on CD4+ T-cells count, together with non 
controllers for comparison.      
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Figure 2.1   Mean Plasma HIV-1 RNA-load (copies/ml) and CD4+ T-cell Counts in Patients in 
HIV-1 Positive Cohorts.  Non controllers shown in green circles with a range of CD4+ T-cell 
counts are used as controls for HIV-1 DNA load data (Chapter 4), and progressors (green triangles, 
a subgroup of non controllers with low CD4+ T-cell counts) are a control group for T-cell data 
(Chapter 3).  Mean CD4+ T-cell count (cells/mm3) and mean HIV-1 RNA-load (copies/ml) were 
calculated by determining the geometric mean of the most recent three values for each patient.   
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Mean viral RNA-loads in discord controllers and typical controllers were all below 2000 
copies/ml, but were compared further in order to determine whether levels were equivalent 
below this threshold.  Viral RNA-loads were found to be indistinguishable (p=0.144, see Figure 
4.2 b).   Most patients in both cohorts had detectable viral RNA-loads below the 2000 copies/ml 
cut-off.  However, a few patients were found to be elite controllers (viral RNA-load < 40 
copies/ml, occasional non-consecutive blips): two (11.1%) of the discord controllers could be 
classed as elite controllers, and 10 (15.6%) of the typical controllers.  There was no significant 
difference of frequency of elite controller in each cohort using Fisher’s exact test.  
 
Viral RNA-loads remained stable for the majority of viraemic controllers; however, for a 
minority control was lost during follow-up.  Careful assessment of the pattern of viral control 
prior to the point at which it was lost was important in order to determine to which cohort the 
controller belonged.  For a minority of patients, classification was complicated by the fact that 
on occasion viral RNA-load was not requested during a clinic visit despite blood being tested 
for CD4+ T-cell count.  These groups of patients are described more fully in Appendix II. 
 
Typical controllers had normal CD4+ T-cell counts (median 699 cells/mm3, interquartile range 
[IQR] 550-843) similar to findings in viraemic controllers cohorts [304].  The discord 
controllers had low CD4+ T-cell counts (median 347 cells/mm3, IQR 298-407).   
 
Thirteen patients (3 discord controllers and 10 typical controllers) had been previously treated 
with ART during pregnancy, but had demonstrable control of viral RNA-load over at least 12 
months subsequently.  
 
CD4+ T-cell percentage was also recorded in discord controllers and compared with typical 
controllers in order to help determine whether low CD4+ T-cell counts were a result of specific 
depletion of this cell type or due to a lower numbers of all T-cell subsets which is seen in some 
ethnic groups.  The geometric mean of the three most recent CD4+ T-cell percentages for each 
patient in each cohort was calculated and results displayed in Figure 2.2.   
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Data presented in Figure 2.2 demonstrate that discord controllers not only have lower absolute 
CD4+ T-cell count, they also have significantly lower CD4+ T-cell percentage (p <0.0001), 
suggesting a specific depletion of CD4+ T-cells.   
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Figure 2.2   Mean CD4+ T-cell Percentage for Discord Controllers and Typical Controllers.  
Horizontal line depicts median of these values, the box represents the IQR and the whiskers the 
range of values.   Median (IQR):  typical controllers:  33.7% (23.8 – 40.0), discord controllers: 
22.3% (17.6 – 26.0).   
 
 
2.3.2   Epidemiological and Clinical Features of Discord Controllers and Typical Controllers 
 
Epidemiological characteristics were recorded for the discord controllers and typical controller 
cohorts in order to determine whether there were features that could distinguish discord 
controllers from typical controllers.  Data as displayed in Table 2.1 shows there was no 
difference in median age (p=0.44), sex distribution (p=0.79), ethnicity, region of birth or risk 
behaviour.  Co-morbid and intercurrent illness for each patient, including those which may be 
related to immunosuppression due to HIV infection, are recorded in Appendix III . 
 
There was no significant difference comparing time since first positive test (best available 
surrogate for time since seroconversion) between the two controller cohorts (p=0.25).  This, 
together with the similar age distribution, suggests that it is likely that the discord controller 
patients did not have a longer duration of HIV-1 infection than typical controllers.  
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Table 2.1   Epidemiological Characteristics of Discord Controllers and Typical 
Controllers 
Data presented in this table are median (IQR) or n (%).  amedian (IQR) of geometric mean 
calculated for each subject using the three most recent CD4+ T-cell counts and HIV-1 RNA-
loads.   
         Typical Controllers 
(CD4+ T-cell count  
>450 cells/mm3)  n = 64 
Discord Controllers 
 (CD4+ T-cell count  
<450 cells/mm3)  n = 18 
Age, years 37.5 (32.0 - 43.0) 38.5 (32.5 - 49.0) 
Female sex 35 (54.7%) 11 (61.1%) 
CD4+ T-cell count, cells/mm3  a   699.3 (550.4 - 843.1) 347.2 (298.0 - 406.6) 
HIV-1 RNA-load, log10 copies/ml a   408.5 (160.7 - 1000.0) 428.6 (100.3 - 1043.0) 
Birth Place  Europe 
                    Africa (Sub-Sahara) 
                    Caribbean 
                    South Asia 
                    Other 
25 (39.1%) 7 (38.9%) 
28 (43.7%) 10 (55.6%) 
6 (9.4%) 0 (0%) 
3 (4.7%) 0 (0%) 
2 (3.1%) (Australia. 
Ecuador) 
1 (5.5%) (New Zealand) 
Ethnicity     White British 
                    White other 
                    Black African  (Sub Saharan) 
                    Black Caribbean 
                    South Asian 
                    Other 
12 (18.8%) 3 (16.7%) 
8 (12.5%) 2 (11.1%) 
28 (43.7%) 11 (61.1%) 
11 (17.2%) 2 (11.1%) 
3 (4.7%) 0 (0%) 
2 (3.1%) (Mixed White and 
Black African; South 
American) 
0 (0%) 
Time since first positive test, years 4.5 (2.5 - 6.5) 4.6 (3.3 - 9.3) 
Risk behaviour  Heterosexual 
                          [Specified abroad] 
                          Homosexual 
                          Blood Products 
                          IVDU 
42 (65.6%) 
[26 (40.6%)] 
11 (61.1%) 
[5 (27.8%)] 
20 (31.3%) 6 (33.3%) 
1 (1.6%) 1 (5.6%) 
1 (1.6%) 0 (0%) 
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2.3.3   HIV-1 Subtypes in Discord Controllers and Typical Controllers 
 
Analysis of HIV-1 subtype in viraemic controllers was undertaken in order to determine 
whether discord controllers were different from typical controllers based on the frequency of 
subtypes isolated.  This was compared with the subtype distribution in the East London HIV-1 
population based on assays over a five year period (2004-9, 3010 patients, data was adjusted to 
remove patients with repeat testing).   
 
For those patients on whom anti-retroviral resistance testing was not available, five discord 
controllers and 13 typical controllers, a nested PCR was used to amplify regions in env and gag 
for sequencing and subtype prediction (Table 2.2).  Apart from two samples (mean viral RNA-
load of <40 and 111 copies/ml; HIV-1 DNA loads of 47.8 and 0 copies/106 CD4+ T-cells, 
respectively; see Figure 4.2), virus was successfully amplified and sequenced from all samples 
tested using the nested PCRs.  For four patients anti-retroviral testing was carried out after 
subtype prediction was obtained by env/gag nested PCRs.  Subtype prediction was found to be 
the same for four patients on whom both methods were used (one subtype C, one subtype B, 
and two subtype  CRF02_AG).  
 
The subtype distribution in the controller cohorts is shown in Table 2.2, and is also displayed 
and compared with the total East London HIV-1 infected population in Figure 2.3.   
 
There was a non-significant trend towards an increased frequency of subtype C in the discord 
controllers compared with typical controllers and the East London HIV-1 population.  In 
addition, there was a non-significant trend towards an increased frequency of subtype 
CRF02_AG in all viraemic controllers compared with the East London HIV-1 population. 
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Table 2.2   HIV-1 Subtypes in Discord Controllers and Typical Controllers 
 
 
 
afor one sample, sequence analysis of nested PCR products indicated either CRF02_AG  
or CRF09_cpx.   
 
 
 
 
 
 
 
 
 
 
 
 
 
HIV-1 subtype 
Typical Controllers  
(CD4+ T-cell count  
> 450 cells/mm3)   n = 41 
Discord Controllers  
(CD4+ T-cell count  
< 450 cells/mm3)   n =15 
B 14 (34.1%) 6 (40.0%) 
C 7 (17.1%) 6 (40.0%) 
CRF02_AG 8 (19.5%) 3a (20.0%) 
A 4 (9.7%) 0 (0%) 
F 2 (4.9%) 0 (0%) 
CRF14_BG 2 (4.9%) 0 (0%) 
Other 1 each of: D; A/C; A/D; B/D 0 (0%) 
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Figure 2.3   HIV-1 subtypes in Discord Controllers, Typical Controllers and the East London 
HIV-1 population.  Percentages displayed for the East London HIV-1 population in (a) is for those 
patient in whom HIV-1 subtype was available as part of anti-retroviral resistance assay.   
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2.3.4   Response of Discord Controllers to ART 
 
A number of patients in the discord controller cohort were started on ART during the course of 
this study.  None of these patients had AIDS at the point of starting ART (i.e. CD4+ T-cell count 
was not below 200 cells/mm3 for any of these patients, and neither did they have AIDS defining 
conditions).  Follow-up of these patients was of relevance in order to further determine whether 
their low CD4+ T-cell counts were suboptimal as would be suggested by CD4+ T-cell gains 
whilst on ART.  It was also of clear clinical interest to clinicians to record whether CD4+ T-cell 
counts recover in the same way that they do in non controllers started on ART.  Patient 2 was 
the only elite controller amongst these patients started on ART.  For the remaining patients, 
viral RNA-load was quickly suppressed to undetectable levels.   
 
Figure 2.4 demonstrates CD4+ T-cell counts where available over 24 months following start of 
ART for these patients (follow-up extended past this for Patient 4, see Table 2.3). 
 
It can be seen that several of these patients responded to ART treatment with a slow and 
progressive recovery in CD4+ T-cell counts over many months, rather than a rapid rise over 4-6 
weeks.   A rapid rise after only 1 month of ART occurred for Patient 3; CD4+ T-cell count rose 
from 249 cells/mm3 1 month before treatment to 411 cells/mm3 1 month after treatment started.  
Whilst the most significant rise in absolute CD4+ T-cell count after 1 month of ART was seen 
for Patient 3, CD4+ T-cell percentage gain by that point was greater for Patients 2, 4 and 5 than 
for Patient 3.  This is due to the fact that absolute CD8+ T-cell counts dropped significantly after 
1 month ART for Patients 2, 4 and 5 (Patient 2: 760 to 536, Patient 4: 1429 to 1005, Patient 5: 
892 to 421 cells/mm3).   
 
By the end of the observation period, a significant increase in absolute CD4+ T-cell count and 
percentage was seen for Patients 3, 4 and 5.  For Patients 1 and 2 the increase in absolute CD4+ 
T-cell count was minimal, but Patient 2 experienced a recovery of CD4+ T-cell percentage due 
to a decrease in total CD8+ T-cell count.  Longer follow-up of these patients may show further 
CD4+ T-cell gains.   
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Table 2.3   CD4+ T-cell values in five Discord Controllers following starting ART 
 
 Change in CD4+ 
T-cell count  
(cells/mm3) 
Change in 
CD4+  
T-cell %  
Change in CD4+ 
T-cell count  
(cells/mm3) 
Change in 
CD4+  
T-cell % 
Total time 
observed 
on ART 
 1 month ART Total increase during time 
observed on ART 
Patient 1 +16 0 +45 +4 12 months 
Patient 2 -23 +6 +50 +10 18 months 
Patient 3 +162 +3 +165 +13 19 months 
Patient 4 -6 +4 +244 +12 42 months 
Patient 5 -1 +12 +157 +19 22 months 
 
 
 
 
In summary, a cohort of 82 viraemic controllers was established comprising 64 typical 
controllers and 18 discord controllers with equivalent viral RNA-loads.  The lower absolute 
CD4+ T-cell count in discord controllers also represented a lower CD4+ T-cell percentage 
suggesting specific depletion of these cells in this cohort.  Epidemiological characteristics in 
each cohort were similar.  No evidence was found for longer duration of HIV-1 infection in 
discord controllers as time since diagnosis and age were also indistinguishable comparing the 
groups.  HIV-1 subtype distribution was similar comparing the controller cohorts, with a non-
significant trend towards increased frequency of subtype C in discord controllers.  Three of five 
discord controllers started on ART experienced slow but progressive CD4+ T-cell recovery, 
with recovery of CD4+ T-cell percentage but not absolute count in a further patient due to a 
decrease in total CD8+ T-cell count.   
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2.4   Discussion 
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Figure 2.4   CD4+ T-cell Count and Percentage in Five Discord Controllers Following 
Starting ART.  CD4+ T-cell values at the point of starting ART available for only patient 5.  For 
the other patients the values shown before 0 months are those taken within three months prior to 
starting ART.    
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2.4   Discussion 
 
The purpose of work described in this Chapter was to determine whether there were 
epidemiological or viral factors such as HIV-1 subtype which could distinguish discord 
controllers from typical controllers.  Additionally, follow-up of discord controllers started on 
ART was undertaken to determine whether CD4+ T-cell counts recovered on ART (which 
would further suggest initial low counts result from CD4+ T-cell loss rather than a normal low 
level due to ethnic variation).   
 
The cut-off of 450 CD4+ T-cells/mm3, used to distinguish typical from discord controllers, was 
selected based on the fact that many laboratories define a normal CD4+ T-cell count to be above 
this value [326].  In addition, the ‘When to start consortium’ [157] have found decreased 
mortality is derived from starting ART in the range 351-450 cells/mm3 rather than waiting for 
counts to drop below 350 cells/mm3.  This further supports the notion that CD4+ T-cell counts 
below 450 cells/mm3 are suboptimal.   
 
All of the patients studied here have viral RNA-loads which are much lower than is usual 
without ART treatment for HIV-1.  In the majority of these patients their immune system does 
not appear to be affected by this low level replication, as far as can be determined with routine 
laboratory surveillance: absolute CD4+ T-cell counts and CD4+ T-cell percentage.  As a result 
these patients typically remain clinically well and do not require treatment with ART.  This is in 
keeping with the fact that low viral RNA-loads usually predict more stable CD4+ T-cell counts 
[243, 244].  However, it is clear from this study that a significant subset do suffer significant 
CD4+ T-cell losses; indeed, 22% of the viraemic controller cohort were found to have 
suboptimal CD4+ T-cell counts and therefore were categorised at the study outset as being 
discord controllers.   
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2.4.1   HIV-1 RNA-load and CD4+ T-cell Values in Discord Controllers and Typical 
Controllers 
 
Viral RNA-load set-point is associated with the rate of disease progression [243, 244, 327].  
Whilst both discord controllers and typical controllers have controlled viral RNA-loads, it was 
important to determine whether viral RNA-loads were comparatively lower in typical 
controllers, which could be viewed as an explanation for higher CD4+ T-cell counts.  There 
were elite controllers in both groups, with a non-significant trend towards more in the typical 
controller cohort.  This is in keeping with the fact that elite controllers have more stable overall 
CD4+ T-cell count trends than do viraemic controllers [318].  Viral RNA-loads were found to 
be similar comparing the two groups (see Figure 4.2 b), suggesting that a relative difference 
here cannot to be proposed to account for lower CD4+ T-cell counts in discord controllers.   
 
To eliminate the effect of the possibility of varying efficiencies of different viral RNA-load 
assays on HIV-1 isolates of differing subtype, patients were not classed as viraemic controllers 
unless their viral RNA-load had been tested on at least two different assay platforms and found 
to have a viral RNA-load  of  <2000 copies/ml on each.  PCRs designed to quantify HIV-1, 
including those used in this study, rely on nucleic acid-based amplification with detection of 
specific target sequences.  Consequently, mismatches at primer and probe sites due to the 
genetic variability of HIV-1 have the potential to reduce the efficiency of hybridisation, 
resulting in the inability to detect viral RNA-load accurately [328].  Any single viral RNA-load 
assay platform will underquantitate a small percentage of the time given the inherent 
heterogeneity of HIV-1 species, hence the need to confirm an atypically low result using a 
second assay.   
 
For three viraemic controllers, control of viral RNA-load was lost during follow-up.  It is 
possible that this was a result of super-infection with another virus; this has previously been 
shown to be a cause of loss of control of viral RNA-load [329].  Sequential analysis of infecting 
virus during viraemic control and after control was lost would therefore have been of interest in 
these patients.  It may also be the case that viral rebound was due to the development of viral 
escape mutations or loss of effective immune responses as has been described previously [330, 
331].  This, together with the varying patterns of HIV-1 RNA-load control and CD4+ T-cell 
homeostasis as shown in Appendix II, further highlights the fact that alternate, as yet undefined, 
factors play a significant role in control of viral RNA-load and CD4+ T-cell homeostasis.   
 
As discussed in Section 1.6.1, there remains some debate regarding whether absolute CD4+ T-
cell count or CD4+ T-cell percentage is a more reliable marker of immune status in HIV-1 
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infected individuals.  Since there is some ethnic variation in normal CD4+ T-cell and total 
lymphocyte counts [332, 333] it could be argued that some patients may have a lower CD4+ T-
cell count on account of their ethnic group.  In those patients one might expect to see low 
absolute CD4+ T-cell counts but normal CD4+ T-cell percentage given total lymphocyte count is 
also lower.  In order to exclude this as a factor leading to spurious inclusion in the discord 
controller cohort, CD4+ T-cell percentage was also assessed in each controller cohort.  The fact 
that CD4+ T-cell percentage was significantly lower in the discord controller group compared 
with typical controllers, together with the fact that ethnicity isn’t significantly different 
comparing the two controller groups, suggests that the lower absolute CD4+ T-cell counts in the 
discord controller group are not merely a feature of ethnic differences and a lower normal CD4+ 
T-cell range, and that these low counts are a result of specific depletion of this cell type. 
 
2.4.2   Epidemiological and Clinical Features of Discord Controllers and Typical Controllers 
 
Epidemiological factors (age, sex, place of birth, ethnicity or risk behaviour) were found to be 
similar when comparing discord controllers and typical controllers.  Therefore, this study did 
not identify a factor other than CD4+ T-cell count which distinguished discord controllers from 
typical controllers.  A higher proportion of the whole viraemic controller cohort were women 
than men as has been reported previously amongst viraemic controllers (definition used viral 
RNA-load <400 copies/ml) [319].  The reason for over-representation of women is not fully 
understood [319].     
 
No association was found between the discord phenotype and time since first positive test 
(surrogate for time since seroconversion) suggesting that the discord controllers are not simply 
those viraemic controllers which have been infected for a longer time period when compared 
with typical controllers.  This supposition is also supported by the fact there was no association 
between discord controller phenotype and age.  Whilst time since diagnosis is not a perfect 
surrogate for time since seroconversion, this data does suggest that the discord controller 
phenotype is not associated with a longer duration of infection compared with typical 
controllers.   
 
There was no evidence of increased opportunistic disease in discord controllers compared to 
typical controllers (Appendix III), despite their lower CD4+ T-cell counts.   
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2.4.3   HIV-1 Subtypes in Discord Controllers and Typical Controllers 
 
The HIV-1 subtype distribution found in the East London HIV-1 cohort studied here is far more 
diverse than is reported for the U.K.  A study based on 5,675 pol gene sequences recorded in 
the United Kingdom Drug Resistance Database found 74.9% sequences to be subtype B, 
10.0% were subtype C, 6.4% subtype A and 1.8% CRF02_AG amongst other less frequent 
subtypes [64].  In the East London HIV-1 population, as shown in Figure 2.3, only 35.7% are 
subtype B demonstrating that there is a far higher representation of non-B subtypes in the East 
London HIV-1 population compared with the U.K. in general.  This is likely to be at least in 
part due to the high proportion of Black African people in the East London HIV-1 population; a 
study based in South London showed that non-B subtype isolates account for 96.8% of 
infections among Black Africans compared with only 14.2% in Caucasians [334].   
 
There was a non-significant trend towards increased frequency of HIV-1 subtype C in the 
discord controllers compared with the typical controller cohort.  Whilst studies have suggested 
increased pathogenicity of subtype D isolates [31], a similar rate of disease progression is 
observed in patients infected with subtype C infection when compared with subtypes A, B and 
CRF02_AG [31].  Therefore, relative pathogenicity of subtype C isolates does not appear to 
explain to any degree the increased frequency of this subtype in discord controllers.   
 
A product for sequencing and subtype prediction was not obtained using either subtyping 
method for two viraemic controllers patients.  Since subtype was not determined in all patients 
tested, it is possible that the subtype data may be skewed slightly by this.   
 
2.4.4   Response of Discord Controllers to ART 
 
In three out of five discord controllers who were treated with ART a clear gain in CD4+ T-cell 
count was observed in keeping with those described by Okulicz et al.[322].  This further 
supports the notion that CD4+ T-cell counts in the discord controller population were low as a 
result of depletion rather than a lower normal range in these patients.  It is also of relevance to 
the clinician treating these patients to know whether CD4+ T-cells recover in the same way that 
they do in non controllers.  It is notable that, in keeping with the study by Okulicz et al., work 
here shows that CD4+ T-cell gains were seen in these patients over a prolonged period, with 
gains continuing to be seen past 12 months of ART.  Indeed, a significant early rise in CD4+ T-
cell count was seen only in one patient (Patient 3, Table 2.3, Figure 2.4).  Where early increases 
in CD4+ T-cell count after starting ART are seen, this has been proposed to be due to 
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redistribution of T-cells resulting from ART-mediated resolution of the immune activation that 
had sequestered CD4+ T-cells within lymphoid tissues [167, 290], suggesting this may have 
been a significant factor for Patient 3.   
 
Even though a significant early rise in absolute CD4+ T-cell count was seen only in Patient 3, 
CD4+ T-cell percentage increases were seen in three further patients after 1 month of ART 
because total CD8+ T-cell counts had decreased significantly during that time.  This has been 
demonstrated previously, with other studies reporting a decrease in either memory CD8+ T-cells 
[335], activated CD8+ T-cells [336] or HIV-1 specific CD8+ T-cells [178] within the first few 
weeks of ART.  It is thought that the reason for this is  that suppression of viral RNA-load 
results in reduced antigen driven expansion of the CD8+ T-cell compartment.  Therefore, the 
early CD4+ T-cell percentage increases in these three patients is likely to represent restoration 
of a more normal CD8+ T-cell profile given the suppressed viral replication, rather than 
reconstitution of the CD4+ T-cell pool.  The fact that ART leads to restoration of a normal CD8+ 
T-cell pool in discord controllers, suggests ART suppresses antigen driven expansion of the 
CD8+ T-cell compartment in this cohort too.  This suggests that there is high level HIV-1 
replication in discord controllers which is not reflected in significant viral RNA-loads.  This 
proposal is further supported by HIV-1 DNA load data which is presented in Chapter 4.  
 
Four of the five patients started on ART were not elite controllers and thus had detectable viral 
RNA-loads.  Viral RNA-load for all four patients went from being detectable to undetectable 
using current standard assays.  It may be that this reduction in viral RNA-load, albeit from an 
already low level, is key to CD4+ T-cell reconstitution.  The fact that CD4+ T-cell count gains 
were seen here, despite already low pre-treatment viral RNA-loads, supports current treatment 
guidelines which emphasise the need to initiate ART on the basis of CD4+ T-cell count rather 
than viral RNA-load [337]. 
 
One study reported that an elite controller with progressive CD4+ T-cell depletion did not 
experience CD4+ T-cell reconstitution on ART [338].  This is in keeping with the fact that CD4+ 
T-cell gains were minimal in the one elite controller (Patient 2) put on ART in this study.  This 
same study reported a decrease in viral RNA-load from 7 to <1 copies/ml (using an 
ultrasensitive research assay) in the elite controller put on ART [338].  This might suggest there 
is a point at which viral RNA-load is so low, decreasing it further does not lead to CD4+ T-cell 
reconstitution.  It must also be noted that this study examined only one elite controller put on 
ART, and it also relies on accurate quantification of extremely low level viral RNA-load. 
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These results taken together suggest that although suppression of viral RNA-load is important 
in reconstitution of CD4+ T-cell count in many patients (even where viral RNA-loads are 
already relatively low as in viraemic controllers with detectable viral RNA-load), there are 
additional factors involved in CD4+ T-cell count reconstitution.   
 
In summary, data presented here demonstrates that a significant subset of viraemic controllers 
have a low CD4+ T-cell count, and suggests that it is low as a result of CD4+ T-cell depletion 
rather than a low count which is normal for those individuals.  These discord controllers appear 
epidemiologically similar to typical controllers and this study finds no evidence that discord 
controllers have been infected for a longer duration than typical controllers.  This study found a 
trend towards a higher representation of the subtype C amongst discord controllers compared 
with typical controllers.  Most discord controllers experience slow recovery of CD4+ T-cell 
counts when put on ART, with early recovery of CD4+ T-cell percentage due to a decrease in 
total CD8+ T-cell counts.     
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CHAPTER 3 
 
 
Characterisation of T-cell Populations in Discord Controllers 
and Typical Controllers 
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3.1   Introduction 
 
In HIV-1 infection the mechanisms leading to depletion of peripheral CD4+ T-cells are not fully 
defined.  Mechanisms which have been proposed and are not mutually exclusive include: 1) 
apoptosis of uninfected CD4+ T-cells as a result of chronic immune activation observed in 
progressive disease [263-265, 267, 339-341]; 2) impaired production of CD4+ T-cells as 
suggested by the preferential depletion of naïve T-cells in progressive disease [265, 295, 296]; 
and 3) sequestration to another site within the body.   
 
Work described in this Chapter was designed to determine the contribution of these first two 
factors to CD4+ T-cell decline in discord controllers.  Therefore, the hypothesis was that 
changes typically associated with disease progression, high level CD4+ and CD8+ T-cells 
activation and depleted naïve CD4+ and CD8+ T-cells, would be more marked in discord 
controllers as compared with typical controllers.  Comparison of discord controllers with typical 
controllers provides the opportunity to distinguish immunological changes associated with 
disease progression from those which result from high viral RNA-load. This distinction is not 
possible with analysis of patients with the typical pattern of progression (high viral RNA-load, 
low CD4+ T-cell count).   
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3.2   Methods 
 
T-cell work was carried out on blood from seven discord controllers with a geometric mean 
CD4+ T-cell count of ≤400 cells/mm3, and from 12 typical controllers with a mean CD4+ T-cell 
count of ≥500 cells/mm3, in order to avoid those patients too near the 450 cells/mm3 cut-off 
which distinguishes these two cohorts.   For comparison, blood was also taken from five 
progressors (viral RNA-load > 10000 copies/ml, CD4+ T-cell ≤400 cells/mm3 (see Figure 2.1) 
and five uninfected patients.  
 
3.2.1   T-cell Immunophenotyping using Flow Cytometry  
 
Seven colour flow cytometry was used to quantify CD4+ T-cell and CD8+ T-cell populations 
and their naïve (CD45RA+CD62L+), central memory (CD45RO+CD62L+) and effector memory 
(CD45RO+CD62L-) subsets in freshly EDTA-anticoagulated blood.  Activation level of a 
particular T-cell subset was defined as percentage activation where an activated cell expressed 
both CD38 and HLA-DR [342].  The following monoclonal antibodies and fluorochromes were 
used: CD3-Pacific Blue, CD4- allophycocyanin(APC)-H7, CD45RA-phycoerythrin (PE)-Cy7, 
CD45RO-phycoerythrin (PE)-Cy7, CD62L-PE, HLA-DR-peridinin chlorophyll protein (PerCP), 
CD38-PerCP-Cy5.5, CLA-FITC, β7 –APC (BD Biosciences, San Jose, CA).   
 
The staining matrix allowing colour compensation on subsequent analysis is shown in 
Appendix I.  Saturating amounts of monoclonal antibodies or their respective isotype controls 
accord to this matrix were incubated with 100µl of whole blood (within 4 hours of collection) 
for 15 minutes at room temperature.  500µl Optilyse C (Immunotech, Marseilles, France) was 
added and incubated at room temperature for a further 15 minutes.  Blood aliquots with single 
colour staining were processed with each run for compensation.  After two washes with 
phosphate-buffered saline containing 2% FCS, 0.02% NaN3 and 1mM EDTA, stained cells 
were re-suspended and fixed in 300µl phosphate-buffered saline 4% paraformaldehyde.  A 
constant volume of Flow-count Fluorospheres (Beckman Coulter, USA) was added to enable 
absolute quantification of cells.  The cells were acquired within 12 hours of fixing on a BD LSR 
II cell analyser with a minimum of 50000 (usually 100000) events acquired per sample. 
 
Efforts taken to preserve expression of surface molecules in T-cells include the use of only 
fresh blood samples which were processed within 24 hours of collection and the use of NaN3 in 
the wash buffer which inhibits the potential redistribution of cell surface markers by either 
endocytosis or shedding. 
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Figure 3.1   Gating strategy for flow cytometric analysis of T-cell subsets.  Example given 
here for activated naïve CD4+ T-cells.    a) Forward and side scatter to define viable cell gate; 
b) Double staining of viable cells with anti-CD3 and anti-CD4. CD4+ T-cells are in the top right 
quadrant; CD4─ T-cells (predominately CD8+ T-cells) are in the bottom right quadrant; c) 
Double staining of CD4+ T-cells with anti-CD45RA and anti-CD62L, naïve CD62L+CD45RA+ 
T-cells, defined with reference to staining with isotype-matched control antibodies, are in the 
top right quadrant; d) Double staining of naïve CD4+ T-cells with anti-CD38 and anti-HLA-
DR, activated CD38+HLA-DR+ T-cells, defined with reference to staining with isotype-
matched control antibodies, are in the upper right quadrant.  The gating procedure was carried 
out to identify central memory CD4+ T-cells (CD3+CD4+CD45RO+CD62L+) and effector 
memory CD4+ T-cells (CD3+CD4+CD45RO+CD62L─), naïve CD8+ T-cells 
(CD3+CD4─CD45RA+CD62L+), central memory CD8+ T-cells 
(CD3+CD4─CD45RO+CD62L+), effector memory CD8+ T-cells (CD3+CD4─  
CD45RO+CD62L─). Within each population activated cells were defined as CD38+HLA-DR+. 
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 Winlist 6.0 software (Verity Software House, Maine) was used for analyses and colour 
compensation.  The gating strategy is shown in Figure 3.1.  CD4+ T-cells were identified within 
a viable cell gate, set on the basis of light scatter, as cells that were CD3+CD4+.  CD8+ T cells 
were identified as mononuclear cells that were CD3+CD4─.  Two-dimensional dot plots, in 
which quadrant gates were set on the isotype controls, were used to define naïve, central 
memory and effector memory populations in both CD4+ and CD8+ populations.  In turn, each of 
these populations were viewed on further 2-dimensional plots to determine the percentage of 
cell with an activated phenotype (co-expression of CD38 and HLA-DR).  The number of flow-
count spheres acquired allowed a precise determination of sample volume acquired allowing 
expression of number of cells per volume of blood. 
 
3.2.2   Statistical Analysis 
 
Statistical analysis and graphical presentations were performed using Prism (version 4.0, 
Graphpad).  Differences in T-cell numbers and percentages in each cohort were assessed using 
a 2-tailed Mann-Whitney U test and results were considered significant if p<0.05.   A correction 
for multiple comparisons was employed using the false discovery rate calculation.  Given the 
small sample numbers, non-significant results were treated with caution.   
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3.3   Results 
 
3.3.1   Patient Demographics and Laboratory Parameters  
 
Demographics together with CD4+ T-cell count and HIV-1 RNA-load distributions in HIV-1 
infected patient groups included in T-cell characteristics experiments are shown in Table 3.1.     
 
Table 3.1  Demographics, HIV-1 RNA-loads and CD4+ T-cell counts in patients tested for 
T-cell characteristics. 
 
 Discord Controllers 
(n = 7) 
Typical Controllers 
(n = 12) 
Progressors 
(n = 5) 
Age, years 37 (21 - 63) 43.5 (30 - 53) 35 (30 - 48) 
Female 86% 42% 
 
40% 
CD4+ cells/mm3 337 
(267 - 400) 
815  
(691 - 971) 
309  
(296 - 339) 
HIV-1 RNA-load 
copies/ml 
675 
(128 - 1320) 
268 
(116 - 926) 
60,682 
(28 603 – 15 5518) 
Age, CD4+ T-cell counts and HIV-1 RNA-loads are expressed as median (range).   
 
 
3.3.2   CD4+  T-cell Subsets 
 
As expected, the total cell numbers were reduced for all CD4+ T-cell populations in progressors 
and discord controllers compared with typical controllers (Figures 3.2 I, a,b,c).  Similar to 
progressors, discord controllers had preferential depletion of naïve CD4+ T-cells compared with 
typical controllers as shown by a reduction in the percentage of total T-cells with a naïve 
phenotype (Figures 3.2 I, d,e,f).  The higher percentage of effector memory cells (Figure 3.2 I, 
f) in discord controllers and progressors is a reciprocal change due to preferential loss of naïve 
cells (as shown by lower absolute numbers; Figure 3.2 I, c).  The percentage of central memory 
cells in blood was similar in all three patient groups (Figure 3.2 I, e).   
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3.3.3   CD4+ T-cell Activation  
 
Progressors showed increased levels of activation in naïve, central memory and effector 
memory CD4+ T-cell subsets (Figures 3.2 I, g,h,i).  In the discord controllers, all subsets of 
CD4+ T-cells tended towards higher levels of activation similar to that seen in progressors.  In 
contrast, typical controllers had low activation levels, indistinguishable from that seen in 
uninfected subjects, apart from a small but significant increase in the frequency of activated 
CD4+ effector T-cells.   
 
In summary of the CD4+ T-cell compartment, discord controllers show changes not seen in 
typical controllers but which are similar to those seen in progressors: preferential depletion of 
naïve CD4+ T-cells and increased CD4+ T-cell activation in all subsets.  
 
3.3.4   CD8+ T-cell Subsets  
 
Unlike progressors but similar to uninfected individuals, typical and discord controllers both 
maintain high levels of naïve CD8+ T-cells (Figures 3.2 II, a,d).  Progressors have a 
preferentially depleted naïve CD8+ T-cell compartment (reduced numbers and percentage of 
total) and have expanded numbers of effector memory CD8+ T-cells compared with all other 
patient groups (Figure 3.2 II, f).   
 
3.3.5   CD8+ T-cell Activation 
 
Higher activation levels were seen in all CD8+ T-cell subsets in all HIV-1 infected groups 
compared with uninfected controls (Figures 3.2 II, g,h,i).  CD8+ T-cell activation levels in 
discord controllers were most similar to those seen in typical controllers in all CD8+ T-cells 
populations (Figures 3.2 II, g,h,i).  Thus, despite the fact that discord controllers share low total 
CD4+ T-cell counts with the progressors, their CD8+ T-cell activation pattern more closely 
resembles that of typical controllers.  
 
In summary of the CD8+ T-cell compartment, discord controllers appear similar to typical 
controllers and dissimilar to progressors, demonstrating preserved naïve CD8+ and only low 
level CD8+ T-cell activation.   
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Figure 3.2   Representation of CD4+ T-cell subsets and percentage activation in Discord 
Controllers and Typical Controllers in, I, CD4+ T-cells and, II, CD8+ T-cells.  Patients 
analysed included discord controllers and typical controllers, together with progressors and 
uninfected subjects for comparison.  Absolute numbers of cells in each of CD4+  and CD8+  T-
cell subsets are shown in a) Naïve (CD45RA+CD62L+), b) central memory (CD45RO+CD62L+), 
and c) effector memory (CD45RO+CD62L-).  Percentage of cells in each of CD4+  and CD8+  T-
cell subsets compared with total CD4+  or CD8+  T-cell pool are shown for d) Naïve, e) central 
memory, and f) effector memory.  Percentage activation of cells in CD4+ T-cell subsets (as 
percentage of total cells in that subset) by patient group is shown in g) - i).  Each central bar 
represents the median value, each box represents the IQR and the whiskers represent the 
minimum and maximum values.  Relevant p values are displayed.  
 
 
 
 
3.3.6   T-cell Characteristics in a Patient Subsequently Started on ART 
 
Although not a specific aim of this work, it was of interest to observe T-cell parameters in one 
discord controller patient (Patient 3) who subsequently started on ART to see if there were any 
suggestions of parameters that might distinguish this individual from those who did not need to 
start ART.   
 
In this patient naïve CD4+ T-cell count was 120.3 cells/mm3, which was 40.4% of total CD4+ T-
cells.  The percentage of activated naïve CD4+ T-cells was 20.5%, in central memory 12.2% 
and in effector memory 21.6%.  Naïve CD8+ T-cell count was 273.4 cells/mm3, which was 
36.8% of total CD8+ T-cells.  The percentage activation was 18.8% in naïve CD8+ T-cells, 
26.3% in central memory CD8+ T-cells and 48.0% in effector memory. 
 
Comparing these results to those seen in Figure 3.2, values look typical for the discord 
controller group, except that central and effector memory CD4+ T-cell activation levels appear 
to be at the lower end of the spectrum.   
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3.4   Discussion 
 
Both chronic immune activation of CD4+ and CD8+ T-cells [263-265, 267, 339-341] and 
preferential depletion of CD4+ and CD8+ naïve T-cells have been reported to be associated with 
progressive disease [265, 295, 296].  Viraemic controllers typically experience significantly 
longer times to progression than non controllers [318].  In keeping with this, immune activation 
has been reported to be lower in elite controllers than in non controllers [320, 343].  However, 
as described here, there is a population of viraemic controllers who do experience disease 
progression with depletion of CD4+ T-cell counts, discord controllers, and as such viral 
replication and progression appear dissociated.  It was therefore of interest to determine whether 
discord controllers displayed those features typically associated with disease progression.  The 
hypothesis for this part of the work was that immunological features typically associated with 
disease progression (selective depletion of naïve CD4+ T-cells, CD4+ and CD8+ T-cell 
activation) would be more marked in discord controllers than in typical controllers, and may 
therefore account for their CD4+ T-cell depletion.   
 
The results described here demonstrate that for the CD4+ T-cell compartment the hypothesis 
may be accepted since discord controllers demonstrated a selective depletion of naïve CD4+ T-
cells and increased numbers of activated CD4+ T-cells compared with typical controllers.  
These CD4+ T-cell features in discord controllers were similar to those found in the progressors.  
It therefore appears that these immunological features are associated with CD4+ T-cell decline 
in viraemic controllers and may account for the depleted CD4+ T-cell counts seen in discord 
controllers.  
 
In contrast, the discord controllers were similar to typical controllers when observing the CD8+ 
T-cell compartment with a preserved naïve CD8+ T-cell pool and relatively low levels of CD8+ 
T-cell activation.  Progressors displayed a depleted naïve CD8+ T-cell pool and higher levels of 
CD8+ T-cells activation compared with both controller groups.  So here the hypothesis must be 
rejected since depletion of the naïve CD8+ T-cell subset and/or high levels of CD8+ T-cells 
activation were not seen in discord controllers, suggesting that these immunological features are 
not associated with CD4+ T-cell decline in viraemic controllers.  
 
The fact that the hypothesis regarding the CD8+ compartment was refuted is at odds with other 
studies which suggest that CD8+ T-cell activation is a predictor of CD4+ T-cell decline, 
independent of CD4+ T-cell count and HIV-1 RNA-load [267, 340, 344].  Instead, results 
presented here support alternate studies in which higher viral RNA-load positively correlates 
with increased CD8+ but not with CD4+ T-cell activation [264, 345], and that this correlation 
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holds regardless of CD4+ T-cell counts [345].  This would predict, as was found in this study, 
low CD8+ T-cell activation levels in discord controllers despite their low CD4+ T- cell counts.   
Results described here show HIV-1 infected groups, including typical controllers, to 
demonstrate significantly higher CD8+ T-cell activation in all compartments than in uninfected 
subjects.  By contrast, CD4+ T-cell activation was found to be similar in typical controllers 
compared with uninfected subjects.  Hunt et al. report results which differ in respect to the 
CD4+ T-cell compartment in that 30 elite controllers (defined as viral RNA load <75 copies/ml) 
were found to have higher CD4+ and CD8+ T-cell activation than uninfected subjects [320].  
The reason for the difference in this result may be because the elite controller group described 
by Hunt et al. were not defined by their CD4+ T-cell counts, thereby having a range of counts 
(350-642 cell/mm3); results in their elite controller group may therefore have been skewed by 
high CD4+ T-cell activation in those elite controllers with low CD4+ T-cell counts.  Indeed, they 
do additionally report a negative correlation between T-cell activation and CD4+ T-cell counts 
in elite controllers; whilst this correlation is seen for both CD4+ and CD8+ T-cell populations, 
the correlation appeared stronger (Spearman’s ρ= - 0.52) and more significant for CD4+ 
activation (p = 0.009) than for CD8+ activation (Spearman’s ρ= - 0.37, p = 0.047), where the 
correlation was weak and only just reached significance.  These findings do appear in keeping 
with results reported in this thesis, since in viraemic controllers CD4+ T-cell decline appears 
more closely associated with CD4+ T-cell activation than with CD8+ T-cell activation. 
 
Since work described in this thesis began, a few other investigators have examined T-cell 
populations in small numbers of viraemic controllers.   Andrade et al. describe a single HIV-1 
elite controller (<50 copies/ml) who experienced a progressive CD4+ T-cell decline despite 
maintaining undetectable viral RNA-load.  This patient was HLA B5801 positive and thought to 
be infected with a subtype B virus.  The level of CD4+ and CD8+ T cell activation in this patient 
was found to be much higher than that seen in 10 elite controllers who maintained normal CD4+ 
T-cell counts [321].  Sedaghat et al. observed CD4+ T-cells counts in 8 elite controllers, and 
found that 3 experienced CD4+ T-cell depletion.  They found no relationship between the level 
of activation of CD4+ or CD8+ T-cells and CD4+ T-cell depletion, but stated this might be due 
to small patient numbers [338].  Kamya et al. studied the slope of CD4+ T-cell counts over time 
in 25 elite controllers (<50 copies/ml).  The slope was not significantly different from 0 in 15 of 
these patients, but was positive in 3 and negative in 7 of them.  Those with increasing and 
decreasing slopes were found not to differ based on CD8+ T-cell activation levels, with the 
authors concluding that CD8+ T-cell activation was not the cause of CD4+ T-cell decline [346].   
So in summary Hunt et al. found both CD4+ and CD8+ T-cell activation to be associated with 
CD4+ T-cell decline in elite controllers (although the association was weak for CD8+ T-cell 
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activation), Andrade et al. found both CD4+ and CD8+ T-cell activation to be associated, 
Sedaghat et al. found neither to be associated and Kamya et al. found CD8+ T-cell activation 
not to be associated with CD4+ T-cell decline in elite controllers.  The published results are 
hence not in agreement highlighting the need for further studies on larger cohorts.   
A study earlier this year reported naïve CD4+ T-cell assessment in a group of 20 elite 
controllers with high CD4+ T-cells counts and 5 with low CD4+ T-cell counts, and compared 
them to non controllers with progressive disease.  They demonstrated reduced proportions of 
naïve CD4+ T-cells in elite controllers, even in those maintaining normal total CD4+ T-cells 
counts; this depletion resembled that seen in non controllers.  Those elite controllers with 
normal total CD4+ T-cells counts were found to differ from those with low counts due to 
preserved thymic function [347].  This conflicts with data presented here where viraemic 
controllers with normal CD4+ T-cell counts had a preserved naïve CD4+ T-cell compartment, 
again highlighting the need for further studies.   
 
It was not possible to thoroughly examine CD4+ T-cell response to treatment as predicted by 
baseline CD4+ T-cell activation as it was not often possible to obtain blood samples leading up 
to ART initiation.  Consequently T-cell data was available for only one patient (Patient 3 from 
Table 2.3 and Figure 2.4) who subsequently started ART.  In this patient a significant early 
increase in CD4+ T-cell count was seen on ART.  This early increase has been proposed to be 
due to redistribution of CD4+ T-cell into the blood from the lymphoid tissues resulting from 
ART-mediated resolution of the immune activation [167, 290].  Contrary to findings here this 
might predict high CD4+ T-cell activation in this patient.  However, a study by Mildvan et al., 
showed that baseline CD4+ T-cell activation itself did not predict CD4+ T-cell recovery in 
response to treatment [348], potentially explaining why CD4+ T-cell activation was not higher 
in this patient.  It should be noted that ART-mediated resolution of immune activation might act 
at the lymphocyte effector site (e.g. GI tract lamina propria) which might explain why levels of 
activation in circulating lymphocytes might not predict response.  Similar studies on a greater 
number of patients would be needed to make any meaningful interpretation.     
 
A potential limiting factor is the small numbers of discord controllers studied.  This was in part 
due to the infrequent nature of the patients themselves, and also due to the complexity of the 
experiments.  Another limitation is that that only a single snapshot for each patient was 
obtained; changes in these T-cell parameters over time in relation to HIV-1 RNA-loads and 
CD4+ T-cells counts would be of interest.  In addition, subset delineation using one or two 
surface markers is not perfect: for example not all CD45RA positive T-cells are naïve (since 
there is some reversion of CD45RO to CD45RA) [349]. 
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In summary, this study demonstrates that compared with typical controllers, discord controllers 
demonstrate preferential depletion of naïve CD4+ T-cells and increased activation of all CD4+ 
T-cell subsets probably accounting for CD4+ T-cell loss.  CD8+ T-cell parameters in discord 
controllers are indistinguishable from those in typical controllers.  In contrast, progressors have 
marked naïve CD8+ T-cell depletion and CD8+ T-cell activation.  It appears that maintenance of 
the CD8+ T-cell compartment is associated with low viral RNA-loads.  In conclusion, the CD4+ 
T-cell compartment but not the CD8+ T-cell compartment of discord controllers is typical of 
patients with progressive disease.     
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CHAPTER 4 
 
 
Quantitative HIV-1 DNA-Loads in Discord Controllers and 
Typical Controllers 
 
 
 
84 
 
4.1   Introduction 
 
The HIV-1 burden in the blood of infected patients can be measured as viral RNA contained in 
virions free in the plasma (viral RNA-load) or cellular viral DNA (viral DNA-load).    In HIV-1 
infection, cellular viral DNA-load is composed of different forms reflecting different stages 
during viral replication in the cell: the linear non-integrated form, the circular non-integrated 
form and the integrated provirus; the latter is the form from which transcription occurs [88].   
 
Quantification of the viral RNA-load form in plasma by PCR has long been the chosen method 
used to monitor viral replication and predict progression both in the research setting and in the 
clinic [244, 315].  In viraemic controllers viral RNA-load is persistently low and most patients 
maintain normal CD4+ T-cell counts [304].  However, as is described in this thesis, some 
viraemic controllers have low CD4+ T-cell counts (discord controllers) and so demonstrate 
disease progression despite their low viral RNA-load; these low viral RNA-loads are similar to 
those found in typical controllers in whom CD4+ T-cell counts are normal (see Table 2.1).  The 
results in Chapter 3 suggest that the CD4+ T-cell depletion is associated with activation of CD4+ 
T-cells, even when there is lack of obvious viral replication in the blood as reflected in the viral 
RNA-load, as seen in discord controllers.  It was not clear, however, based on viral RNA-load 
measurement alone, whether there are in fact higher levels of HIV-1 replication in a concealed 
or cryptic site which does not give rise to high viral RNA-load.  This concealed or 
compartmentalised replication may play a direct role in CD4+ T-cell depletion or may drive 
immune activation which leads to CD4+ T-cell depletion.  Thus the hypothesis for this Chapter 
is that, despite the lack of evidence of viral replication as suggested by low viral RNA-load, 
viral replication continues to be associated with CD4+ T-cell depletion in viraemic controllers.   
 
In order to address this hypothesis it was necessary to examine another marker of viral 
replication.  HIV-1 DNA-load has been proposed as an alternate marker for ongoing replication 
in vivo, based on findings such as the fact that it is a marker for disease progression independent 
of viral RNA-load [350, 351].  Other studies demonstrate that viral DNA-loads are maintained 
by viral replication because they are suppressed by ART [352, 353] and that a significant 
correlation was observed between HIV-1  DNA load and unspliced RNA transcripts in patients 
on ART with undetectable viral RNA-loads [354].  Using HIV-1 DNA load as an alternate 
marker for viral replication, the stated hypothesis would predict that discord controllers have 
higher viral DNA-loads than typical controllers.  Quantitative HIV-1 DNA-load assays have 
been reported previously, but before analysis of patient samples, a number of these were 
selected to evaluate further and determine the most appropriate method for the study. 
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The first part of this work is therefore the development and validation of a quantification HIV-1 
DNA-load assay for use on PBMC samples from viraemic controllers (Sections 4.2 and 4.3).  
Subsequent Sections describe the use of the assay on blood from discord controllers and typical 
controllers (together with HIV-1 non controllers for comparison) to determine whether viral 
DNA-load correlates with CD4+ T-cell decline.  
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4.2   Development of a Quantitative HIV-1 DNA-Load Assay 
 
Since sensitive quantification of HIV-1 DNA was crucial, it was decided to design a Taqman 
real-time quantitative PCR assay (qPCR) as with careful assay design it provides sensitive and 
reproducible results with a wide dynamic range.   
 
Given the worldwide increasing spread of HIV-1 genetic variants, it is mandatory that nucleic 
acid assays detect all HIV-1 subtypes.  This is particularly important for this study because of 
the high prevalence of non-B subtypes in the East London HIV-1 cohort.  Two primer-probes 
sets targeting HIV-1 LTR and HIV-1 Integrase were selected for assessment using qPCR 
following work which had previously been carried out (Barts and the London NHS Trust 
Diagnostic Virology Laboratory).  Primers and probes binding highly conserved regions of the 
HIV-1 genome were assessed using conventional PCR methods which demonstrated their 
efficacy on a wide variety of HIV-1 subtypes.   
 
It was anticipated that viral DNA-loads could be very low in viraemic controllers [314].  
Therefore, a method based on initial recovery and concentration of PBMCs was used, as used 
by other groups [313, 353, 355], to enhance sensitivity of the assay. 
 
Since most HIV-1 in the blood is associated with CD4+ T-cells, and because CD4+ T-cell counts 
are inherently variable in this population group, it was decided to report results as viral DNA 
copies/106 CD4+ T-cells rather than viral DNA copies/106 PBMCs (composed of both 
lymphocytes and monocytes).  The assay was designed to quantify total HIV-1 DNA-load (as 
opposed to integrated proviral DNA or unintegrated viral DNA) since in HIV-1 infection there 
is good evidence to suggest total HIV-1 DNA-load is a good marker of on-going viral 
replication  [313, 350, 352, 353, 356]. 
 
Therefore, the aim of this part of the work was to develop a qPCR for quantification of total 
viral DNA-load in PBMCs, which would then be reported as HIV-1 DNA copies/106 CD4+ T-
cells.   
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4.2.1   Construction of a Standard Curve for HIV-1 LTR and HIV-1 Integrase qPCR  
 
The HIV-1 primer and probe sequences used for development of the viral DNA-load assay are 
shown in Table 4.1.  Both probes were labelled with a FAM (6-carboxy-fluorescein) reporter 
dye.   
 
Table 4.1.  Primer and probe sequences for HIV-1 LTR and HIV-1 Integrase qPCR 
HIV-1 LTR Forward Primer 5' - GCCTCAATAAAGCTTGCCTTGA 
[357] 
Reverse Primer 5' - GGCGCCACTGCTAGAGATTTT 
[358] 
Probe 5’ - AAGTAGTGTGTGCCCGTCTGT 
[359] 
HIV-1 Integrase 
[360] 
Forward Primer 5' - GGTTTATTACAGGGACAGCAGAGA 
Reverse Primer 5’ - ACCTGCCATCTGTTTTCCATA 
Probe 5’ - ACTACTGCCCCTTCACCTTTCCAGAG 
 
 
A plasmid dilation series was needed in order to construct a standard curve for target copy 
quantification.  Products from conventional PCR of HIV-1 LTR and HIV-1 Integrase were TA-
cloned, screened with subsequent purification of high copy number plasmid containing the 
relevant insert. (see Appendix I).  One of each set was selected, and their concentrations 
established by spectrophotometry (NanoDrop spectrophotometer, used according to 
manufacturer’s instructions).  Using the DNA concentration determined using the Nanospot and 
the molarity of the plasmid with insert an expected copy number was calculated.  From this a 
10-fold dilution series was created, (1 = neat, 2 = 1 in 10 dilution, etc.), and dilutions 5 -12 were 
tested using the assays under development.  
 
The HIV-1 LTR assay was assessed initially.  The final 25µl PCR mixture contained 2×PCR 
QuantiTect Multiplex RT-PCR No Rox Mix (Qiagen), 0.2µM of each primer and 0.2µM probe.  
Thermocycling on the ABI 7500 Realtime PCR machine were 95°C for 15 minutes for 
activation of the Taq DNA polymerase; then 40 cycles of 95°C for 15 seconds and 52°C for 1 
minutes.  5µl of plasmid dilution were added to duplicate wells for dilutions 5 to 11.  17 
reactions of the 12th dilution were prepared. Amplification reaching the threshold was seen in 
dilutions 5 to 11; for dilution 11, which contained an expected 4 copies per reaction, Ct values 
of 36.07 & 40.01 were obtained.  For the 12th dilution with a predicted 0.4 copies per reaction, 4 
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of 17 signalled, which is in keeping with the predicted copy number.  This PCR was further 
optimised by increasing the anneal-elongation temperature from 52°C, as suggested by Luo et 
al. [359], to 60°C.  This improved PCR efficiency giving a standard curve slope of -3.39.   
 
The HIV-1 Integrase assay was analysed in a similar fashion with 10-fold dilutions.  PCR 
mixture and conditions were as described for the HIV-1 LTR assay.  The final dilution to 
amplify was the 10-11 dilution, for which it was expected there would be 2.9 copies per reaction 
based on molarity calculations.  Twenty replicates of the 12th dilution were then tested, and 
seven were found to signal again in keeping with the predicted 0.29 copies per reaction.    
 
Dilutions 7 to 11 were selected for routine use for standard curve construction.  This was 
because the copy number these dilutions represented was in the region of expected HIV-1 viral 
DNA-loads based on reports in the literature and because these dilutions also gave Cts which 
were in the middle of the range (15-30).   
 
The five plasmid dilutions for construction of the standard curve for the HIV-1 LTR and HIV-1 
Integrase assays were run in duplicate.  The ABI prism 7500 SDS 1.2 programme was then used 
to construct a standard curve for each assay.  A typical example of a standard curve generated 
for the HIV-1 LTR assay is shown in Figure 4.1.   
 
 
 
Figure 4.1   Example standard curve for HIV-1 LTR assay.   
HIV-1 LTR 
 
Slope: -3.36 
r2: 0.9922 
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The efficiency of the assay was calculated using the formula:   
efficiency = (10-1/slope -1) ×100  
Hence the standard curve shown in Figure 4.1 for that particular HIV-1 LTR assay has an 
efficiency of 98.4%.   
 
For all subsequent assays, as is recommended for qPCR, standard curve r2 values were 
maintained at ≥0.99 ensuring good linearity and efficiency was maintained at  90-110% . 
 
4.2.2   Sensitivity of the HIV-1 LTR and HIV-1 Integrase qPCRs on Patient Samples 
 
Five blood samples from HIV-1 infected individuals were selected for testing with the HIV-1 
LTR and HIV-1 Integrase qPCRs.  So that viral DNA copy number could be expressed as per 
cell equivalent, a qPCR for the cellular house-keeping gene β-globin was run in parallel (this 
gene was selected since it is known there are always two copies per cell).  This qPCR, which 
was adapted [361] from a previously published assay [362], used 0.4µM of each primer 
(Forward, 5’ – GTGCACCTGACTCCTGAGGAGA, Reverse, 5’ - 
CCTTGATACCAACCTGCCCAG) and 0.1µM FAM reporter dye (6-carboxy-fluorescein) 
labelled probe (5’ –AAGGTGAACGTGGATGAAGTTGGTGG).  A standard curve was 
developed as part of the work described here by creating a dilution series of high copy number 
plasmid with the PCR product insert in the same way as for HIV-1 LTR and HIV-1 Integrase 
assays (again r2 values were ≥0.99 and efficiency 90-110%).   
 
Since the sensitivity of the assay was important, PBMCs were first isolated from the blood 
samples.  EDTA blood samples from five HIV-1 infected patients were centrifuged at 200g for 
10 minutes at room temperature.  Pastettes were used to aspirate the buffy coat from each and 
DNA was extracted using the Qiagen EZ1 biorobot and DNA Tissue programme according to 
the manufacturer’s instructions into a 200µl eluate (6 water samples were also included as 
negative extraction controls).  An internal inhibition control is important when employing PCR 
for use on blood due to the frequent presence of PCR inhibitors.  For this purpose a fixed 
concentration of phocine herpes virus (PhHV) was added to each sample before extraction so 
that its subsequent detection using a parallel qPCR would provide an internal amplification 
control.   
 
5µl of the extracted DNA was analysed in duplicate for the four separate qPCRs: HIV-1 LTR, 
HIV-1 Integrase, β-globin and PhHV.  In addition, six test wells were used for negative 
extraction controls (NEC) and two wells for water as no template controls (NTC); these controls 
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were used in all subsequent experiments too.  The PhHV qPCR run in parallel used the 
following primers: Forward, 5’ – CGTTCCAACAACACAACCTACTG, Reverse, 5’ - 
CTCTCATATCATCATTCAACTCAGTGT; and probe : 5’-
ACCACCAATTACTCCTAGTCCACCACCG.  The probe was labelled with a JOE reporter 
dye (6-carboxy-4’, 5’-dichloro-2’, 7’-dimethoxy-fluorescein).  
 
Mean Ct values obtained from test wells were then compared with the standard curve to 
determine copy number.  The results of the qPCR for the five patient samples are presented in 
Table 4.2 and show good correlation between HIV-1 copy number as assessed by the HIV-1 
LTR and HIV-1 Integrase qPCRs.  The PhHV Ct values were found to be within range for all 
samples (acceptable range 33.5 – 35.5 Ct) suggesting no significant qPCR inhibition.   
 
 
Table 4.2.  Target copy number in blood from five patients using HIV-1 LTR and HIV-1 
Integrase and β-globin qPCRs  
Sample  HIV-1 LTR HIV-1 Integrase  β-globin 
1 4.4 8.12  3.19x108 
2 58.67 46.41  3.85x108 
3 114.31 122.2  6.76x108 
4 34.16 11.18  6.66x108 
5 62.79 26.5  4.07x108 
NTC & NEC ND ND  ND 
NTC – no template control.  NEC – negative extraction control.  ND – not detected.   
 
 
A further experiment designed to assess relative sensitivity of the two HIV-1 qPCRs used a 
sample with a very high viral RNA-load (1782250 copies/ml).  The buffy coat layer was 
removed and from this a 5-fold dilution series in PBS was prepared. The neat buffy coat with 
four dilutions and a negative control underwent DNA extraction using the Qiagen EZ1 biorobot 
as described in Section 4.2.2.  The result of this experiment, as shown in Table 4.3, showed that 
the HIV-1 LTR qPCR appeared to have superior sensitivity.  For this reason, the LTR set was 
selected for use for all subsequent experiments, together with the qPCR for β-globin  and PhHV. 
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Table 4.3.  Target copy number in dilution series of PBMCs from blood of patient with 
high HIV-1 RNA-load using HIV-1 LTR, HIV-1 Integrase and β-globin qPCRs  
Sample HIV-1 LTR  HIV-1 Integrase  β-globin 
Neat Blood 9.4 2.8 2.3x106 
5-1 0.5 & 0 0.88 5.8x105 
5-2 0.5 & 0 ND 8.6x104 
5-3 ND ND 9.6x103 
5-4 ND ND 3.4x103 
NTC & NEC ND ND ND 
NTC – no template control.  NEC – negative extraction control.  ND – not detected.   
 
 
4.2.3   Validation of HIV-1 DNA-load Assay on Patients Infected with Varying HIV-1 
Subtypes 
 
Ten samples of differing HIV-1 subtypes were selected, the buffy coat layer removed and DNA 
extracted using the EZ-1 extraction procedure.    Samples were tested as described previously 
using the HIV-1 LTR, β-globin, PhHV qPCRs.   
 
HIV-1 LTR copies/106 PBMC were calculated using the following formula (there are 2 LTR 
copies per HIV-1 virus, and also 2 β-globin copies in every human cell) : 
 
HIV-1 DNA copies/106 PBMC    =      LTR copies      × 106 
                                                          β-globin copies 
 
CD4+ T-cell percentage was obtained from routine laboratory data available on the day (or near 
to the day) the sample was taken which was subsequently used for viral DNA-load assessment.  
Since this value gives what percentage of lymphocytes are CD4+ it was used to estimate HIV-1 
LTR copies /106 CD4+ T-cells (since the majority of PBMCs are lymphocytes) using this 
formula: 
 
HIV-1 DNA copies /106 CD4+ T-cells     =       HIV-1 LTR copies/106 PBMC     × 100 
                                                                                   % CD4+ T-cells 
 
92 
 
The experiment demonstrated amplification from all samples, with viral DNA-loads ranging 
from 10-545 copies/106 PBMC prior to conversion to copies/106 CD4+ T-cells. 
 
It was noted, however, the internal PhHV controls showed evidence of PCR inhibition (2.5 
cycle right shift of the Ct).  HIV-1 copy number would not be reliable in view of this.  After 
several experiments designed to determine the potential cause of this it was found to be due to 
metal beads present in the extraction eluate which were used as part of the EZ1 biorobot 
extraction process.  Centrifuging the eluate at high speed and applying a magnet to the tube in 
order to pipette off the sample without the metal beads resolved this inhibition problem.  
 
4.2.4   Inter-Assay and Intra-Assay Reproducibility of HIV-1 LTR and β-globin qPCRs 
 
Separate HIV-1 LTR and β-globin qPCR results were obtained for eight patient samples.  As 
demonstrated by the duplicate copy number values for HIV-1 LTR in run 1 and 2 (Table 4.4), 
intra-assay variability was found to be minimal.  Inter-assay variability was also minimal as 
shown by the values obtained for HIV-1 LTR copies / 106 PBMCs in each run for each sample.  
This demonstrates that the assay has good intra and inter assay reproducibility.   
 
Table 4.4  Inter-assay and intra-assay variability for HIV-1 LTR and β-globin qPCRs. 
 
HIV-1 LTR  
copies 
β-globin  
copies 
HIV-1 LTR copies/106 
PBMC 
 
1 2 1 2 1 2 
1 143.4 110.7 95.4 97.4 350236 422072 362.8 228.4 
2 31.0 7.1 23.4 32.7 889404 813633 21.4 34.5 
3 ND ND ND ND 672812 530451 0 0 
4 1.3 0.4 0.2 0.6 616095 485927 1.4 0.8 
5 ND ND ND ND 705341 476486 0 0 
6 20.0 132.0 99.0 91.1 716092 860252 106.1 110.5 
7 88.5 113.7 77.7 89.5 1064632 699953 95.0 119.4 
8 31.0 41.0 22.9 15.3 953261 1297324 37.8 14.7 
1 and 2 denote different qPCR runs, with duplicate aliquots tested on each run.   
HIV-1 LTR copies/106 PBMC for each run (1 and 2) calculated using mean for LTR copies. 
ND – not detected.   
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4.3   Discussion of Quantitative HIV-1 DNA-Load Assay 
 
Previous studies have used various methods of reporting HIV-1 DNA-load in blood: copies/106 
PBMC [313, 353, 355], copies / 106 CD4+ T-cells [363, 364] or copies/µL of whole blood [365].  
Most methods use Ficoll-Hypaque separation of whole blood to purify the PBMCs as described 
in the method here.   We expected viral DNA-loads to be particularly low in viraemic 
controllers [314].  The advantages and disadvantages of the various ways of reporting HIV-1 
DNA-load in blood are reviewed by Avettand-Fènoël et al. [366].   
 
Reporting viral DNA-load as copies/ml of whole blood is susceptible to inconsistencies in the 
Ficoll-Hypaque separation procedure between samples, but may eliminate the influence of 
variation in cell counts in blood.  The use of a parallel β-globin qPCR allowed normalisation of 
the HIV-1 DNA copies for 106 cells.  Normalising the results minimises the influence of 
variations in the steps preceding quantification that are essentially linked to the yield of the 
DNA extraction step.  Reporting viral DNA-load as copies/106 PBMCs means that the 
denominator cells include all those which might be HIV-1 target cells (CD4+ T-cells and 
monocytes).  Expressing results as copies/106 CD4+ T-cells disregards monocytes, less often 
infected than circulating CD4+ T-cells, but has the advantage of not being influenced by the 
variation in circulating CD4+ T-cell pool (the main reservoir in blood).  Given the fact that the 
purpose of this study was to compare two groups defined by their different CD4+ T-cell counts, 
it was crucial that the results should not be open to bias introduced by differing CD4+ T-cell 
counts; thus it was decided to report results expressed as copies/106 CD4+ T-cells rather than 
copies/106 PBMCs. However, a potential problem with this approach is that all HIV-1 DNA is 
attributed to a CD4+ T-cell reservoir, whereas in fact some may be harboured by circulating 
monocytes.  Although this is typically a minor viral reservoir, in certain populations the amount 
of HIV-1 DNA in monocytes can be higher, such as in HIV-1 associated dementia [136].  
Another issue with the method used is that copies/106 CD4+ T-cells was estimated from 
copies/106 PBMCs using percentage CD4+ T-cells; this is only an approximation since 
nucleated cells in PBMC suspensions are composed of lymphcotyes, monocytes and natural 
killer cells [367].  However, lymphocytes are the predominant cell type (around 85%) [367] and 
so this calculation should give a reasonable prediction of copies/106 CD4+ T-cells.  Whilst small 
errors may persist, since this calculation method was used for all samples it should still provide 
a reliable method for comparing viral DNA-load between the groups which is the main aim of 
the study.  Another approach would have been to purify the CD4+ T-cells from the PBMCs 
before DNA extraction.  However, this could lead to a severe loss of cells and compromise 
sensitivity.  In addition, the PBMC samples from many of the patients had been accumulated 
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over time and therefore were frozen, which is likely to have led to clumping on thawing thereby 
affecting the efficiency and reproducibility of CD4+ T-cell sorting [368].   
 
Taqman real-time qPCR allows simultaneous amplification and quantification, which eliminates 
the need for further manipulation of PCR products.  This limits the risk of contamination.  The 
qPCRs were thoroughly validated and optimised.  Good specificity was ensured by the 
inclusion of multiple no template controls.  Further specificity assurance was provided by using 
an assay which used a specific probe (unlike SYBR Green based amplicon).  In terms of 
sensitivity of the HIV-1 LTR qPCR, the dynamic range of the assay was shown to be wide, 
covering at least five orders of magnitude (see Figure 4.1).  The limit of detection of the HIV-1 
LTR qPCR as suggested using molarity calculations was <1 copies per reaction.  It was not 
possible to further define sensitivity since there is no agreed standard and there are no 
commercial assays for HIV-1 DNA-load quantification.  The inclusion of an internal PCR 
inhibition control (PhHV) ensured inhibition was detected readily and the problem addressed.  
The assay demonstrated good intra (all samples had duplicate HIV-1 LTR qPCR on each run) 
and inter assay (several samples were repeated on different runs for verification) reproducibility.  
The exponential amplification phase of the qPCRs showed a strong linear relationship between 
the threshold cycles (Ct, number of amplification cycles required to reach a set threshold) and 
the log10 of the input copy number (r2 value was consistently ≥0.99).  The qPCRs were also 
quick and easy to perform, minimising the chances for error.  Crucially in this setting the assay 
was both designed (choice of primers and probes) and validated for use on a wide range of 
HIV-1 subtypes including the various non-B subtypes encountered when testing samples from 
the East London HIV-1 population.   
 
HIV-1 DNA–loads obtained here were compared with those in the literature.  Using this assay 
viral DNA-loads ranged from 10-545 copies/106 PBMC (prior to conversion to copies/106 CD4+ 
T-cells); this is comparable to values found by Rouzioux et al. in untreated HIV-1 infected 
subjects: 2.45 - 3.32, median 2.86 log10 copies/106 PBMCs (which is 282 – 1622, median 724 
copies/106 PBMCs).  However, values obtained here were approximately a log10 lower than 
those reported by Gibellini et al.: 2063 ± 2144 (mean +/- 1SD), range 126-9736, copies/106 
cells [369].  It is difficult to compare the results of these studies as different quantitative 
techniques were used and on differing populations.    
 
In summary, this work describes a novel real-time qPCR that allows quantification of HIV-1 
DNA-load over a wide dynamic range with good inter and intra assay reproducibility.  This 
assay has excellent sensitivity and can be used for HIV-1 DNA-load quantification of a wide 
range of HIV-1 subtypes and has been validated for use on PBMC samples. 
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4.4   Methods 
 
4.4.1   Summary Method for Quantitative HIV-1 DNA-load Assay 
 
Samples were tested using the HIV-1 DNA-load assay from a range of discord controllers, 
typical controllers and non controllers.  Non controllers were selected on the basis of being 
ART-naïve HIV-1 infected persons, infected >12 months with a viral RNA-load >10000 
copies/ml and a range of CD4+ T-cell counts (see Figure 2.1, non controllers are shown in 
green).  Age, sex and routine laboratory results (see Section 2.2.2) were recorded for each 
patient.  A geometric mean was calculated of the last three CD4+ T-cell counts and HIV-1 
RNA-loads prior to the date of the sample used for HIV-1 DNA-load was taken.  Following on 
from assay development, here is the summarised protocol used for viraemic controller patient 
samples: 
 
PBMCs had been previously cryopreserved from patient’s blood, prepared by Ficoll-Hypaque 
separation of EDTA anticoagulated blood (see Appendix I).  DNA was extracted from these 
cells after thawing using the EZ1 Qiagen biorobot and DNA Tissue programme according to the 
manufacturer’s instructions into a 200µl eluate.  A fixed concentration of PhHV was added to 
each sample before extraction as an internal amplification control.  A final 25µl qPCR mixture 
contained 5µl of DNA extracted from PBMC, 2×PCR QuantiTect Multiplex RT-PCR No Rox 
Mix (Qiagen), 0.2µM of each HIV-1 LTR primer (F1 5'-
AGCCTCAATAAAGCTTGCCTTGA-3'; R1 5'-GGCGCCACTGCTAGAGATTTT-3') and 
0.2µM probe (AAGTAGTGTGTGCCCGTCTGT, fluorescent label).  Thermocycling 
conditions (ABI 7500) were 95°C for 15 minutes; then 40 cycles of 95°C for 15 seconds and 
60°C for 1 minute.  Duplicate HIV-1 LTR and β-globin qPCRs were run in parallel for each 
sample and mean value calculated.  An external plasmid dilution series was run in order to 
construct a standard curve for both HIV-1 LTR and β-globin, so that copy number could be 
determined in the test samples.  This data allowed viral DNA-loads to be expressed as per cell 
(PBMC) equivalent.  This was run each time to allow for differing efficiencies of a particular 
qPCR run, thus allowing robust comparison of values obtained on different runs.   
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4.4.2   Statistical Analysis 
 
Statistical analysis and graphical presentations were performed using Prism (version 4.0, 
Graphpad) and results were considered significant if p<0.05.  To determine significant 
differences in viral DNA-loads between cohorts, a 2-tailed Mann-Whitney U test was applied.  
Spearman's test was used to determine correlation between viral DNA-load and 
contemporaneous CD4+ T-cell count. 
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4.5   Results  
 
4.5.1   Patient Demographics and Laboratory Parameters  
 
Demographics together with CD4+ T-cell count and HIV-1 RNA-load distributions in patient 
groups tested using the HIV-1 DNA load assay are shown in Table 4.5.   
 
Table 4.5  Demographics, HIV-1 RNA-loads and CD4+ T-cell counts in patients tested for 
HIV-1 DNA-load. 
 Discord Controllers 
(n = 11) 
Typical Controllers 
(n = 16) 
Non Controllers 
(n = 10) 
Age, years 38 (22 – 64) 42.5 (31 – 71) 42 (28 – 66) 
Female 63% 8% 10% 
CD4+ T-cells/mm3 339  
(251 – 424) 
775  
(499 – 1326) 
399  
(258 – 716) 
HIV-1 RNA-load 
(copies/ml) 
412  
(49 – 1296) 
391 
(40-1745) 
15,809 
(10,041 – 169049) 
Age, CD4+ T-cell counts and HIV-1 RNA-loads are expressed as median (range).   
 
 
4.5.2   HIV-1 DNA-load in Discord Controllers and Typical Controllers 
 
Using the HIV-1 DNA-load assay developed in Section 4.2, viral DNA-loads were measured in 
discord controllers, typical controllers and non controllers.  This generated a value for viral 
DNA copies/106 PBMCs for each patient.  This was then used together with the CD4+ T-cell 
percentage obtained from a contemporaneous result from the routine laboratory testing (see 
Section 2.2.2) to calculate a value for the viral DNA-load (copies/106 CD4+ T-cells).  The 
results are shown in Table 4.6.   
 
Viral RNA-load (copies/ml) and viral DNA-load (copies/106 CD4+ T-cell) for each cohort 
tested are shown in Figure 4.2.  Viral RNA-load in the discord controller cohort is similar to 
that found in typical controllers (Figure 4.2 b).  In contrast, the discord controllers have 
significantly higher levels of viral DNA-load than typical controllers; these levels were found to 
be comparable to those in non controllers (Figure 4.2 a). 
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Table 4.6. HIV-1 DNA-load /106 PBMCs, CD4+ T-cell percentage and HIV-1 DNA-load 
/106 CD4+ T-cells for each patient tested.    
Patient  HIV-1 DNA-load  
copies / 106 PBMCs 
   CD4+ T-cell %  
  (of lymphocytes) 
 HIV-1 DNA-load 
copies / 106 CD4+ T-cells 
Discord Controllers 
1 1.33  10  13.27  
2 70.32  4.6  1528.68  
3 62.30  9.6  648.92  
4 24.98  10.5  237.87  
5 22.44  10.2  220.02  
6 78.70  10.32  762.59  
7 47.37  8.53  555.35  
8 44.98  5.83  771.47  
9 53.21  7.59  701.04  
10 33.20  5.52  601.44  
11 23.52  9.1  258.44  
Typical Controllers 
1 2.74  9.2  29.74  
2 7.80  7.5  103.99  
3 0  19.2  0.00  
4 1.91  4.0  47.83  
5 33.26  11.7  284.26  
6 14.04  8.0  175.50  
7 31.26  14.3  219.28  
8 25.02  11.2  223.43  
9 0  16.8  0.00  
10 0.33  8.4  3.90  
11 19.82  14.2  203.26  
12 14.79  11.5  128.53  
13 80.72  10.7  755.25  
14 2.12  10.2  20.77  
15 7.99  11.4  69.86  
16 1.21  19.7  6.16  
Non Controllers 
1 110.43  12.6  876.45  
2 78.15  10.5  744.25  
3 97.91  6.9  1419.04  
4 119.06  13.8  862.74  
5 52.62  5.4  974.53  
6 1.46  5.5  26.56  
7 34.41  4.3  800.32  
8 124.74  5.7  2188.41  
9 131.66  11.1  1186.09  
10 174.97  6.7  2611.52  
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Figure 4.2    HIV-1 DNA-loads and RNA-loads in Discord Controllers, Typical Controllers 
and Non Controllers.  HIV-1 RNA-load (copies/ml), a, and HIV-1 DNA-load (copies/106 
CD4+ T-cells), b, are both displayed on a log10 scale.  Each central bar represents the median 
value, each box represents the IQR.  Whiskers show the minimum and maximum values. 
Median (range) copies/106 CD4+ T-cells for each group: typical controllers, 87 (0 - 755); 
discord controllers, 601 (13 – 1529); non controllers, 852 (27 – 2188).   
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Figure 4.3 shows log10 HIV-1 DNA-load plotted against mean CD4+ T-cells/mm3 for all 
viraemic controller patients (discord controllers and typical controllers).  A strong inverse 
relationship between viral DNA-load and CD4+ T-cell count was demonstrated.   
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Figure 4.3   HIV-1 DNA-load Plotted Against Mean CD4+ T-cells/mm3 for all Viraemic 
Controllers.  HIV-1 DNA-load (copies/106 CD4+ T-cells) displayed on a log10 scale.  Mean 
CD4+ T-cell count is the geometric mean of the last three counts prior to the date of the sample 
used for HIV-1 DNA-load.   
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4.6   Discussion  
 
Discord controllers have lower CD4+ T-cell counts but equivalent HIV-1 RNA-loads compared 
with their typical controller counterparts; one explanation would be that discord controllers 
have higher levels of HIV-1 replication despite the fact this is not reflected in the viral RNA-
load.  In order to determine whether HIV-1 replication is higher in discord controllers than 
typical controllers, HIV-1 DNA-load was measured as a further marker of viral replication.  
HIV-1 DNA-load has been shown to be a marker of viral replication and disease progression.  
For example, it has been shown that the HIV-1 DNA-load in PBMCs from untreated patients 
provides an estimate of the cellular viral reservoir, which is established soon after infection 
[350, 370] and independently predicts disease progression [313, 350, 351].  HIV-1 DNA-load 
decreases over time in patients on ART [369].  Furthermore, higher HIV-1 DNA-loads are 
associated with suboptimal recovery of CD4+ T-cell count in patients on ART [371, 372].  A 
negative correlation between viral DNA-load and CD4+ T-cell count is also seen in HIV-2 
infected patients, where viral RNA-load is often undetectable [373-375].    
 
HIV-1 DNA-loads may be determined by measuring total cellular viral DNA, which includes 
both integrated provirus and unintegrated virus (unintegrated linear DNA, as well as 1-LTR and 
2-LTR circles) (see Section 1.4).  It could be argued that measuring integrated HIV-1 DNA-
load would be a more appropriate measurement since it is from this integrated form that 
transcription leading to progeny virions occurs [88].  A method has been described for 
quantification of integrated HIV-1 DNA using an Alu-LTR PCR technique whereby one primer 
anneals to the HIV-1 LTR and a second in the highly repeated chromosomal Alu element [376].  
However, integrated HIV-1 DNA appears remarkably stable, with one study showing that after 
48 weeks ART a 5-fold reduction in the total HIV-1 DNA-load was seen without a parallel 
decrease in integrated viral DNA [352].  Since ART is well documented to lead to a decrease in 
viral replication, it follows that integrated HIV-1 DNA may not be an accurate marker of 
current replication.  Further studies confirm that integrated HIV-1 DNA forms have a very long 
half-life [377] and as such are likely to represent the fundamental latent viral reservoir [86].  In 
contrast, unintegrated HIV-1 DNA, the more unstable form, has been proposed to be a good 
marker for ongoing replication in vivo [356].  Work from several groups has shown the 
persistence of 2-LTR circular forms in PBMCs of HIV-1 infected individuals in the absence of 
detectable viral RNA-loads, and has been correlated with residual cryptic viral replication [356, 
378].  As such, many of the papers which have reported that HIV-1 DNA-load is a marker of 
progression or of high viral replication have employed assays measuring total cellular HIV-1 
DNA-load (including the unstable unintegrated forms) [313, 350, 352, 353].  For this reason, an 
assay which determined total cellular HIV-1 DNA-load was developed.    
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Of note, the range of HIV-1 DNA loads obtained during this work were more narrow that was 
seen for HIV-1 RNA loads; this more restricted range of values for HIV-1 DNA loads has been 
reported previously [379].   
 
Work described here found low HIV-1 DNA-loads in typical controllers: median 87 (range 0 – 
755) copies/106 CD4+ T-cells; when expressed as copies/106 PBMCs values are median 7.90, 
(range 0 - 80.72).  This is in keeping with findings in other studies for example, Lambotte et al. 
found in elite controllers a mean total HIV-1 DNA-load of 32 (range 0 – 251) copies / 106 
PBMCs [314].  Julg et al. found HIV-1 DNA-loads to be 12.79 ± 20.92 DNA copies/106 
PBMCs in elite controllers and 94.80 ± 95.47 in viraemic controllers [380].   
 
A literature search suggests that HIV-1 DNA-loads have not previously been reported in 
viraemic controllers with low CD4+ T-cell counts, i.e. discord controllers.  Work reported here 
shows that HIV-1 DNA-loads in discord controllers, median 601 (range 13 – 1529) copies/106 
CD4+ T-cells, are significantly higher than in typical controllers, and that they are equivalent to 
levels found in HIV-1 non controllers, median 852 (range 27 – 2188) copies/106 CD4+ T-cells.   
 
Thus it is possible to accept the hypothesis that there is higher HIV-1 replication in discord 
controllers compared with typical controllers as measured by HIV-1 DNA load, which is not 
apparent by observation of viral RNA-load alone.   
 
In summary, using a qPCR to measure cellular HIV-1 DNA-load in blood, work here 
demonstrates that discord controllers with low CD4+ T-cell counts (<450cells/mm3) have 
significantly higher HIV-1 DNA-loads than typical controllers who have normal CD4+ T-cell 
counts (>450cells/mm3).   HIV-1 DNA-loads in discord controllers are equivalent to those 
found in HIV-1 non controllers.  An inverse correlation between HIV-1 DNA -load and CD4+ 
T-cell count is seen in the viraemic controller cohort as a whole.   
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CHAPTER 5 
 
 
Gut-Tropic CD4+ T-cells in Discord Controllers and Typical 
Controllers, and the Relationship between HIV-1 DNA-load 
and subsequent HIV-1 RNA-load blips and CD4+ T-cell 
decline 
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5.1   Introduction 
 
It was reported in the last Chapter that cellular HIV-1 DNA-loads were high in discord 
controllers despite the lack of cell free plasma virus.  This raises the possibility that viral 
replication may be compartmentalised.  The GI tract, including both GALT (Peyer's patches and 
solitary lymphoid follicles) and lymphocyte effector sites (lamina propria and intraepithelial 
sites), has been proposed to be a major viral reservoir in HIV-1 disease [108, 381].  Study of 
SIV infection of rhesus macacques demonstrates that early on infected cells are seen in the 
lamina propria as well as in GALT, but that later on infected cells appear more restricted to 
GALT [382].  CD4+ T-cells in the GI tract have been shown to be 10 times more frequently 
infected than those in peripheral blood in early HIV-1 infection, highlighting the potential for 
compartmentalised viral replication at this site [383].  Further evidence for such 
compartmentalised viral replication at this site comes from the finding that productively 
infected CD4+ T-cells in GALT and the lamina propria are observed many years after the 
initiation of ART and long after suppression of viral RNA-load in the blood [384, 385].  In 
addition, distinct HIV-1 populations have been identified in the GI tract as a result of local 
genetic evolution, indicating that viral replication at this site may occur independently from the 
blood [386]. 
 
In order to study the possibility of compartmentalised viral replication in the GI tract most 
rigorously mucosal tissue samples would be taken to examine viral replication levels at this site 
in discord controllers and typical controllers.  However, the invasiveness of such a procedure 
and the ethical constraints therefore surrounding this means such specimens are not commonly 
obtained.  Consequently, two possible consequences of such compartmentalised viral 
replication in discord controllers were examined: evidence for enhanced migration of 
lymphocytes to the GI tract, potentially also accounting for depleted CD4+ T-cells; and 
secondly the possibility that high viral DNA-load, and the compartmentalised viral replication it 
may represent, manifests itself as subsequent viral RNA-load blips.  These two possibilities will 
now be discussed in more detail.   
 
In HIV-1 infection the degree of inflammation within the GI tract correlates with viral 
replication levels [387, 388], this inflammation is likely to lead to migration of lymphocytes to 
this site.  Migration of effector memory T-cells to intestinal mucosa and in the entry of naïve T-
cells to GALT is facilitated by the interaction between integrin α4β7 on T-cells and mucosal 
addressin cell adhesion molecule (MAdCAM-1) in the vascular endothelium [389-392].  The 
α4β7 integrin is expressed on naïve T-cell in response to the vitamin A metabolite retinoic acid 
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[393].  In inflammatory bowel disease (IBD) and coeliac disease there is an enhanced level of 
lymphocyte migration to inflamed sites in the gut and consequently the level of T-cells in the 
blood expressing the gut homing integrin α4β7 are decreased [394, 395].  Furthermore, early 
during HIV-1 infection when viral replication and CD4+ T-cell depletion in the GI tract is 
known to be very high, a significant depletion of blood CD4+ T-cells expressing α4β7 integrin is 
also seen [396].  These α4β7 expressing CD4+ T-cells are found abundantly in the GI tract and 
have been shown to be more susceptible to HIV-1 infection than cells not expressing the integin 
[397].  The integrin, which appears in a complex with CD4, may act in such a way to capture 
the virus thus enhancing infection rates since it has been shown to bind the HIV-1 envelope 
protein gp120 prior to engagement with CD4 and CCR5 [292, 398].   
 
Therefore, the first specific hypothesis for the work described here was that inflammation 
arising from compartmentalised viral replication in the GI tract of discord controllers leads to 
increased T-cell migration to this site, which can be measured as depletion of α4β7+ 'gut tropic' 
CD4+ T-cells from the circulation in this group compared with typical controllers.  It would 
follow that such enhanced migration of α4β7+ CD4+ T-cells to the GI tract would also result in 
enrichment of cells highly susceptible to infection at this site, thus enhancing infection even 
further.  Therefore, an experiment was designed to determine whether there were fewer α4β7+ 
CD4+ T-cells in blood from discord controllers compared with typical controllers.  
 
If viral replication is compartmentalised in discord controllers at a site such as the gut, the 
ongoing concealed replication might result in virions intermittently ‘spilling’ into the 
circulation.  This would result in a spike or ‘blip’ in HIV-1 RNA-load.  Indeed, higher HIV-1 
DNA-loads in patients on ART have been shown to predict failure of treatment with viral RNA-
load increases or blips [355, 399-401] thus suggesting the high viral DNA-loads represent high 
albeit concealed viral replication.   Further to this, since HIV-1 DNA-load is a prognostic 
marker for disease progression in non controllers [313, 350, 351] it may be that this is also the 
case in viraemic controllers.  Therefore, a second hypothesis was formulated whereby HIV-1 
DNA-loads in viraemic controllers would predict subsequent HIV-1 RNA-load blips, CD4+ T-
cell decline and the need for ART initiation.   
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5.2  Methods 
 
5.2.1 Identification of Gut-tropic T-cells using Flow Cytometry 
 
The same patient groups were analysed as described in Chapter 3: discord controllers with a 
CD4+ T-cell geometric mean of ≤400 cells/mm3 and typical controllers with mean CD4+ T-cells 
≥500 cells/mm3, avoiding those patients too near the 450 cells/mm3 cut-off together with 
progressors and uninfected controllers.  The method for staining T-cells and for flow cytometry 
is described in Section 3.2.1.   
 
Since no α4β7 monoclonal antibody was available, a β7-specific antibody was used as a 
surrogate.  Whilst β7 is also found to form the heterodimer receptor αEβ7 (also known as 
CD103β7) there are very few T-cell in the blood expressing this heterodimer; it is more often a 
characteristic of GI tract intra-epithelial lymphocytes facilitating retention of lymphocytes at 
this site via interactions with E-cadherin [392, 402].  Therefore, those T-cells in blood 
expressing β7 can be assumed to be α4β7+. 
 
Central memory (CD3+CD45RO+CD62L+) and effector memory (CD3+CD45RO+CD62L-) 
CD4+ and CD8+ T-cells were stained with β7–APC and appropriate isotype control in order to 
determine those expressing β7.  Data was again analysed using Winlist software in order to 
determine the percentage of cells expressing β7 amongst each  CD4+ T-cell population.   
 
In order to determine whether HIV-1 DNA-load predicts subsequently HIV-1 RNA increases or 
CD4+ T-cell decline, subsequent routine laboratory values (see Section 2.2.2) were recorded for 
those patients in whom HIV-1 DNA-load was determined.  For HIV-1 RNA the highest viral 
load over 1 year subsequent to HIV-1 DNA-load determination was recorded, together with the 
highest value obtained throughout all follow-up.  CD4+ T-cell count change from baseline (date 
of viral DNA-load) to the very next CD4+ T-cell count (typically at 2-3 months), between 
baseline and last CD4+ T-cell count obtained during the first year follow-up and between 
baseline and the last value obtained during follow-up were recorded.  Which of these patients 
were subsequently started on ART was also recorded, although HIV-1 RNA-loads and CD4+ T-
cell counts whilst on treatment are not included in the follow-up analysis.   
 
107 
 
5.2.2   Statistical Analysis 
 
Statistical analysis and graphical presentations were performed using Prism (version 4.0, 
Graphpad).  Differences in percentage β7 expression were assessed using a 2-tailed Mann-
Whitney U test and results were considered significant if p < 0.05.  A spearman test was used to 
determine correlation between HIV-1 DNA-load and subsequent HIV-1 RNA-load peaks and 
change in CD4+ T-cell count.  
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5.3   Results 
 
Patients analysed for all T-cell homing work were as described earlier in Table 3.1.  
 
5.3.1   Percentage α4β7 Expression in CD4+ T-cells in Discord Controllers and Typical 
Controllers 
 
As is shown in Figure 5.1, no difference in α4β7 expression in effector memory CD4+ T-cells 
was observed between discord controllers and typical controllers.  Neither were any significant 
differences in α4β7 expression observed in naïve or central memory CD4+ T-cell subsets.  
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Figure 5.1  Percentage α4β7 expression in CD4+ T-cells in Discord Controllers and Typical 
Controllers.  Patients analysed included discord controllers and typical controllers, together with 
progressors and uninfected subjects for comparison.  Percentage of CD4+ T-cells expressing β7 in 
a) naïve, b) central memory, and c) effector memory subsets.  Each central bar represents the 
median value, each box represents the IQR and the whiskers represent the minimum and maximum 
values.  Relevant p values are displayed. 
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5.3.2   Ability of HIV-1 DNA-load to Predict Change in HIV-1 RNA or CD4+ T-cell in 
Viraemic Controllers. 
 
HIV-1 DNA-load and subsequent HIV-1 RNA peaks and change in CD4+ T-cell count in 
Viraemic Controllers is shown in Table 5.1.   
 
No significant correlation was seen between HIV-1 DNA-load with either subsequent HIV-1 
RNA or subsequent CD4+ T-cell change (Spearman tests).  High HIV-1 DNA-load was not 
associated with subsequent loss of control of viral RNA-load.  This was further exemplified by 
the loss of HIV-1 RNA-load control in patients with low HIV-1 DNA-load (patients 9 and 10).  
Also, HIV-1 RNA continued to be controlled in some patients with very high HIV-1 DNA-load 
(patients 18, 19, 23 and 26).  Neither was high HIV-1 DNA-load associated with subsequent 
CD4+ T-cell loss.  For example, patient 10 showed progressive loss despite low level HIV-1 
DNA-load, yet others, such as patient 19, experienced a significant CD4+ T-cell gain by the end 
of follow-up despite high level HIV-1 DNA-load.  In line with this, high HIV-1 DNA-load was 
not associated with the subsequent initiation of ART.  Patients 10, 18, 20, 24, 26 and 27 were 
started on ART, with many with equivalently high HIV-1 DNA-loads (13, 19, 22, 23, 25) not 
requiring ART during the follow-up period.   
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Table 5.1  Viraemic Controller HIV-1 DNA-loads and subsequent HIV-1 RNA-load peaks 
and CD4+ T-cell change.    
Patient HIV-1 DNA-
load 
(copies/106 
CD4+ T-cells) 
HIV-1 RNA 
highest value 
1 year 
(copies/ml) 
HIV-1 RNA 
highest value 
all follow-up 
(copies/ml) 
CD4+ 
change at 
next test 
(cells/mm3) 
CD4+ 
change 1 
year 
(cells/mm3) 
CD4+ 
change all 
follow-up 
(cells/mm3) 
Typical Controllers 
1 29.74 NDA NDA NDA NDA NDA 
2 103.99 697 1118 -28 -86 -168 
3 0.00 161 161 -368 -368 -118 
4 47.83 <40 <40 -187 -75 -4 
5 284.26 1403 1403 +125 +125 -41 
6 175.50 NDA 17213 NDA NDA -209 
7 219.28 443 39669 +192 +156 -224 
8 223.43 135 10069 -313 -313 -661 
9 0.00 2973 102902 +193 +193 -254 
10 3.90 1643 19837 -106 -82 -246 
11 203.26 NDA 2318 +108 -105 -105 
12 128.53 NDA NDA NDA NDA NDA 
13 755.25 NDA NDA -140 -140 -188 
14 20.77 NDA NDA -127 -138 -138 
15 69.86 NDA 435 NDA NDA -235 
16 6.16 117 6166 +84 +259 +208 
Discord Controllers 
17 13.27 125 991 -6 -86 -66 
18 1528.68 240 240 -20 -20 -20 
19 648.92 NDA 825 NDA NDA +170 
20 237.87 1132 1320 +7 +11 -141 
21 220.02 NDA NDA NDA NDA NDA 
22 762.59 14584 28614 NDA NDA NDA 
23 555.35 986 1160 +39 +49 -34 
24 771.47 85 18755 -25 0 0 
25 701.04 3015 281642 +31 -20 -41 
26 601.44 NDA 273 +40 -34 -147 
27 258.44 46 286 +55 -47 -214 
NDA – no data available. 
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5.4   Discussion 
 
The majority of CD4+ T-cells lost during early HIV-1 infection are from sites within the GI 
tract [108, 118-120].  HIV-1 infection of CD4+ T-cells at this site appears key to this dramatic 
loss since there is a preferential depletion of CCR5+CD4+ T-cells (i.e. those cells bearing HIV-1 
receptors) which are present in high numbers in the GI tract lamina propria [121, 122].  This 
feature, as well as evidence of enhanced or independent viral replication [383, 386] and the 
presence of immune activation at this site despite successful treatment with ART [383], 
suggests that the GI tract may present a unique immunological environment which is 
particularly permissive to HIV-1 replication.  This has led to the hypothesis that HIV-1 may 
‘hide’ at this site, for example during ART [385, 403].  It is therefore also plausible that the 
virus might ‘hide’ from the immune system at this site in discord controllers in whom viral 
RNA-load levels are also suppressed, whilst destruction of CD4+ T-cells at this site continues.   
 
Migration of lymphocytes to GALT and to diffuse effector sites in the epithelium and lamina 
propria is mediated by a cell surface marker called integrin α4β7 [292, 404].  This integrin is 
present on the cell surface of a small population of circulating T-cells. The major ligand for α4β7, 
MAdCAM-1 [389], is selectively expressed on the endothelium of the intestinal vasculature 
[405] and is present in increased concentrations in inflamed tissue from patients with Crohn’s 
disease and ulcerative colitis [406, 407].  Antibody-mediated inhibition of integrin α4β7 reduces 
inflammation in animal models of colitis [408], and integrin β7 knockout mice have small Peyer 
patches and have lower densities of lamina propria CD4+ T-cells [409].   
 
Studies on patients with Crohn’s disease and ulcerative colitis, which are characterised by 
inflamed bowel mucosa, show that the proportion of systemic gut homing T-cells (expressing 
α4β7) are decreased compared with controls [395].  A further study found that in patients with 
active coeliac disease MAdCAM-1 expression in duodenal biopsies was significantly higher 
than in normal mucosa, and that percentage of T-cells in blood expressing β7-positive was 
significantly lower in untreated coeliac disease compared with controls, but normalised after a 
gluten-free diet [394].  This led to the hypothesis that there is enhanced migration to the GI tract 
of CD4+ T-cells in discord controllers compared with typical controllers accounting for their 
lower peripheral CD4+ T-cell counts; if this were the case it could be expected that a lower 
proportion of circulating CD4+ T-cells would express α4β7 in discord controllers.   
 
The GI mucosa in HIV-1 infected patients is typically inflamed [384] and so lymphocyte 
recruitment to this site would be likely to be enhanced.  In keeping with this, all HIV-1 infected 
subjects demonstrated a trend towards lower percentage α4β7 expression in effector memory 
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CD4+ T-cells compared with uninfected controls.  Therefore, the data presented here supports 
the concept underlying this work that differences in gut inflammation due to viral replication at 
this site are reflected in the level of gut-tropic T-cells in blood.  In contrast to the results 
presented here, Mavinger et al. have recently demonstrated an excess of circulating CD4+ T-
cells expressing α4β7 in HIV-1 positive individuals compared with uninfected controls [410].  
They hypothesise that this is due to defective homing leading to accumulation of T-cells 
expressing α4β7 in the blood.  They further hypothesise that defective homing leads to 
inadequate gut mucosal immune defence leading to increased microbial translocation and 
therefore increased T-cell activation.  It might appear that these results conflict with data shown 
here, however, Mavinger et al. did not differentiate the different T-cell subsets expressing α4β7 
and so it is possible that this excess in HIV-1 positive subjects were naïve T-cells.  Further 
studies are needed to define lymphocyte trafficking in HIV-1 infection and whether HIV-1 
infection leads to accumulation or depletion of circulating gut-tropic CD4+ T-cells.   
 
However, results presented here do not support the hypothesis that there is enhanced CD4+ T-
cell migration to the GI tract in discord controllers, since the percentage of peripheral CD4+ T-
cells expressing α4β7 were found to be equivalent comparing discord controllers with typical 
controllers.  Thus these experiments demonstrate no evidence of enhanced recruitment to the GI 
tract in discord controllers compared with typical controllers.    
 
Of note is there high percentage of naïve T-cells which express α4β7, since if these cells have 
yet to encounter antigen they would not be expected to expressing a homing marker.  This is a 
curious result, but might be at least in part explained by the fact that some of the CD45RA 
expressing T-cells may in fact be effector T-cells in which CD45RO has reverted to CD45RA.   
 
Another possible feature of compartmentalised viral replication is that it could give rise to either 
subsequent loss of control of viral RNA-load, if replication ceased to be restricted to the 
compartment, or disease progression as demonstrated by circulating CD4+ T-cell loss.   Since 
high HIV-1 DNA-load in viraemic controllers might be due to such compartmentalised 
replication it might predict loss of control of viral RNA-load or CD4+ T-cell loss in these 
patients; this would be useful in the clinic to determine which viraemic controllers are most at 
risk of progressive disease and might therefore benefit from ART.  Indeed, it has previously 
been reported that all three markers (viral RNA-load, CD4+ T-cell count and viral DNA-load) 
should be combined to obtain a better picture of the dynamics of HIV-1 disease for each patient 
[313].  The data presented here on a small number of patients found no association between 
viral DNA-load and loss of RNA-load control or CD4+ T-cell depletion in viraemic controllers.  
However, this study is limited and was not designed to determine this rigorously, since a small 
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group was studied and CD4+ T-cell counts and HIV-1 RNA-loads were taken at inconsistent 
and irregular times during follow-up.   
 
In conclusion to this Chapter, although there was evidence of reduced gut tropic effector 
memory CD4+ T-cells in all HIV-1 infected groups there was no significant difference between 
discord controllers and typical controllers.  Therefore, if there is an enhanced level of 
compartmentalised viral replication in the GI tract of discord controllers this does not impact T-
cell homing to the GI tract that can be measured in blood.  Furthermore, no evidence is found to 
suggest that HIV-1 DNA-load predicts HIV-1 RNA increase or CD4+ T-cell decline during 
follow-up, which is a possible outcome of such compartmentalised viral replication.   
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CHAPTER 6 
 
 
General Discussion and Future Work 
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6.1   Introduction 
 
Viraemic controllers are rare patients with the capacity to control HIV-1 RNA-load in the 
absence of therapy.  Whilst the reasons for this control are not completely understood, there is 
irrefutable evidence that untreated individuals with low viral RNA-load tend to demonstrate 
slower rates of CD4+ T-cell decline in the blood and clinical progression than those with high 
viral RNA-load [304, 315, 316].  However, viral RNA-load by itself does not fully explain the 
variability in the rate of CD4+ T-cell decline [259, 260].  Indeed, it has been reported previously 
that maintenance of a low viral RNA-load does not confer absolute protection against disease 
progression; for example, an individual in the Sydney Blood Bank Cohort who was infected 
with a partially attenuated HIV-1 isolate eventually developed immune deficiency despite a 
persistently low viral RNA-load [411].  Furthermore, CD4+ T-cell declines are seen in HIV-2-
infected individuals despite very low or undetectable viraemia [265].  
 
In line with this, several patients were observed within the East London HIV-1 infected 
population with low viral RNA-load and counter intuitively they had low CD4+ T-cell counts.  
The work described in this thesis developed from this observation and the clinical uncertainty 
that often accompanies these patients.  Work here aims to study those patients with controlled 
viral RNA-load, but who demonstrated low CD4+ T-cell counts and hence progression to AIDS, 
termed here ‘discord controllers’.  Specifically, the aims were to determine whether this cohort 
differed from typical controllers with maintained CD4+ T-cell counts, in terms of 
epidemiological factors, virological characteristics or immunological factors.  We also 
hypothesised that analysis of discord controllers with comparison to typical controllers would 
allow immunological changes associated with disease progression and those due to high viral 
RNA-load to be distinguished; this is not possible with analysis of patients with the typical 
pattern of progression (high viral RNA-load, low CD4+ T-cells).   
 
Very few papers describe such ‘discord controllers’ despite the considerable uncertainly in the 
clinic since markers of progression are discordant.  A few such papers describe these patients in 
terms of routine laboratory parameters [316-319], whereas others looked at a limited number of 
T-cell characteristics of these patients in an attempt to understand why there is disease 
progression [320, 321, 338, 346, 347] and have been discussed in light of the data presented in 
Chapter 3, which presents a comprehensive assessment of T-cell populations in these patients.  
The work described here involves a cohort of 18 discord controllers, which is larger than those 
previously described.  None of the papers already published examined epidemiological features 
or viral subtype of the discord controller cohort compared with typical controllers, which is of 
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interest in terms of understanding genetic or viral features which might predispose to this 
disease phenotype.  No study examined HIV-1 DNA-load in these patients which is of interest 
in terms of understanding if the phenotype is driven by viral replication.  Only one team of 
investigators (not published at the time of starting this work) have described the response to 
ART in discord controllers [318, 322]; determining this response is of interest both clinically 
and in terms of understanding the mechanism of pathology in this cohort.   
 
6.2   Epidemiological Features of Discord Controllers and Typical Controllers 
 
Since none of these previous studies described epidemiological characteristics of discord 
controllers, it was important to determine whether any factor was over-represented in this 
group.  However, median age, sex distribution, ethnicity, region of birth and risk behaviour 
were all found to be similar comparing the two controller groups.  
 
It is important to note that there is variation in lymphocyte reference ranges comparing people 
of different ethnicities, and that there have been reports of lower CD4+ T-cell counts in people 
of Afrocarribean background [333].  However, it seems unlikely that this has confounded the 
results since no difference in ethnicity was found when comparing discord controllers and 
typical controllers.  Other data collected during the course of this work confirm this notion since 
discord controllers were found to have higher HIV-1 DNA-loads and a distinct T-cell subset 
distribution compared with typical controllers.  Furthermore, of the five patients observed on 
ART three had significant increase in CD4+ T-cell count after starting ART, suggesting 
inhibition of replication had stalled CD4+ T-cell loss.  Similar findings are also described in the 
recent paper by Okulicz et al. who show that CD4+ T-cell gains in viraemic controllers starting 
ART were only slightly lower than those observed in non controllers.  Gains were found to be 
more significant in those with CD4+ T-cell counts of <500 cells/mm3 than in those with CD4+ 
T-cell ≥500 cells/mm3 at ART initiation [322].  The assertion that the low CD4+ T-cell counts in 
discord controllers is not merely a variation in CD4+ T-cell nadir is also further supported by 
the fact that percentage CD4+ T-cells was significantly lower in discord controllers compared 
with typical controllers (suggesting that there was a more marked absence of CD4+ T-cells in 
comparison with other lymphocytes subsets in the discord controllers).  The suggestion is also 
strengthened by the finding of significantly higher HIV-1 DNA-loads in the discord controllers 
compared with typical controllers, as will be discussed further in Section 6.6.   
 
A crucial question was whether discord controllers are in fact a continuum of the typical 
controllers resulting from CD4+ T-cell decline over time and as such have been infected for 
longer.  It is not often possible to obtain data regarding date of seroconversion, so time since 
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first positive HIV-1 test was recorded as a surrogate for this.  There is no significant difference 
comparing the two controller cohorts, suggesting the discord controllers are a distinct 
phenotype.  The fact that age distribution is similar comparing cohorts also supports this.   
 
6.3   HIV-1 Subtypes in Discord Controllers and Typical Controllers 
 
Given the fact that some HIV-1 clades appear to behave differently in terms of transmission and 
pathogenicity, for example clade D may be more pathogenic [32], it was logical to argue that a 
specific HIV-1 clade might predispose to the discord phenotype.  There was a trend towards 
increased frequency of subtype C in the discord cohort compared with typical controllers, but 
there are no reports of increased pathogenicity of this subtype.   Larger studies would be needed 
to determine whether there is a true association between subtype C HIV-1 and the discord 
controller phenotype.  If confirmed, a theoretical possibility explaining this association might be 
that subtype C virus leads to significant levels of compartmentalised replication and as such 
viral RNA-load might not be an accurate reflection of HIV-1 replication levels.   
 
6.4   Summary of HIV-1 RNA-loads, HIV-1 DNA-loads and T-cell Characteristics 
in Discord Controllers and Typical Controllers 
 
A summary of HIV-1 RNA-loads, HIV-1 DNA-loads and T-cell Characteristics in discord 
controllers and typical controllers is shown in Table 6.1. 
 
These results show that the CD4+ T-cell compartment in discord controllers differ from that in 
typical controllers and is indistinguishable from that seen in progressors.  Both discord 
controllers and progressors exhibit low total peripheral CD4+ T-cell counts, high HIV-1 DNA-
loads, depleted naïve CD4+ T-cell and increased CD4+ T-cell activation.  In contrast, when 
observing the CD8+ T-cell compartment discord controllers do not look like progressors (CD8+ 
T-cell subset distribution and activation levels) and are indistinguishable from typical 
controllers. 
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Table 6.1.  Summary of HIV-1 RNA-loads, HIV-1 DNA-loads and T-cell 
characteristics in Discord Controllers and Typical Controllers.  
 
Discord 
Controllers 
Typical 
Controllers 
Progressors  Uninfected 
HIV-1 RNA-load Low Low High Negative 
HIV-1 DNA-load High Low High Negative 
CD4+T-cell counts Low Normal Low Normal 
Naive CD4+  T-cells Low Normal Low Normal 
CD4+ T-cell % Activation High Normal High Normal 
Naïve CD8+  T-cells Normal Normal Low Normal 
Effector CD8+  T-cells Normal Normal High Normal 
CD8+  T-cell % Activation Low Low High Normal 
Effector CD4+  T-cell % α4β7  High High Highest Normal 
 
 
6.5   Why do CD4+ T-cells Decline Despite HIV-1 RNA-load Control in Discord 
Controllers? 
 
The observation that elevated CD4+ T-cell activation is common to both progressors and 
discords suggests that it may be the main mechanism leading to CD4+ T-cell decline in both 
groups.  Since data was obtained at a single time point only, it is not possible to determine using 
only the data obtained here whether the CD4+ T-cell activation is a cause or consequence of 
CD4+ T-cell depletion; it could be argued, for example, that CD4 T-cell depletion might lead to 
activation as a homeostatic response to low numbers.  However, the fact that numerous studies 
have demonstrated that T-cell activation predicts disease progression [263-265, 267, 339-341] 
and conversely that initiation of ART leads to a rapid decline in T-cell activation which is 
followed by CD4+ T-cell count restoration [120], means that it is reasonable to assume that in 
discord controllers, like progressors, CD4+ T-cell activation is a driving factor in CD4+ T-cell 
depletion.  As well as leading to clonal exhaustion and activation-induced cell death [203], 
immune activation is thought to accelerate progression by constantly generating new CD4+ T-
cell targets since HIV-1 favours infection of activated CD4+ T-cells [112]. 
 
The fact that CD4+ T-cell activation occurs in discord controllers without the presence of 
significant viral RNA-load might seem unexpected.  Whilst many patients with significant T-
cell activation and consequent disease progression disease do have high viral RNA-loads, the 
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uncoupling of activation and viral RNA-load has been described previously: in SIV infection of 
sooty mangabeys (the natural host) viral RNA-load is high and yet T-cell activation is low 
[412]; furthermore, in a study of ART naïve children, percentage CD4+ T-cell activation was 
seen to be associated with viral DNA-load and not with viral RNA-load [413] similar to the 
findings here in discord controllers.   
 
Lower numbers and percentages of naïve CD4+ T-cells were observed in both discord 
controllers and progressors compared with typical controllers and uninfected subjects.  
Therefore, a deficiency in CD4+ T-cell regeneration capacity may be a contributing factor as 
suggested by other studies [295].  The decreased naïve CD4+ T-cell numbers might also be 
related to the increased activation level of these cells in discord controllers, since it known that 
activation can drive these cells into an effector phenotype [414].   
 
Another possibility is that circulating CD4+ T-cells are sequestrated to another site.  Activation 
has also been shown to induce display of adhesion and chemoattractant receptors which lead to 
sequestration of T-cells to exit the lymphoid circulation to non-lymphoid sites [415].  
Therefore, a model could be proposed whereby immune activation not only drives peripheral 
CD4+ T-cell depletion through direct cytopathic effect, clonal exhaustion and apoptosis, but 
also through driving naïve cells into an effector phenotype which then exit to a non-lymphoid 
site.  Whilst an increase in the effector memory phenotype was not seen in discord controllers 
compared with typical controllers (just a reciprocal increase in percentage due to naïve CD4+ T-
cell loss), only the blood compartment was studied, so the possibility that naïve cells have been 
driven into this phenotype and moved out of the circulation to their effector site cannot be 
excluded.   
 
Based on findings that the GI tract is a major site of HIV-1 replication and CD4+ T-cells 
depletion [113, 120], work described here investigated the possibility of enhanced sequestration 
to this site in discord controllers.   The percentage of α4β7 expressing effector memory CD4+ T-
cells tended to be lower in HIV-1 positive subjects compared with uninfected subjects, 
suggesting enhanced migration of these cells to the GI tract in all infected groups due to GI 
inflammation and/or viral replication at this site.  This was not more marked in discord 
controllers compared with typical controllers, suggesting no evidence of enhanced sequestration 
to the GI tract in discord controllers compared with typical controllers.    
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6.6   Why Doesn’t High HIV-1 DNA-load Give Rise to High HIV-1 RNA-load in 
Discord Controllers? 
 
Transcription from integrated HIV-1 DNA gives rise to progeny HIV-1 virions and HIV-1 
DNA integration results from infection of susceptible cells [88].  Therefore it is not clear why 
high HIV-1 DNA-loads seen in discord controllers, equivalent to those in non controllers, does 
not result in higher viral RNA-load.  It could be argued that the high HIV-1 DNA-load in 
discord controllers mostly represents provirus-containing cells in latently infected resting 
memory cells rather than virus-producing cells.  However, this seems an unlikely scenario 
based on several observations regarding total HIV-1 DNA (including unintegrated and 
integrated forms): total HIV-1 DNA-load decreases in patients put on ART as replication is 
suppressed [352, 353]; high total HIV-1 DNA load in patients on ART predicts viral RNA-load 
blips which suggests that higher viral DNA-load represents residual replication [355, 399-401]; 
total HIV-1 DNA-load predicts disease progression independently of viral RNA-load [313, 350].  
Therefore, it seems likely that higher viral DNA-loads in discord controllers represent high viral 
replication level, particularly in view of their depleted circulating CD4+ T-cell counts.  This 
raises the important question of why this replication does not result in higher viral RNA-load in 
discord controllers.   
 
It is a theoretical possibility that high level replication might lead to high HIV-1 DNA-load and 
yet low viral RNA-load if this replication is in large part compartmentalised.  The central 
nervous system [416, 417] and the genital tract [418, 419] are well described candidate sites 
amongst others based on work demonstrating the generation of local viral variants or 
persistence of the virus during ART.  The work described in Chapter 5 of this thesis focused on 
the possibility of compartmentalised replication in the GI tract based on observations suggesting 
enhanced or independent viral replication may occur at this site [383, 386] and because of the 
huge loss of CD4+ T-cells at this site suggesting its particular importance in disease progression 
[120].  Whatever the site of such compartmentalisation, replication at this site could give rise to 
infected cells which contain HIV-1 DNA and re-enter the circulation (accounting for high viral 
DNA-load), and yet the free virus remains restricted to the site of replication (e.g. due to a 
physiological barrier such the blood-brain barrier) where it degrades either over time or as a 
result of the immune system.  
 
Observation of the pattern of disease in HIV-2 infection might provide further clues to 
understand the uncoupled viral DNA- and RNA-load in discord controllers.  For a given CD4+ 
T-cell count viral DNA-load is similar when comparing HIV-1 with HIV-2 infection, although 
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viral RNA-load is much lower in HIV-2 infection [265].  The picture in HIV-2 infection 
therefore bears some resemblance to that seen in typical and discord controllers, where disease 
progression appears correlated with HIV-1 DNA-load but not viral RNA-load which remains 
low.  In HIV-2 infection, virus-specific CD8+ T cells maintain a polyfunctional profile similar 
to that in HIV-1 LTNPs [420].  Indeed, it could be that CTL mediated killing of productively 
infected cells might control viral RNA-load without having a significant effect on resting 
memory CD4+ T-cells in which the HIV-1 provirus is integrated quiescently; hence HIV-1 
DNA-load would be preserved in these long-lived cells and yet viral RNA-load would be low.   
 
A further explanation that can be offered is that HIV-1 replication may be occurring in discord 
controllers in low-level bursts which may or may not give rise to transient viraemia.  This 
transient burst of replication might therefore maintain and even increase numbers of infected 
cells over time, thereby leading to high cellular HIV-1 DNA loads and also the immune 
response to antigen, but only reflected in the viral RNA-load so transiently that it is easily 
missed by the infrequent laboratory tests.  Such transient viraemia has been described in 
patients on ART and has been proposed to result from bursts of replication originating from 
infected resting memory cells [421-423].  A further possibility that could account for high HIV-
1 DNA-load despite low RNA-load is that replication is predominantly occurring by cell to cell 
transmission as has been described previously [90].  It may also be that there is a defect in 
virion release from infected cells; intracellcular HIV-1 RNA levels would be expected in be 
elevated in discord controllers if this were the case.   
 
On the other hand virions may be being produced effectively in discord controllers but cleared 
rapidly from the blood by humoral immune mechanisms.  This may be due to enhanced 
efficiency of this arm of the immune system in discord controllers, or might be due to a 
virological feature.  Indeed, in HIV-2 infection the virus has been shown to expose epitopes 
inducing nAbs in a way that does not occur in HIV-1 infection, which might explain the low 
plasma viral RNA-load in HIV-2 infection [424, 425].  These possibilities can be readily 
explored.   
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6.7   Why is the CD8+ T-cell Compartment Different in Discord Controllers 
Compared with Progressors? 
 
Whilst not a specific aim of this work, is it worth discussing why the CD8+ T-cell compartment 
is markedly different comparing discord controllers with progressors, despite the fact CD4+ T-
cells depletion is a feature of both.  Progressors were found to have a depleted naïve population, 
an expanded effector memory population and enhanced activation within the CD8+ T-cell 
compartment.  It is possible that the CD8+ T-cell compartment changes seen in progressors may 
be a feature of high viral RNA-load rather than of disease progression.  One explanation is that 
the high viral RNA-load might drive the proliferation of ‘passenger’ HIV-1 specific CTLs 
(those CTL which proliferate in response to viral antigen without themselves having effect on 
control of virus) [181].  This might account for the high numbers of effector memory CD8+ T-
cells in progressors, and is also supported by the finding that HIV-1 specific CD8+ T-cell have 
been shown in decay following ART-mediated suppression of viral RNA-load [178].  
Functional analysis or specificity of effector memory CD8+ T-cells was not undertaken, but if it 
were it may show that these cells are specific for HIV-1 variants no longer present in the viral 
population, accounting for the fact viral RNA-load is uncontrolled in progressors.  In terms of 
T-cell activation the findings described here are supported by a study by Giorgi et al., who 
found higher viral RNA-load to be correlated with CD8+ but not CD4+ T-cell activation [264].   
 
Whilst the CD8+ T-cell compartment appears similar in the discord controllers and typical 
controllers it may be that there are qualitative differences of this compartment between 
controller groups.  For example, the typical controllers may produce large numbers of HIV-1 
specific ‘driver’ CTL which rapidly locate to tissues and control infection at these sites by 
targeting infected cells, hence reducing CD4+ T-cell destruction.  Functional studies would be 
needed in order to ascertain whether such qualitative differences exist.   
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6.8   What Implications Have These Findings Got for the Wider HIV-1 Infected 
Population? 
 
This study enabled immunological changes associated with disease progression and those due to 
high viral RNA-load to be distinguished, and suggests that CD4+ T-cell activation is not merely 
an effect of significant viral RNA-load, which itself leads to CD4+ T-cell loss via some other 
mechanism.  The observation that HIV-1 DNA-load is associated with CD4+ T-cell activation 
and CD4+ T-cell decline even in the absence of significant viral RNA-load supports a 
mechanistic link between viral replication (even if compartmentalised), chronic immune 
activation (CD4+ compartment only) and progressive immunodeficiency.  
 
The proposal that T-cell activation might be a stronger predictor than viral RNA-load of disease 
progression is most clearly supported by the fact that T-cell activation distinguishes pathogenic 
from non-pathogenic SIV infection in which viral RNA-loads are equivalent in each, but it is 
activation which is associated with progression in non-natural hosts (see Section 1.9.1) [412].  
Silvestri et al. describe activation in the T-cell compartment as a whole in pathogenic SIV 
infection in non-natural hosts, but it appears that this activation is more sustained in CD4+ T-
cells than in CD8+ T-cells.  This might explain findings described here which suggest that CD4+ 
T-cell activation may be more strongly associated with progression than CD8+ T-cell activation.  
Further studies are required to delineate more specifically whether immune activation leading to 
disease progression affects both T-cell compartments or whether it is restricted to the CD4+ T-
cell compartment.   
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6.9   Future Work 
 
One significant limitation of this study is its cross-sectional nature, since establishing cause and 
effect in such studies is difficult.  Longitudinal studies on individual patients could examine 
differences in patients’ immune systems and virus before and after loss of control of viral RNA-
load control, or before and after CD4+ T-cell depletion.  
 
This thesis looked primarily at enumerating T-cells of a certain phenotype.  However, 
evaluation of T-cell functional assays and effects on viral function in HIV-1 controllers would 
be helpful in elucidating further the mechanism of viral control.  Further questions are yet to be 
answered here, including the specificity of the activated T-cells and whether this differs 
between controllers who do and don’t maintain CD4+ T-cell counts.  Whole-genome association 
analysis, as has been described in viraemic controllers [305], may also be used to delineate 
specific features of the immune system in viraemic controllers which might predispose them to 
the discord controllers phenotype.   
 
It would be of interest to determine whether the excess HIV-1 DNA levels in discord controllers 
compared with typical controllers represents unintegrated HIV-1 DNA as expected given its 
close relationship with viral replication [356].  It would also be useful to determine which CD4+ 
T-cell population is the main reservoir for HIV-1 DNA in discord controllers, with resting 
memory CD4+ T-cells [370] and macrophages [426] both potential reservoirs.  Intracellular 
CD4+ T-cell HIV-1 RNA levels could be measured in future studies in order to determine 
whether a defect in release of virus from infected cells might account for high HIV-1 DNA-
loads and yet low RNA-load in discord controllers.   
 
Further work on examining the potential factors driving excess immune activation seen in some 
HIV-1 infected groups including discord controllers could be undertaken.  This would include 
HIV-1 antigens, non-HIV-1 antigens such as translocated microbial products, cytokines, 
stimulation through toll-like receptors or some combination of these or other factors.  Several 
papers have determined levels of translocation from the gut by examining bacterial LPS levels 
in blood [320] or by employing bacterial ribosomal 16S quantitative DNA PCR [427].  
Determining whether this might account for increased CD4+ T-cell activation in discord 
controllers would help to determine why these patients experience disease progression.   
 
The work presented here did not show that HIV-1 DNA-load predicts disease progression in 
viraemic controllers.  However, a larger study group and sequential HIV-1 DNA-loads would 
be needed to examine this more thoroughly. 
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6.10   Conclusions 
 
Study of the discord controller cohort provides a unique opportunity to understand the 
relationships between low level viraemia, adaptive immune responses and disease progression 
in HIV-1 infected individuals.  This understanding could have a bearing on the development of 
therapeutic vaccine approaches and in understanding the mechanisms underpinning CD4+ T-cell 
count decline.   
 
The results presented in this thesis are consistent with a model whereby cellular HIV-1 DNA 
proviral load predicts naïve CD4+ T-cell depletion and CD4+ T-cell activation, whereas viral 
RNA-load is associated with naïve CD8+ T-cell depletion, effector CD8+ T-cell compartment 
expansion and CD8+ T-cell activation.   
 
How do these findings help clinicians?  They remove some of the mystery surrounding why 
some patients with low viral RNA-load also have low CD4+ T-cell counts.  They confirm the 
relationship between ongoing viral replication and disease progression as shown by high HIV-1 
DNA-load in discord controllers.  In addition, they provide strong support for emerging efforts 
to manipulate the immune system, in particular those targeting immune activation and highlight 
the fact that immune activation levels could be a useful measure in assessing potential 
therapeutic vaccines. 
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APPENDIX  I 
 
a) Recovery of PBMCs from EDTA Anti-coaglulated Blood using Ficoll-Hypaque 
Separation 
  
1. Centrifuge to separate plasma and remove plasma into 50ml tube. 
2. Dilute remaining blood with approximately equal volume phosphate buffered saline (PBS). 
3. Add 15 ml Lymphoprep (Axis-Shield) to fresh 50ml tube. 
4. Carefully layer 30 ml of the blood/PBS solution on top of the Lymphoprep (do not mix). 
5. Centrifuge at 800 x g for 25 minutes at room temperature. 
6. Pipette off the white ‘buffy’ layer between the two phases into a 50ml tube – these are 
PBMCs. 
7. Fill up the tube with PBS to 50 ml. 
8. Centrifuge at 800 x g for 5 minutes  plus brake to pellet PBMCs. 
9. Repeat wash step to obtain clear, clean looking pellet. 
10. Resuspend pelleted PBMCs in 90% fetal calf serum (FCS) and 10% dimethyl sulfoxide 
(DMSO) and freeze slowly.  
11. Store in liquid nitrogen. 
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b) Production of High Copy Number Plasmids with PCR Inserts for qPCR Standard 
Curves  
 
1. The appropriately sized (bp) band was excised from the agarose gel with a scalpel.   
2. Gel extraction and PCR purification using the QIAquick Gel Extraction Kit (Qiagen). 
3.  ‘A-tailing’ of purified PCR fragments - 
a. Template 10µl , 10x buffer 2µl ,Taq polymerase 0.16µl (2 U/µl) , dNTPs 0.2µl (1 
mM final concentration). 
b. Incubate for 10 minutes at 72°C, then inactivate polymerase by freezing. 
4. A-tailed PCR fragments were ligated into TOPO TA vector (Invitrogen) according to 
instructions for chemically competent Escherichia coli. 
5. Transform Bacteria - 
a. 50µl of a heavy culture suspension of DH5α Escherichia coli was added to 2 µl 
TOPO ligation reaction.   
b. It was then heat shocked by putting the eppendorf in 42°C water bath for 30 
seconds, following by moving to ice for 2 minutes.   
c. 200µl soc medium was then added, and incubated at 30°C for 30 minute. 
6. Blue White screening - 
a. 50µl from each transformation was spread on agar plate containing ampicillin and 
incubated overnight at 37°C.   
b. Of the hundreds of colonies 10 white colonies were picked off into 45ml LB 
medium (with ampicillin) and incubated at 30°C overnight.   
c. This was then centrifuged to pellet the bacteria.  
7. Purification of Plasmid DNA according to manufacturer’s instructions for the QIAprep Spin 
Miniprep Kit.   
8. In order to verify ligation of the PCR product a digest with eco R1 was performed - 
a. Buffer H 2µl, ecoR1 1µl, plasmid 5µl, water 12µl. 
b. Run on 2% agarose gel with ethidium bromide to check the appropriate sized insert.   
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c) Monoclonal Antibody Staining Matrix for Immunophenotpying using Flow Cytometry 
Tube FITC 
 
PE PerCP PerCP-
Cy5.5 
PC7 APC 
 
APC-
H7 
Pacific Blue 
1 - - - - - - - - 
2 CD8 - - - - - - - 
3 - CD8 - - - - - - 
4 - - CD4 - - - - - 
5 - - - CD8 - - - - 
6 - - - - CD45RA - - - 
7 - - - - - Beta7 - - 
8 - - - - - - CD4 - 
9 - - - - - - - CD3 
-         
10 CLA CD62L HLA-DR CD38 CD45RA Beta7 CD4 CD3 
11 CLA CD62L HLA-DR CD38 CD45RO Beta7 CD4 CD3 
12 CCR4 CD62L HLA-DR CD38 CD45RA Beta7 CD4 CD3 
13 CCR4 CD62L HLA-DR CD38 CD45RO Beta7 CD4 CD3 
14 - - - - - - mIgG1 CD3 
15 - mIgG1 - - mIgG1 - CD4 CD3 
16 - mIgG1 - - mIgG2a - CD4 CD3 
17 rIgM CD62L mIgG2a mIgG1 CD45RA rIgG2a CD4 CD3 
18 mIgG2b CD62L mIgG2a mIgG1 CD45RA rIgG2a CD4 CD3 
19 rIgM CD62L mIgG2a mIgG1 CD45RO rIgG2a CD4 CD3 
20 mIgG2b CD62L mIgG2a mIgG1 CD45RO rIgG2a CD4 CD3 
 
Single colour tubes 1-9 are for colour compensation during analysis of data.  Isotype controls 
are labelled as either mouse IgG (mIgG) or rat IgG (rIgG). 
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APPENDIX  II 
 
a) Loss of HIV-1 RNA-load Control in some HIV-1 Controllers 
 
To describe this cohort fully, it was important to determine whether viral RNA-load and CD4+ 
T-cell counts remained relatively stable for the majority of patients over time.  This was 
particularly important when determining to which cohort the controller belonged.  Whilst for 
most patients, viral RNA-load was stable, for a minority these values changed over time 
atypically (see Figure A.1).   
 
 Loss of viral control 1:  For one patient, over a period of over three years, viral RNA-
load remained low with stable CD4+ T-cell counts.  After this viral RNA-load increased 
dramatically, with a concomitant fall in CD4+ T-cell counts.   
 
 Loss of viral control 2:  In the typical-controller cohort two patients who fulfilled the 
controller inclusion criteria based on laboratory data available at our centre for 3.7 
years (values prior to this not available; time since first positive test until loss of control 
of 6.4 years) and 3.5 years (i.e. for all values from the point of the first positive HIV-1 
test), lost their controller status with a significant rise in viral RNA-load (latest values 
of 36411 and 4357 copies/ml) but maintained normal CD4+ T-cell counts (732 and 708 
cells/mm3 respectively).   
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Loss of viral control 1: CD4+ T-cell count drops concomitant with rise in HIV-1 RNA-load. 
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Loss of viral control 2: HIV-1 RNA-load increases whilst CD4+ T-cell count is steady 
 
Figure A.1  CD4+ T-cell count and viral RNA-load over time for two patients in whom 
viral control was lost.     
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b) Incomplete HIV-1 RNA-load Measurements for Some Viraemic Controllers 
 
For a minority of patients, classification was complicated by the fact that on occasion viral 
RNA-load was not requested during a clinic visit despite blood being tested for CD4+ T-cell 
count.  For example, one patient showed consistently low with normal CD4+ T-cell counts for 
2.3 years following first positive test (last viral RNA-load was 95 copies/ml at which point 
CD4+ T-cell count was 510 cells/mm3).  However, viral RNA-load was not checked for a 10 
month period following this, during which time CD4+ T-cell counts dropped (310 & 326 
cells/mm3) prompting initiation of ART (see Figure A.2).  This patient was classed as a typical 
controller since the CD4+ T-cell count was > 450 cells/mm3 at the last point viral RNA-load 
was known to be suppressed.   
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Figure A.2   Patient with incomplete values for HIV-1 RNA-load.   
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APPENDIX  III  
 
Table  A.1  Co-morbid and Intercurrent illness for each Viraemic Controller 
 
Patient Clinical Condition 
Typical Controllers 
1 Raynauds disease, seizure (unknown cause), depression 
2 Neurosyphilis, genital HSV infection, spondylosis, gallstones 
3 Nil 
4 Nil 
5 Genital HSV 
6 Hepatitis C virus infection, asthma, hypogonadism 
7 Syphilis 
8 Cervical intraepithelial neoplasia 2, sickle cell trait 
9 Nil 
10 Hepatitis C virus infection 
11 Depression 
12 Nil 
13 Nil 
14 Genital HSV 
15 Nil 
16 Nil 
17 Nil 
18 Nil 
19 Nil 
20 Nil 
21 Nil 
22 Tuberculous (TB) adenitis, syphilis  
23 Psoriasis, Hypertension 
24 Nil 
25 Nil 
26 Psychiatric problems, ischaemic heart disease, genital HSV, herpes zoster 
Shingles march 08.   27 Nil 
28 Nil 
29 Nil 
30 Nil 
31 Nil 
32 Syphilis 
33 Syphilis  
34 Repeated urinary tract infections   
35 Nil 
36 Nil 
37 Nil 
38 Nil 
39 Depression 
40 Nil 
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41 type 2 diabetes with retinopathy, haemophilia, hepatitis C virus infection, 
ulcerative colitis  
42 Depression  
43 Irritable bowel syndrome 
44 Nil 
45 Dermatitis 
46 Pulmonary TB, renal failure unknown cause  
47 Glucose-6-phosphatase dehydrogenase deficiency 
48 Nil 
49 Nil 
50 Gall bladder polyps   
51 Latent TB 
52 Nil 
53 Nil 
54 Latent TB, schizoaffective disorder 
55 TB adenitis 
56 Nil 
57 TV  
58 Depression 
59 Nil 
60 Nil 
61 Genital warts  
62 Nil 
63 Nil 
64 Oral and anogenital candidiasis 
Discord Controllers  
1 Haemophilia, hepatitis C virus infection 
2 Herpes zoster, oral HSV infection, genital warts 
3 Nil 
4 Nil 
5 Syphilis, scabies, gonococcal infection, shingles 
6 Nil 
7 Nil 
8 Supra-ventricular tachycardia, peripheral neuropathy due to ART 
9 Nil 
10 Sickle cell trait  
11 Nil 
12 Sinusitis, syphilis 
13 Nil   
14 Hepatitis C virus infection, syphilis, Gilbert’s syndrome, dyspepsia 
(biopsy helicobacter pylori positive) 
15 Mitral valve stenosis, tricuspid valve regurgitation  
16 Syphilis, genital warts 
17 Nil 
18 Nil 
Those conditions which could be considered to be opportunistic (infections and neoplastic 
conditions) are shown in bold.  
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APPENDIX  IV 
 
Abstract of Paper Describing this Work, Accepted for Publication in Journal of 
Acquired Immune Deficiency Syndrome 
 
Full article included at the back of the thesis.  
 
Journal of Acquired Immune Deficiency Syndrome. 2012;61:407–416.   PMID:   22902723 
Disease Progression in Human Immunodeficiency Virus-1 Infected Viremic Controllers.   
 
Groves KC, Bibby DF, Clark DA, Isaksen A, Deayton JR, Anderson J, Orkin C, Stagg AJ, 
McKnight A. 
 
Abstract 
 
BACKGROUND:  
The mechanism of CD4 T-cell decline in Human Immunodeficiency Virus-1 (HIV-1) infection 
is unclear, but the association with plasma viral RNA-load suggests viral replication is 
involved. Indeed, viremic controller patients with low RNA-loads typically maintain high CD4 
T-cell counts. Within a local cohort of 86 viremic controllers, we identify a subgroup (18 
'discord controllers') with low CD4 T-cell counts which present clinical uncertainty. The 
underlying mechanism accounting for CD4 T-cell decline in the face of low or undetectable 
plasma (RNA) viral load remains unresolved. The objective of this study was to investigate the 
viral and host immune system dynamics in discord controllers by measuring cellular HIV-1 
DNA-load, T-cell populations and T-cell activation markers. 
 
METHODS:  
We compared discord controllers (RNA-load <2000 copies/ml, <450 CD4 T-cells/mm) with 
typical controllers (RNA-load <2000 copies/ml, >450 CD4 T-cells/mm) and progressors (RNA-
load >10,000 copies/ml, <450 CD4 T-cells/mm). We quantified CD4/CD8 naïve/ central-
memory/ effector-memory subsets (CD45RA/RO ± CD62L), activation levels (CD38HLA-DR) 
and HIV-1 DNA-load. 
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RESULTS:  
Discord controllers resembled progressors showing high DNA-load, depletion of naïve CD4 T-
cells and higher activation in all CD4 T-cell subsets, compared with typical controllers. They 
were similar to typical controllers with lower CD8 T-cell activation compared with progressors. 
 
CONCLUSIONS:  
Our data are consistent with a relationship between CD4 T-cell activation and disease 
progression. HIV-1 DNA-load may be a better marker of viral replication and disease 
progression than RNA-load. Lower level CD8 T-cell activation correlates with low RNA-load, 
but not with disease progression or DNA-load. 
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BASIC AND TRANSLATIONAL SCIENCE
Disease Progression in HIV-1–Infected Viremic Controllers
Katherine C. Groves, MBChB, BMedSci,*† David F. Bibby, BSc, PhD,† Duncan A. Clark, BSc, PhD,†
Are Isaksen, BSc,‡ Jane R. Deayton, FRCP, PhD,*‡ Jane Anderson, MBChB, FRCP, PhD,k
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and Áine McKnight, MiBiol, MSc, PhD*
Background: The mechanism of CD4+ T-cell decline in HIV-1
infection is unclear, but the association with plasma viral RNA load
suggests viral replication is involved. Indeed, viremic controller
patients with low viral RNA loads typically maintain high CD4+
T-cell counts. Within a local cohort of 86 viremic controllers, we
identify a subgroup (18 “discord controllers”) with low CD4+ T-cell
counts that present clinical uncertainty. The underlying mechanism
accounting for CD4+ T-cell decline in the face of low or undetectable
plasma (RNA) viral load remains unresolved. The objective of this
study was to investigate the viral and host immune system dynamics
in discord controllers by measuring cellular HIV-1 DNA load, T-cell
populations, and T-cell activation markers.
Methods: We compared discord controllers (viral RNA load
,2000 copies/mL, ,450 CD4+ T-cells/mm3) with typical control-
lers (viral RNA load ,2000 copies/mL, .450 CD4+ T-cells/mm3)
and progressors (viral RNA load .10,000 copies/mL, ,450 CD4+
T-cells/mm3). We quantiﬁed CD4+/CD8+ naive/central memory/
effector memory subsets (CD45RA/RO 6 CD62L), activation levels
(CD38+HLA-DR+), and HIV-1 DNA load.
Results: Discord controllers resembled progressors showing high
viral DNA load, depletion of naive CD4+ T-cells, and higher acti-
vation in all CD4+ T-cell subsets, compared with typical controllers.
They were similar to typical controllers with lower CD8+ T-cell
activation compared with progressors.
Conclusions: Our data are consistent with a relationship between
CD4+ T-cell activation and disease progression. HIV-1 DNA load
may be a better marker of viral replication and disease progression than
viral RNA load. Lower level CD8+ T-cell activation correlates with low
viral RNA load but not with disease progression or viral DNA load.
Key Words: HIV-1, viremic controller, HIV-1 DNA, plasma RNA
load, activation
(J Acquir Immune Deﬁc Syndr 2012;61:407–416)
INTRODUCTION
After HIV-1 seroconversion, CD4+ T-cells, the main
target cell population, decline over the asymptomatic phase
leading to progressive immunodeﬁciency. Although it
is known that HIV-1 is cytopathic for CD4+ T-cells, the
mechanisms leading to CD4+ T-cell depletion are not fully
understood. It is suggested that the proportion of infected
CD4+ T-cells is too small to fully account for the extent of
CD4+ T-cell decline,1 and an increased death rate is observed
in nontarget cells, such as CD8+ T-cells.2 In keeping with this,
Rodriguez et al3 showed that in untreated individuals, plasma
HIV-1 RNA load only minimally predicts CD4+ T-cell
decline, with current evidence suggesting that immune acti-
vation is the major predictor of disease progression.4–11 Stud-
ies also suggest that naive T-cell compartments are
preferentially depleted in progressive disease10,12,13; it is not
known whether this is due to impaired production, sequestra-
tion to another site or phenotype, or destruction of naive
T-cells. In addition, HIV-1 DNA load has been shown to
predict disease progression.14–16
Some patients, viremic controllers, maintain low plasma
viral RNA loads without antiviral medications. The vast ma-
jority of these patients are infected with replication-competent
virus, and yet typically maintain high CD4+ T-cell counts.17
However, cases of progressive CD4+ T-cell depletion despite
continued control of viral RNA load have been described.18–20
We term these patients “discord controllers” to reﬂect the dis-
crepancy in viral RNA load and CD4+ T-cell counts. This
patient subset presents uncertainty in clinical management
because parameters that are normally associated with progres-
sion (viral RNA load and CD4+ T-cell count) are uncoupled.
The mechanism leading to this discrepancy is unclear, although
aberrant immune activation causing T-cell decline in the face of
low plasma viral RNA load is one potential explanation.
We hypothesized that those changes typically associ-
ated with disease progression, depleted naive CD4+ and CD8+
T-cells, high level CD4+ and CD8+ T-cell activation, and high
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HIV-1 DNA loads, would be more marked in discord
controllers as compared with typical controllers (low viral
RNA load, high CD4+ T-cells). Furthermore, we hypothe-
sized that analysis of discord controllers with comparison to
typical controllers would allow immunologic changes associ-
ated with disease progression and those due to high plasma
viral RNA load to be distinguished; this is not possible with
analysis of patients with the typical pattern of progression
(high HIV-1 RNA load, low CD4+ T-cells). Our aims based
on these hypotheses were to analyze these factors typically
associated with disease progression in discord controllers as
compared with typical controllers and patients with a typical
progression pattern.
METHODS
Study Groups
Patients were recruited, with informed written consent,
from outpatient clinics at Barts and The London and Homer-
ton University Hospital Trusts. All patients were HIV-1
seropositive and HIV-2 seronegative. Serology was not
available for 1 patient, but sequence analysis as part of
antiretroviral resistance testing demonstrated HIV-1 infection.
Viremic controllers were deﬁned as having plasma HIV-1
RNA loads below 2000 copies per milliliter [$3 measure-
ments over 12 months without antiretroviral therapy (ART)],
deﬁnition in line with that used by the International HIV
Controller Consortium. The controller cohort was divided into
2 groups based on the geometric mean of the last 3 CD4+
T-cell counts: typical controllers .450 cells/mL (mm3), dis-
cord controllers ,450 cells/mm3. The reason 450 cells/mm3
was used as the cutoff was based on the fact many laboratories
deﬁne a normal CD4+ T-cell count to be above this value.21
In addition, the “When to start consortium”22 have found
decreased mortality when ART is started in the range 351–
450 cells/mm3 instead of waiting until they are below
350 cells/mm3, further supporting the suggestion that this range
is abnormally low. The geometric mean of the 3 most recent %
CD4+ T-cells for each controller cohort was calculated to deter-
mine whether the lower absolute CD4+ T-cell count in the
discord controllers was reﬂected in a lower % CD4+ T-cells.
Epidemiological data were collected including age, sex, time
since ﬁrst positive test, ethnicity, country of birth, and blood-
borne virus risk behavior.
Controls were (1) Viremic noncontrollers, for viral DNA
load studies: ART-naive HIV-1–infected persons, infected .12
months with a viral RNA load .10,000 copies per milliliter; for
T-cell studies controls comprised (2) HIV-1 progressors, deﬁni-
tion as for viremic noncontrollers but with CD4+ T-cell counts
,450 cells/mm3, and (3) uninfected subjects.
Plasma HIV-1 RNA loads and CD4+ T-cell counts were
stable for most controller patients. Two typical controllers,
however, with low viral RNA load for 3.7 and 3.5 years
subsequently showed a signiﬁcant rise in viral RNA load
while maintaining good CD4+ T-cell counts (geometric
means of 732 and 708 cells/mm3, respectively). Another
patient with low viral RNA loads and good CD4+ T-cell
counts for 2.3 years subsequently experienced a fall in
CD4+ T-cell count, but without an viral RNA load measure-
ment, prompting initiation of ART. Thirteen patients (3 dis-
cord controllers and 10 typical controllers) were treated with
ART during pregnancy but controlled plasma viral RNA load
for at least 12 months both before and after ART. Controllers
mentioned in this paragraph are included in the analysis of
patient characteristics and clade analysis but were not used for
viral DNA load and T-cell analysis. In addition, T-cell work
was carried out only on those discord controllers with CD4+
T-cell geometric mean of #410 cells/mm3, and those typical
controllers with a mean of $500 cells/mm3, to avoid those
patients too near the cutoff.
CD4+ T-Cell Counts and Viral RNA Loads
Routine laboratory CD4+ T-cell counts were performed
using BD FACS Sample Prep Assistant with Trucount beads,
acquiring samples on a BD FACSCanto II ﬂow cytometer.
FACSCanto clinical software was used for data analysis.
Plasma viral RNA load was measured using Roche Ampli-
prep/COBAS Taqman HIV-1 Test v1.0 (Roche Molecular Sys-
tems, Inc, Pleasanton, CA; detection limit of 40 copies/mL). At
least 1 sample from each patient was also tested using a different
assay to conﬁrm the low viral RNA load. Individual patient
viral RNA loads and CD4+ T-cell counts are reported as the
geometric mean of last 3 measurements or last 3 before ART.
If a patient had achieved viremic control (,2000 copies/mL,
.12 months), but subsequently viral RNA load rose above
2000 copies per milliliter, the last date of viremic control was
determined to be the last date an viral RNA load measurement
would still contribute to a geometric mean of,2000 copies per
milliliter.
Rate of change of CD4+ T-cell count was calculated
using the geometric mean of the 3 most recent values (x)
and the mean of the oldest recorded values (y), and the time
between them (z): [(y 2 x)/z]. Patients were only included in
this calculation if the values spanned at least 3 years.
Clade Analysis
Some patients’ clades were obtained during routine
genotypic antiretroviral resistance testing (RNA sequence
from protease and AA 1–335 of reverse transcriptase). This
assay has demonstrated efﬁcacy in picking up a wide variety
of subtypes including recombinant subtypes.23 For patients on
whom genotypic antiretroviral resistance testing was unavail-
able, previously described env24 and gag25 polymerase chain
reactions (PCRs) were used in parallel to accurately determine
recombinant subtypes. Ampliﬁed products were sequenced
using the second round forward and reverse primers from
each PCR on an ABI 3100 Genetic Analyzer (Applied Bio-
systems Inc., Foster City, CA). Sequences were analyzed
using SeqScape V2.1.1 software and subtyped using the RE-
GA online typing tool (Stanford University, 2006).
HIV-1 DNA Load Determination
DNA was extracted from cryopreserved peripheral blood
mononuclear cells using Qiagen EZ1 DNA Blood Kit on the
Qiagen BioRobot EZ1. A ﬁxed concentration of phocine
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herpes virus was added to each sample before extraction as an
internal ampliﬁcation control. A quantitative HIV-1 PCR,
amplifying the long-terminal repeat (LTR) region, was designed
based on previously described reverse transcriptase–polymerase
chain reaction.26,27 A ﬁnal 25 mL PCR mixture contained 5 mL of
peripheral blood mononuclear cells DNA, 2· PCR QuantiTect
Multiplex RT-PCR No Rox Mix (Qiagen), 0.2 mM of each
primer (F1 59-AGCCTCAATAAAGCTTGCCTTGA-39; R1
59-GGCGCCACTGCTAGAGATTTT-39), and 0.2 mM probe
(AAGTAGTGTGTGCCCGTCTGT, ﬂuorescent label). Thermo-
cycling conditions (ABI 7500) were 95°C for 15 minutes, then
45 cycles of 95°C for 15 seconds, 60°C for 1 minute, and 72°C
for 5 minutes. Mean values were calculated from duplicate
PCRs. Quantitative PCR for b-globin (adapted from Lo et al28)
was run in parallel. An external plasmid dilution series was run
to construct a standard curve allowing viral DNA loads to be
expressed as per cell equivalent.
T-cell Immunophenotyping Using
Flow Cytometry
Seven-color ﬂow cytometry was used to quantify
CD4+ and CD8+ T-cell populations and their naive
(CD45RA+CD62L+), central memory (CD45RO+CD62L+),
and effector memory (CD45RO+CD62L2) subsets in EDTA-
anticoagulated blood. Activation levels were determined by
measuring the percentage of T-cells coexpressing CD38 and
HLA-DR. The following monoclonal antibodies and ﬂuoro-
chromes were used: CD3-Paciﬁc Blue, CD4-allophycocyanin
(APC)-H7, CD45-RA-phycoerythrin(PE)-Cy7, CD45-RO-PE-
Cy7, CD62L-PE, HLA-DR-peridinin chlorophyll protein
(PerCP), CD38-PerCP-Cy5.5 (BD Biosciences, San Jose, CA).
Saturating amounts of monoclonal antibodies/isotype
controls were incubated with 100 mL of whole blood (within
4 hours of collection) for 15 minutes at room temperature.
Optilyse C (Immunotech, Marseilles, France) was added for
15 minutes at room temperature. Blood aliquots with single-
color staining were processed with each sample for compen-
sation. After 2 washes with phosphate-buffered saline
containing 2% fetal calf serum, 0.02% NaN3, and 1 mM
EDTA, stained cells were resuspended and ﬁxed in 300 mL
phosphate-buffered saline 4% paraformaldehyde. A constant
volume of Flow-count Fluorospheres (Beckman Coulter,
Brea, CA) was added to enable absolute quantiﬁcation of
cells. The ﬁxed stained cells were acquired within 12 hours
of ﬁxing on a BD LSR II cell analyzer (BD Biosciences) with
a minimum of 50,000 (usually 100,000) events acquired per
sample.
Winlist 6.0 software (Verity Software House, Topsham,
ME) was used for analyses and color compensation (gating
strategy shown in Fig. 1). CD4+ T-cells were identiﬁed within
a viable cell gate, set on the basis of light scatter, as cells that
were CD3+CD4+. CD8+ T-cells were identiﬁed as mononu-
clear cells that were CD3+CD42. Two-dimensional dot plots,
in which quadrant gates were set on the isotype controls, were
used to deﬁne naive, central memory, and effector memory
populations in both CD4+ and CD8+ T-cell populations. In
turn, each of these populations were viewed on further
2-dimensional plots to determine activation level (percentage
of cells coexpressing CD38 and HLA-DR). The number of
ﬂow-count spheres acquired allowed a precise determination
of sample volume acquired, allowing expression of number of
cells per volume of blood.
Statistical Analysis
Due to the rarity of these patients even in a large total
HIV-1–infected cohort, power calculations were not under-
taken to determine sample sizes; instead, all patients fulﬁlling
the controller inclusion criteria and available to consent to the
study were included. Therefore, it is necessary to interpret
non-statistically different results with caution.
Analysis was performed using Prism (version 4.0;
Graphpad Software, San Diego, CA) and results considered
signiﬁcant if P, 0.05. Viral RNA and DNA loads were log10
transformed before statistical analysis. To determine differen-
ces in HIV-1 RNA/DNA loads, age, time since ﬁrst positive
test and T-cell ﬂow data, a 2-tailed Mann–Whitney U test was
applied. Fisher’s exact test (2-tailed) was used when comparing
sex distribution, ethnicity, country of birth, risk behavior, and
clade in each cohort. A correction for multiple comparisons
was employed using the false discovery rate calculation.
RESULTS
Controller Phenotype
A cohort of 82 HIV-1 viremic controllers was estab-
lished: 64 typical controllers and 18 discord controllers
(Table 1). Approximately 3000 patients attend the clinics,
thus viremic controllers represent 2.7% (discord controllers
0.6%, typical controllers 2.1%) of all infected patients.
Comparing the 2 controller cohorts, plasma viral RNA loads
were indistinguishable (P = 0.71). Nine typical controllers
and 1 discord controller were elite controllers (viral RNA load
below 50 copies/mL, occasional nonconsecutive blips). There
was no difference in median age (P = 0.44), sex distribution
(P = 0.79), ethnicity, region of birth, or risk behavior. No
signiﬁcant difference was found comparing time since ﬁrst
positive test (best available surrogate for time since serocon-
version) between the 2 controller cohorts (P = 0.25), but
a larger cohort may reveal a difference. The %CD4+ T-cells
in the discord controllers [median 22.3, interquartile ratio
(IQR) 17.6–26.0] was signiﬁcantly lower than that seen in
the typical controllers (median 33.7, IQR 23.8–40.0, P ,
0.0001). The rate of change of CD4+ T-cell count was not
signiﬁcantly different comparing the 2 cohorts (discord con-
trollers, median 22.9, IQR 226.4 to 21.0; typical control-
lers, median 2.1, IQR216.5 to234.6, P = 0.2174); however,
again, a larger study could reveal a difference here.
Clade Distribution in Controller Cohorts
The clade distribution in the East London HIV-1–infected
population is diverse,23 with around 64% of isolates being non-
clade B (D. A. Clark, PhD, and D.F. Bibby, PhD, unpublished
data). We investigated whether there was a skew regarding
infecting viral clade in discord controllers. It was not possible
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to obtain a product for 2 samples tested (plasma viral RNA load
,50 and 111 copies/mL). As shown in Table 1, there was
a non-signiﬁcant trend towards an increased frequency of clade
C in the discord controllers (40.0%) compared with typical
controllers (17.1%) and also compared with the total tested
HIV-1 population (25.1%) (D. A. Clark, PhD, and D.F. Bibby,
PhD, unpublished data over 5 years at Department of Virology,
Barts and the London NHS Trust).
Depleted Naive CD4+ T-Cell Compartment in
Discord Controllers
HIV-1 infection, as it progresses, leads to decline of
CD4+ naive T-cells.10,12 We measured the number and per-
centage of these naive cells (CD45RA+CD62L+), central
memory T-cells (CD45RO+CD62L+), and effector memory
T-cells (CD45RO+CD62L2) in blood from participants in
each cohort.
As expected, lower CD4+ T-cell numbers were seen in
each subset in progressors and discord controllers compared
with typical controllers and uninfected patients (Figs. 2A–C).
A more marked depletion of the naive subset was seen in both
discord controllers and progressors compared with the other
patient groups (percentage of total CD4+ T-cells, Fig. 2D).
The higher percentage of effector memory cells in progressors
and discord controllers compared with typical controllers
(Figs. 2C, F) represents a reciprocal change due to marked
loss of naive cells. The percentage of central memory T-cells
was similar in all 3 patient groups (Fig. 2E).
Increased CD4+ T-Cell Activation in
Discord Controllers
High-level CD4+ T-cell activation is associated with
disease progression.5,8 We, therefore, measured T-cell
activation level (percentage of cells coexpressing CD38+
and HLA-DR+) in blood. Progressors and discord controllers
had comparably increased levels of activation in naive, central
memory, and effector memory CD4+ T-cell subsets
(Figs. 2G–I) compared with typical controllers and uninfected
subjects. Typical controllers demonstrated a trend toward
increased activated effector memory CD4+ T-cells as previ-
ously reported.29
Naive CD8+ T-Cell Levels Are Not Depleted
Compared With Typical Controllers
So far, our results suggest that the CD4+ T-cell
compartment is similar in discord controllers and progres-
sors. We next characterized the CD8+ T-cell population.
FIGURE 1. Gating strategy for flow
cytometric analysis of T-cell subsets.
A, Forward and side scatter to define
viable cell gate. B, Double staining of
viable cells with anti-CD3 and anti-
CD4. CD4+ T-cells are in the top
right quadrant; CD42 T-cells (pre-
dominately CD8+ T-cells) are in the
bottom right quadrant. C, Double
staining of CD4+ T-cells with anti-
CD45RA and anti-CD62L, naive
CD62L+CD45RA+ T-cells, defined
with reference to staining with iso-
type-matched control antibodies, are
in the top right quadrant. D, Double
staining of naive CD4+ T-cells with
anti-CD38 and anti-HLA-DR, acti-
vated CD38+HLA-DR+ T-cells, defined
with reference to staining with iso-
type-matched control antibodies, are
in the upper right quadrant.
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Controller groups had similar numbers and percentages of
CD8+ naive T-cells compared with uninfected controls,
whereas the progressors had a marked depletion of this cell
type (Figs. 3A, D). Progressors had an expanded number of
effector memory CD8+ T-cells compared with all other
groups (Fig. 3F).
CD8+ T-Cell Activation Is Not Higher in
Discord Controllers Compared With
Typical Controllers
CD8+ T-cell activation (CD38+ HLA-DR+) was
increased in all T-cell subsets of all HIV-positive patients,
even in typical controllers, compared with uninfected controls
as has been demonstrated by Lopez et al.30 This is in keeping
with the proposition that CD8+ T-cell subset alterations are
a highly sensitive marker of HIV-1 infection. This increased
activation was more marked in progressors in all subsets,
especially in the memory compartments (Figs. 3G–I); in
keeping with a previous report showing increased memory
CD8+ T-cell activation in noncontrollers compared with con-
trollers.31 In comparison, activation was equivalently low in
both controller cohorts (Figs. 3G–I). Thus, despite the fact
that discord controllers have low CD4+ T-cell counts (like
progressors), their CD8+ T-cell activation pattern more
closely resembles that of typical controllers.
TABLE 1. Patient Characteristics and Clade of Infecting Virus in Controller Cohorts
Typical Controllers
(CD4+ Count .450 cells/mm3),
n = 64
Discord Controllers
(CD4+ Count ,450 cells/mm3),
n = 18*
Age, yrs 37.5 (32.0–43.0) 38.5 (32.5–49.0)
Female sex, n (%) 35 (54.7) 11 (61.1)
CD4+ T-cell count, cells/mm3† 699.3 (550.4–843.1) 347.2 (298.0–406.6)
Plasma viral RNA load, log10 copies/mL† 408.5 (160.7–1000.0) 428.6 (100.3–1043.0)
Place of birth, n (%):
Europe 25 (39.1) 7 (38.9)
Africa (Sub-Sahara) 28 (43.7) 10 (55.6)
Caribbean 6 (9.4) 0 (0)
South Asia 3 (4.7) 0 (0)
Other 2 (3.1) (Australia, Ecuador) 1 (5.5) (New Zealand)
Ethnicity, n (%)
White British 12 (18.8) 3 (16.7)
White other 8 (12.5) 2 (11.1)
Black African (Sub Saharan) 28 (43.7) 11 (61.1)
Black Caribbean 11 (17.2) 2 (11.1)
South Asian 3 (4.7) 0 (0)
Other 2 (3.1) (Mixed white and black African;
South American)
0 (0)
Time since ﬁrst positive test, yrs 4.5 (2.5–6.5) 4.6 (3.3–9.3)
Risk behavior
Heterosexual 42 (65.6) 11 (61.1)
Speciﬁed abroad 26 (40.6) 5 (27.8)
Homosexual 20 (31.3) 6 (33.3)
Blood Products 1 (1.6) 1 (5.6)
IVDU 1 (1.6) 0 (0)
Clade, n‡ (%) n = 41 n = 15
B 14 (34.1) 6 (40.0)
CRF02_AG 8 (19.5) 3 (20.0)§
C 7 (17.1) 6 (40.0)
A 4 (9.7) 0 (0)
F 2 (4.9) 0 (0)
CRF14_BG 2 (4.9) 0 (0)
Other D; A/C; A/D; B/D 0 (0)
Data presented in this table, when not stated to be n (%) are median (IQR).
*Three patients in this cohort started ART due to their low CD4+ T-cell count (viral RNA load/CD4+ values before starting ART were used).
†Median (IQR) of geometric mean calculated for each subject using 3 most recent CD4+ T-cell count and plasma viral RNA load values.
‡Data obtained using genotypic antiretroviral resistance testing for 28 typical controllers and 10 discord controllers, and using nested PCR for 13 typical controllers and 5 discord
controllers; a product was not ampliﬁed for 2 samples tested using the nested PCRs (plasma viral RNA load ,50 and 111 copies/mL).
§For 1 sample, sequence analysis of nested PCR products indicated either CRF02_AG or CRF09_CPX. Statistical analysis employed a Mann–Whitney U test for plasma viral
RNA load, age, time since ﬁrst positive test, and a Fisher’s exact test for sex distribution, ethnicity, country of birth, and clade in each cohort. IVDU indicates intravenous drug use.
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Higher HIV-1 DNA Load in the Discord
Controller Cohort Compared With
Typical Controllers
Viremic controllers typically have low HIV-1 DNA
loads in addition to low viral RNA loads.32 Because discord
controllers have low CD4+ T-cell counts, we hypothesized
that high levels of viral replication were nevertheless ongoing
and that this may be reﬂected in higher viral DNA loads.
Plasma viral RNA load and cellular viral DNA load were
determined for controllers and a group of noncontrollers
(Fig. 4). We found discord controllers to have signiﬁcantly
higher viral DNA loads (median 601, range 13–1529 copies
per 106 CD4+ T-cells) than typical controllers (median
87, range 0–755 copies per 106 CD4+ T-cells) and that
viral DNA loads were as high as those seen in noncontrol-
lers (high viral RNA loads) (median 852, range 27–2188
copies per 106 CD4+ T-cells), suggesting signiﬁcant ongoing
viral replication.
ART in Discord Controllers Leads to Modest
Recovery of CD4+ T-Cell Counts
Typically, after initiation of ART in a patient, plasma
viral RNA load becomes undetectable and CD4+ T-cell count
FIGURE 2. Representation of CD4+
T-cell subsets by patient group.
Patients analyzed included 7 patients
with discord controller phenotype
[median (IQR) for viral RNA load 675
(128–1320) copies/mL, CD4+ T-cells/
mm3 337 (267–400)]; 12 patients
showing the typical controller phe-
notype [viral RNA load 268 (116–926)
copies/mL, CD4+ T-cells/mm3 815
(691–971)], 5 progressors [viral RNA
load 60,683 (28,603–155,518) cop-
ies/mL, CD4+ T-cells/mm3 309 (296–
339)], and 5 uninfected subjects.
Progressors: age 35 (30–48) years,
female 40%, CD4+ T-cell count 309
(287–346) cells/mm3, HIV-1 RNA
load 60,682 (23,947–232,854) copies
per milliliter, all reported as median
(range). Absolute numbers of cells in
CD4+ T-cell subsets are shown in (A)
naive (CD45RA+CD62L+), (B) central
memory (CD45RO+CD62L+), and (C)
effector memory (CD45RO+CD62L2).
Percentage of cells in CD4+ T-cell
subsets compared with total CD4+
T-cell pool are shown for (D) naive,
(E) central memory, and (F) effector
memory. Percentage activation of
cells in CD4+ T-cell subsets (as per-
centage of total cells in that subset) by
patient group is shown in (G–I). Each
central bar represents the median
value, each box represents the IQR,
and the whiskers represent
the minimum and maximum values.
Statistical analysis employed a Mann–
Whitney U test.
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increases.33 During this study, 5 patients in the discord con-
troller group started ART. This resulted in an increase from
308 to 353 CD4+ cells/mm3 over 12 months of ART, 269 to
319 CD4+ cells/mm3 over 19 months, 249 to 414 CD4+ cells/
mm3 over 19 months, 269 to 460 CD4+ cells/mm3 over
23 months, and 284 to 441 CD4+ cells/mm3 over 22 months
of ART. An early rise was seen for only 1 patient where CD4+
T-cell count rose from 249 to 411 cells/mm3 after just 1 month
of ART; CD4+ T-cell recovery occurred over many months
for the other patients, and indeed counts continued to increase
past 12 months of ART for 2 of the patients.
It was observed that although absolute CD4+ T-cell
counts rose early for only 1 patient, %CD4+ T-cells did rise
early for 3 patients due to the fact that absolute CD8+ T-cell
count dropped markedly after 1 month of ART (760–536,
1429–1005, and 892–421 cells/mm3). Other studies have
described a decrease in either memory CD8+ T-cells,34 acti-
vated CD8+ T-cells,35 or HIV-1-speciﬁc CD8+ T-cells36
within the ﬁrst few weeks of ART that may account for the
decrease we see in total CD8+ T-cells.
In summary, discord controllers share many character-
istics with progressors, namely high HIV-1 DNA loads,
a depleted naive CD4+ T-cell population with increased
CD4+ T-cell activation levels; in contrast, the CD8+ T-cell
compartment in discord controllers is more similar to that
seen in typical controllers.
FIGURE 3. Representation of CD8+
T-cell subsets by patient group.
Patients analyzed as described in
Figure 2: discord controllers, typical
controllers, progressors, and unin-
fected subjects. Absolute numbers of
cells in CD8+ T-cell subsets are shown
in (A) naive (CD45RA+CD62L+), (B)
central memory (CD45RO+CD62L+),
and (C) effector memory
(CD45RO+CD62L2). Percentage of
cells in CD8+ T-cell subsets compared
with total CD8+ T-cell pool are shown
for (D) naive, (E) central memory, and
(F) effector memory. Percentage acti-
vation of cells in CD8+ T-cell subsets
(as percentage of total cells in that
subset) by patient group is shown in
(G–I). Each central bar represents the
median value, each box represents
the IQR, and the whiskers represent
the minimum and maximum values.
Statistical analysis employed a Mann–
Whitney U test.
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DISCUSSION
In HIV-1 infection, low viral RNA loads usually predict
good CD4+ T-cell counts.37 We describe a cohort of HIV-1–
infected patients, who, despite maintaining low viral RNA
loads (similar to typical controllers), have low CD4+ T-cell
counts (similar to typical progressors) indicating disease pro-
gression. We show that these patients, termed discord control-
lers, in addition to having low CD4+ T-cell counts have high
viral DNA loads, preferentially depleted naive CD4+ T-cells
and increased CD4+ T-cell activation, similar to typical pro-
gressors. This ﬁnding supports Hunt et al18 who show that
lower CD4+ T-cell counts correlate with higher CD4+ T-cell
activation even among controllers. Of note, the increased CD4+
T-cell activation was similar in discord controllers and progres-
sors, despite progressors having much higher plasma viral
RNA loads of the latter groups, suggesting that factors inde-
pendent of viral RNA load are driving CD4+ T-cell activation.
With regard to the CD8+ T-cell compartment, discord
controllers were more similar to typical controllers. Both
controller cohorts have higher numbers of naive CD8+ T-cells
and lower levels of CD8+ T-cell activation compared
with progressors. These observations suggest that a more
preserved CD8+ T-cell compartment is associated with control
of plasma viremia but not necessarily with lack of disease pro-
gression as is shown in discord controllers. Some studies sug-
gest that CD8+ T-cell activation is a predictor of disease
progression, independent of CD4+ T-cell count and HIV-1
RNA.4,6,38 However, we do not ﬁnd this to be the case in our
controller population. Indeed, our observations are more in
keeping with alternate studies, which show that higher plasma
viral RNA load positively correlates with increased CD8+ T-cell
activation,5,30 and that this correlation holds regardless of CD4+
T-cell counts.30 Functional analysis of the CD8+ T-cells present
in these patient cohorts may highlight differences in cellular
response to HIV-1, which confer protection against disease
progression.
There was no association between the discord pheno-
type and age or time since ﬁrst positive test (best available
surrogate for time since seroconversion). Although time since
diagnosis is not a perfect surrogate for time since serocon-
version, this data suggests that the discord controller pheno-
type is not associated with a longer duration of infection
compared with typical controllers. However, this study was
not powered or designed to determine this fully. The fact that
there is a trend toward lower %CD4+ T-cells in the discord
controller cohort argues against suggestions that lower abso-
lute CD4+ T-cell counts in the discord controller group are
merely a feature of lower total lymphocyte counts associated
with ethnic variation. The ﬁnding that the rate of change of
CD4+ T-cell count was indistinguishable comparing the 2
controller cohorts might also support this premise. There
was a trend toward an over-representation of clade C in the
discord cohort; however, larger studies are required to con-
ﬁrm this association and determine whether this clade predis-
poses to the discord controller phenotype.
Initiation of ART in 5 patients achieved a modest gain
in CD4+ T-cell numbers similar to those described recently by
Okulicz et al39 further supporting the notion that low CD4+
T-cell counts in the discord controller population are not
merely due to a lower “normal” CD4+ T-cell count, for exam-
ple, due to ethnic variation. An increase over the ﬁrst 10
weeks of ART has been suggested to be due to “redistribu-
tion” of CD4+ T-cells trapped in lymphoid.40 The fact that this
type of early rise occurred for only 1 of the 5 patients suggests
that redistribution was not the predominant mechanism lead-
ing to CD4+ T-cell recovery in these patients.
Unintegrated HIV-1 DNA is less stable than integrated
“proviral” DNA, and as such has been proposed, together
FIGURE 4. HIV-1 DNA load compared with HIV-1 RNA load in
patient groups. A, viral DNA load (DNA copies per 106 CD4+
T-cells; log10 scale) as compared with B, Plasma viral RNA load
(copies/mL; log10 scale) by patient group. Each central bar
represents the median value, each box represents the IQR, and
the whiskers represent the minimum and maximum values.
Viremic noncontrollers: age 42 (28–66) years, female 10%,
CD4+ T-cell count 399 (258–716) cells/mm3, HIV-1 RNA load
15,809 (10,041–169,049) copies per milliliter, all reported as
median (range). Median (range) of CD4+ T-cell count values
(cells/mm3) within 12 months before the sample tested for
plasma HIV-1 DNA load were 339 (251–424) for discord
controllers; 775 (499–1326) for typical controllers; 399 (258–
716) for viremic noncontrollers. Statistical analysis employed
a Mann–Whitney U test.
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with total HIV-1 DNA, to be a marker for ongoing replication
in vivo.41 This notion is further supported by observations that
DNA reservoirs are maintained by viral replication that may be
suppressed by ART42,43 and that total HIV-1 DNA correlates
inversely with CD4+ T-cell counts and predicts disease pro-
gression.15,16 Compared with typical controllers, we found sig-
niﬁcantly higher viral DNA loads in the discord controllers,
which was equivalent to that seen in progressors suggesting
high levels of ongoing replication in vivo. It is unclear why this
high cellular viral DNA load does not result in a higher-level
plasma viral RNA load in the discord controllers. Given the
crucial role of the CD8+ compartment in control of plasma viral
RNA load,44–46 the low plasma viral RNA load in the discord
controllers may be contingent on a CD8+ T-cell compartment
that is maintained in a subset distribution and activation pattern
similar to typical controllers. Another possibility is that viral
replication is strictly compartmentalized; the gastrointestinal
tract (lamina propria and organized lymphoid tissue) is a poten-
tial candidate because it has been shown to be an important site
of HIV-1 replication and of CD4+ T-cell sequestration and
depletion.47 Alternatively, discord controllers may be infected
with a virus that predominantly spreads directly from cell to
cell. Another scenario is that virus may be released efﬁciently
into the blood but cleared by humoral immune mechanisms.
These possible scenarios that may not be mutually exclusive
are currently under investigation.
With respect to the mechanism of CD4+ T-cell loss in
discord controllers, our observations favor a model where
CD4+ T-cell depletion is driven, at least partly, by CD4+
T-cell activation. This activation seems to be associated with
high-level viral replication as suggested by high total HIV-1
DNA loads. This is in keeping with a large body of evidence,
which suggests that immune activation is associated with
more rapid clinical progression and CD4+ T-cell decline.4–11
This may result from clonal exhaustion and drainage of mem-
ory T-cell pools. Concomitantly, naive CD4+ T-cell depletion
may result from this high immune activation driving cells into
another phenotype but may also be due to a deﬁciency of CD4+
T-cell regeneration or sequestration to another site. Sequential
studies in individual patients are required to further elucidate
this, given the dynamic nature of HIV-1 infection.
In summary, we have identiﬁed a subset of HIV-
1–infected patients, discord controllers, who despite
maintaining low plasma viral RNA loads experience disease
progression. With the exception of CD8+ T-cell subset distri-
bution and activation, we show that discord controllers are
similar to progressors, based on the CD4+ T-cell compartment
and HIV-1 DNA load, further supporting data that plasma
viral RNA load alone does not lead to CD4+ T-cell decline.
Rather, we have demonstrated increased CD4+ T-cell activa-
tion in discord controllers, which may relate to the higher viral
DNA load in this group. This higher viral DNA load suggests
comparatively higher levels of virus turnover in the discord
controllers, despite controlled plasma viral RNA loads, possi-
bly explaining disease progression. Moreover, the fact that
spontaneous control of viral replication does not necessarily
confer protection against disease progression highlights the
need to intensify the search for new therapies aimed at normal-
izing perturbations of the T-cell compartment.
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